**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 64068

**Manuscript Type:** REVIEW

**Hepatitis C virus: A critical approach to who really needs treatment**

Kouroumalis E *et al*. Treatment reappraisal in HCV

Elias Kouroumalis, Argyro Voumvouraki

**Elias Kouroumalis,** Department of Gastroenterology, University of Crete Medical School, Heraklion 71500, Crete, Greece

**Argyro Voumvouraki,** First Department of Internal Medicine, AHEPA University Hospital, Thessaloniki 54621, Greece

**Author contributions:** Kouroumalis E devised the paper, wrote the draft and reviewed the literature; Voumvouraki A collected the literature and finalized the draft.

**Corresponding author: Elias Kouroumalis, MD, PhD, Emeritus Professor,** Department of Gastroenterology, University of Crete Medical School, Voutes, Heraklion 71500, Crete, Greece. kouroumi@uoc.gr

**Received:** February 8, 2021

**Revised:** April 14, 2021

**Accepted: December 31, 2021**

**Published online:**

**Abstract**

Introduction of effective drugs in the treatment of hepatitis C virus (HCV) infection has prompted the World Health Organization to declare a global eradication target by 2030. Propositions have been made to screen the general population and treat all HCV carriers irrespective of the disease status. A year ago the new severe acute respiratory syndrome coronavirus 2 virus appeared causing a worldwide pandemic of coronavirus disease 2019 disease. Huge financial resources were redirected, and the pandemic became the first priority in every country. In this review, we examined the feasibility of the World Health Organization elimination program and the actual natural course of HCV infection. We also identified and analyzed certain comorbidity factors that may aggravate the progress of HCV and some marginalized subpopulations with characteristics favoring HCV dissemination. Alcohol consumption, HIV coinfection and the presence of components of metabolic syndrome including obesity, hyperuricemia and overt diabetes were comorbidities mostly responsible for increased liver-related morbidity and mortality of HCV. We also examined the significance of special subpopulations like people who inject drugs and males having sex with males. Finally, we proposed a different micro-elimination screening and treatment program that can be implemented in all countries irrespective of income. We suggest that screening and treatment of HCV carriers should be limited only in these particular groups.

**Key Words**: Hepatitis C, Comorbidities, Screening and treatment policy; Hepatitis C virus; Review

Kouroumalis E, Voumvouraki A. HCV: Who really needs treatment. A critical approach. *World J Hepatol* 2021; In press

**Core Tip:** Elimination of hepatitis C virus (HCV) by 2030 according to the World Health Organization policy seems highly unlikely because of the funding re-direction due to the coronavirus disease 2019 pandemic. It is important therefore to re-evaluate the treatment policies based on a more realistic and feasible approach. HCV disease has a very prolonged natural course, and even HCV-related cirrhosis has a lower mortality compared to other cirrhosis etiologies. However, liver related morbidity and mortality is increased when certain comorbidities accompany the initial HCV infection. A review of the current knowledge allows for a more or less accurate identification of these comorbidities. Therefore, an eradication program is proposed based on screening and treating only these particular groups.

**INTRODUCTION**

Hepatitis C virus (HCV) is genetically variable. Seven genotypes and more than 60 subtypes have been identified so far. Genotype 1 is the most prevalent worldwide[1]. A 30% difference among genotypes and a 15% difference among subtypes of the same genotype exist at the nucleotide level. In addition, an enormous diversity within the same infected individual may be present in the form of the so called quasi-species differing by 1%-10% in the nucleotide sequence[2,3]. They are categorized on the basis of the hypervariable regions in the envelope protein and the nonstructural 5A protein. These quasi-species are generated through error-prone replication and pose the major obstacle in the development of an effective vaccine. The E2 variability is mainly located in three highly variable regions designated as HVR1 (aa384–409), HVR2 (aa460–485) and igVR (aa570–580)[4,5].

With an estimation of approximately 2 million new infections each year, the real number of individuals harboring HCV may well be underestimated[6]. Most new cases go undetected because they are mostly asymptomatic. Underestimation is not limited to low-income countries. In the United States the incidence of new HCV cases has nearly doubled in the past 10 years primarily because of people who inject drugs (PWID). It is suggested that the recorded increase is only a fraction of the true number as the majority probably escapes detection[7,8].

Intravenous drug use is not the main route of transmission in low and middle income countries. In Egypt, PWID was a risk factor only in urban areas, while the main risk factor was hospital care[9,10] and intra-familial transmission of the virus[11]. This is also true for Greece[12]. Increased incidence of the disease has also been reported in China but without an epidemiological explanation[13]. In the European Union one of the additional problems is the increased immigration from countries with a high prevalence of HCV. A crude estimation has shown that approximately one in seven adults infected by HCV in the 31 countries of the European Economic Area is a migrant, and at the same time HCV prevalence is also high in some Eastern European countries. These facts pose a challenge for the budgets of many European Union countries[14].

In 2016, the World Health Organization (WHO) initiated a campaign to reduce HCV infection rates by 90% by 2030 using the new and highly effective direct acting antivirals (DAAs). The campaign called for an increase of HCV screening and unlimited access to DAA treatment[15].

However, there are inherent limitations to this approach[16,17]. Even in the most favorable trials, DAAs do not achieve viral elimination in as many as 2%-10% of cases. Moreover, there is mounting concern that DAAs can select resistant variants that may reduce their effectiveness. Also, DAAs are expensive for most developing countries, while asymptomatic cases pose a worldwide problem as only 20% of infections are diagnosed and of those only 15% are properly treated[18]. This is further complicated by the fact that many new cases are found in marginalized populations like PWIDs and males having sex with males (MSM). These groups pose an additional problem as they are prone to reinfection[16].

As a result, only a few countries will be able to eliminate HCV by 2030. High-income countries will not achieve HCV eradication before 2050 as 80% of them are not on track to meet HCV elimination targets by 2030 and 67% are off target by at least 20 years[19,20]. The vast majority of low and middle-income countries are at a very preliminary stage[21-23]. Unfortunately, the latter are countries like Pakistan, Egypt, China and India, which have the largest numbers of chronic HCV infections.

The coronavirus disease 2019 (COVID-19) pandemic has dramatically changed health priorities around the world. It is not surprising that financial resources have been redirected in an effort to fight the new enemy. Therefore, major problems in the different programs of HCV elimination are to be expected even among high-income countries. Disruptions to hepatitis programming have already been reported in Egypt and Italy, two countries with different incomes and COVID-19 problems, and many more are certain to follow[24]. Moreover, the odds are against the control of HCV infection without an effective and widely available vaccine[25,26].

Therefore, in the present review, the problems of managing chronic hepatitis C will be analyzed, the populations that are in real need for treatment will be identified and a new, more realistic target of treatment will be proposed that may overcome the difficulties in the global effort to eliminate the disease.

**Can we eradicate HCV by 2030 with DAAs treatment?**

The number of new HCV infection rates is increasing worldwide despite the use of the highly effective DAAs. Most of the new infections go undetected as they are asymptomatic. Only 50% of infected people are aware of their infection in the United States[27]. DAAs do not protect from reinfection. Therefore, certain marginalized groups like intravenous drug users may be reinfected[17].

Yet, many investigators are convinced that eradication is possible by treating all HCV carriers, including pediatric patients[28], even in low-income countries provided that cost reduction policies will be adopted[29]. An even more optimistic view has been presented. Since 2015, after the wide use of DAAS in Spain, a profound reduction in HCV cirrhosis hospitalization has been reported. The investigators predicted that by 2025, HCV-cirrhosis will have practically disappeared as a cause of hospital admissions[30]. However, in most instances conditions are set and reservations are expressed (Table 1).

A model projection of the impact of DAA treatment on the elimination of HCV infection showed that the WHO target for 2030 could be achieved only after an annual net regression of 7%.Currently the projections made indicate that the annual regression is only 0.4% worldwide, and therefore elimination will be impossible[31]. Projection studies of different scenarios[32], such as those including countries with a high prevalence of HCV such as Pakistan[33], have indicated that HCV elimination may be feasible but only after substantial new investments from national budgets even in Europe[34]. Conditions that should be fulfilled before elimination can be on target have been described for special populations like HIV + PWID or HIV + MSM. Harm and behavior risk reduction interventions in addition to DAA treatment and a substantial increase of screening, showed improved results[35].

***Treatment failure and non-compliance***

One hundred percent sustained virologic response (SVR) is not feasible even with the latest DAAs. The best treatment results are reported as 90%-97% in most series. This means that 3%-10% of treated patients do not achieve an SVR and may become resistant to available regimens[36]. Response rates may even be lower than 90% in certain groups. Thus, in a recent large meta-analysis reviewing 49 reports, SVR was lower than 90% in 11/49 studies of patients without hepatocellular carcinoma (HCC)[37]. In a real-life cohort of cirrhotic patients, viral clearance was obtained by 88% (175/199) of patients with varying responses among genotypes[38].

Compliance with treatment is another obstacle in the eradication of HCV. This is particularly evident in special groups. In a recent study, compliance was associated with the time of drug dependence. Those with shorter periods of drug dependence had the highest compliance with an inadequate 47% compared with the even worse 38% of longer-time users[39]. In France, drug uptake was low in HCV patients with PWID and alcohol use disorders (AUD) despite an improvement after DAA introduction as compared to interferon (IFN)-based treatments[40].

***Resistance of old and new subtypes***

Quasi-specie is the concept that explains the development of resistance to DAAs[41]. Low levels of resistance-associated substitutions < 15% in the NS5A region have no significant effect on treatment outcomes, but proportions greater than 15% at baseline are associated with treatment failures[42]. Furthermore, presence of NS5A resistance-associated substitutions may be responsible for the low 83% SVR reported in the ASTRAL-4 trial in certain genotypes[43]. Similarly, in a Chinese study of sofosbuvir (SOF)/velpatasvir (VEL), NS5A resistance was responsible for 89% SVR in non-cirrhotic patients with subtype 3b, while only 50% of cirrhotic patients achieved SVR after 12 wk of SOF/velpatasvir[44].

It is clear today that baseline resistance-associated substitutions to DAAs can have a significant effect on the treatment of “older” genotypes preventing SVR in many patients[45].

However, the real problem occurred when newly identified subtypes appeared in many countries. HCV classification now includes a larger number of subtypes, like 1 L, 2r, 3k, 4w, 6xa, 7a and 8a, 6 and probably many more[1]. They were extremely rare in countries where research is usually done, but they are relatively common in some low and middle-income countries as well as in immigrants in Europe and North America originating from these countries. Some of those subtypes are inherently resistant to several NS5A inhibitors[46,47]**.**

In line with these findings, a Rwandan study with SOF/ledipasvir (LDV) showed an SVR rate of only 56% in the subtype 4r, much lower than the 93% SVR in patients with other genotype 4 subtypes[48]. A very recent report studied infections with unusual subtypes from Africa and South East Asia. The report claims that only pibrentasvir (PIB)was effective against all, and the recommendation given is to use a combination of glecaprevir (GLE) and PIB as first-line treatment for these patients. However, no data that these subtypes were indeed sensitive to GLE were presented[49].

It should be noted that in these countries only generic DAAs with an inherent resistance against these subtypes exist. It will therefore not be long before these resistant subtypes spread across Europe or North America. In an unselected cohort of African immigrants infected with an unusual genotype, including the novel subtype 1p, the SVR was 75%[50]. These studies indicate that the need for research on new drugs should not stop because these failures could jeopardize all HCV elimination efforts[51,52].

***Occult HCV***

Occult HCV infection (OCI) refers to the presence of HCV RNA in hepatocytes or peripheral blood mononuclear cells (PBMCs), without HCV RNA in serum. OCI has been demonstrated in hemodialysis patients, HCV/HIV coinfection and HBV-HCV coinfection but also in 3% of the general population[53]. In a recent study, the prevalence of OCI in HIV-infected individuals was 11.4%. Most patients were infected with the subtype 3a followed by the subtypes 1a and 1b[54]. OCI is also common in patients with malignant lymphoproliferative disorders. Ultrastructural examination of PBMCs demonstrated intracytoplasmic vacuoles enclosing viral-like particles[55]. The prevalence of OCI after treatment with DAAs was found to be considerably high. As a consequence, a dual testing for HCV RNA done in both PBMCs and serum at the end of treatment with DAAs as well as during validation of the SVR was recommended[56], a reasonable suggestion that will however increase the cost. Parts of the HCV 5’-noncoding region genomic RNA sequences were demonstrated at the DNA level in the extrachromosomal circular DNA fraction of PBMCs resulting in OCI[57].

***Reinfection***

The problem of reinfection may become a real obstacle in the near future. Reinfection mostly occurs in patients with persistent risk factors like PWID. A 10%-15% risk of reinfection after 5 years of SVR has been repeatedly reported[58]. China, Russia and the United States have the highest number of PWID with a very high HCV prevalence, and therefore the risk of reinfection is also very high. An additional issue is that reinfection rates have not been studied in low-income countries where both intra-community transmission and transmission through medical practice are still very common[59]. A recent meta-analysis of 36 studies has demonstrated a relapse rate of around 6/100 person years among drug users. There was no difference between IFN-based and DAA treatment, but patients receiving opioid agonist therapy had a lower reinfection rate[60].

Most HCV cases are reinfected with a different strain of the virus after SVR. However, some patients relapse with the same strain they had at the commencement of treatment[61,62]. Interestingly enough, reinfection rates seem to be higher after spontaneous clearance of the virus than after successful DAA treatment (at least for the first few years of the reported follow-up)[63].

Relapse or reinfection by a new strain is possibly related either to exhaustion of HCV-specific T cells or to the emergence of escape mutations. In this respect, it is interesting that DAAs do not lead to a reversion of the T cell exhaustion observed in chronic HCV infection[64].

***Cost of treatment***

An additional serious problem in the HCV elimination project is the cost of treatment. Most studies consider eradication programs cost-effective with almost all of them using Markov mathematical models.

A study from Switzerland claimed that a break-even for the health system will be achieved by 2031 if all fibrotic stages were treated[65]. In the United States, treatment of all eligible HCV patients with SOF/LDV would require investing 65 billion dollars over the next 5 years[66].

A more recent study in the United States reported that the pangenotypic SOF treatments (SOF/VEL, SOF/VEL/voxilaprevir) were considerably more cost saving than the equally effective GLE/PIB treatment[67].In a Hong Kong study, elbasvir/grazoprevir was the least costly DAA treatment, dominating over most other DAAs for genotype 1 patients at a quality-adjusted life-year of 9000-11000 United States dollars[68].

In India, the use of SOF/VEL is proposed over SOF/ledipasvir or SOF/daclatasvir (DCV) to all HCV-infected people but only if there are no budget constraints. If budget is a problem, SOF/VEL is recommended for cirrhotic patients only[69].In a recent study from Japan, GLE/PIB generated higher quality-adjusted life-years and lower lifetime costs compared to all other DAAs[70].

Even in low income-countries like Vietnam, all DAA treatments for patients with genotypes 1 and 6 were cost-effective, but the combination of SOF/VEL was the most cost-effective among them[71].

In contrast, SOF/VEL treatment was not the most cost-effective option for patients with genotype 1b compared with other oral DAA agents in China. Therefore, a price reduction of SOF/VEL would be necessary to make it cost-effective and simplify treatment, achieving thus the goal of HCV elimination[72].

In Italy, a Markov model has shown that treating all HCV patients at an early stage of the disease is cost effective for the Italian Healthcare System[73].

A different approach was adapted in another Italian study that estimated the break-even point in time. This is the period of time required for the total saved costs to be recovered by the Italian National Health System investment in DAA treatment. The break-even point in time was not achieved for those treated in 2015 due to high DAA prices and severity of disease of treated patients. On the other hand, the estimated break-even point in times were 6.6 years and 6.2 years for those treated in 2016 and 2017, respectively. The total cost savings after 20 years would be €50.13 million and €55.50 million/1000 patients treated in 2016 and 2017, respectively[74].

In the elimination scenario, viremic cases would decrease by 78.8% in 2030 compared to 2015. The direct and indirect costs would range from €3.2-3.4 billion by 2030, but elimination of HCV would be impossible without an extensive screening program. The WHO elimination strategy can possibly be achieved and is cost-saving despite the financial uncertainty of DAA cost in Greece[75].

In Spain, incremental cost-effectiveness ratio for screening of the general population plus treatment was reported to be below the accepted willingness-to-pay thresholds in most studies, and therefore screening plus DAA strategy is considered to be cost-effective[76]. The same results were reported from Belgium where a policy of broad screening plus DAA treatment was advocated[77].

In Germany by contrast, after a cost analysis, the recommendation was to screen all of the PWID population while applying a less extensive screening in the MSM and general population[78]. Screening all South Korean patients twice followed by SOF/LDV treatment was cost-effective as compared to the current high-risk screening, while GLE/PIB was not cost-effective[79].

However, there are many reservations as to the cost-effectiveness of the WHO elimination program[80]. The amount required for Pakistan has been estimated at 3 billion United States dollars[33]. A price analysis of some of the most commonly used DAAs across 30 countries has shown that DAAs are unaffordable in many countries. Prices at that time were variable and unaffordable, being a threat to the sustainability of many health systems[81]. Treatment prices have since fallen and are currently 25000 dollars in the United States. Even so, this cost is prohibitive without medical insurance. Only 37% of patients were treated in the United States for financial reasons[82]. Pharmaceutical companies are allowed to sell DAAs at higher prices in high-income countries and at low prices in low-income countries[83]. In Pakistan, generic drugs brought the cost of DAAs down to 60 United States dollars per treatment, which is the lowest price in the world[31].

The cost of quality-adjusted life-year gained in 60-year-old patients was approximately 9000 United States dollars at current DAA prices in Japan. HCV treatment would only be cost-effective within the next 5-20 years after a price reduction of 55%-85%[84].

In low-middle income countries of Africa, elimination programs cannot be financially viable without a substantial increase in health funding or a gross decrease in assay prices. Screening strategies would require 8%-25% of the annual health budget in these countries only to diagnose 30% of HCV-infected individuals[83].

However, an alternative low cost approach is usually neglected. A study in Dundee, Bristol and Walsall has demonstrated that needle and syringe programs are effective and low-cost interventions in the highly vulnerable PWID population, at least as far as transmission reduction is concerned[85].

An earlier report has indicated that Markov models have many flaws. Alcohol drinking is a factor that is not acknowledged in many cost analyses. Yet alcohol influences the outcome of HCV infections[86].

A serious event has changed all estimations. The severe acute respiratory syndrome coronavirus 2 pandemic has redirected a substantial amount of national health spending in almost all countries worldwide. Even if recent estimations expect approximately 72000 more liver-related deaths after 1 year of the elimination program delay, the number is small compared to more than 1 million deaths attributed to COVID-19 disease in less than a year[24].

In view of the above, one question still remains. Why are more expensive recommendations proposed when all reported trials indicate > 90% SVR? This is evident if one compares the European Association for the Study of the Liver (EASL) recommendations of 2017, 2018 and 2020. Resistance cannot be the sole answer[87-89]. Three SOF-based treatments not only had SVR > 90% but their effects were equally fast in a series of patients with advanced fibrosis or cirrhosis[90]. Even low-priced generic DAAs were both clinically effective and cost-effective[91,92]. Similar efficacy between SOF/DCV and SOF/VEL in genotypes 2 and 3 was also reported in a real world study[93]. In a very recent study on genotype 2, SOF in combination with DCV, LDV or VEL and GLE/PIB had similar high SVR rates, irrespective of cirrhosis or chronic kidney disease[94], and similar results were reported in a real-life recent study of three regimens including SOF/DCV, SOF/VEL and GLE/PIB tested in genotype 3[95]. SOF/LDV SVR rate was 97% compared to 100% of SOF/VEL in GT6 after 12 wk of treatment[96,97]. In a meta-analysis of 34 studies, SOF/DCV, SOF/VEL, SOF/VEL/voxilaprevir and GLE/PIB were found to have similar SVRs in both non-cirrhotic (95.24%) and cirrhotic (89.39%) patients[98]. Better results for SOF/LDV compared to SOF/VEL were reported in PWID[99,100].

It should be noted however that no real direct comparisons exist in most reported studies as exemplified in an emulated randomized trial where SOF/VEL were equally effective as SOF/LDV in genotype 1 patients[101].

Although cause-specific analysis demonstrated that persons with SVR were less at risk for liver-related mortality than those without SVR or never treated patients, the expected decrease in overall mortality has not yet been observed. These findings may raise hopes for the future, but the final elimination result remains to be proven[102].

No analysis of difficulties in HCV eradication would be complete without mentioning HCV vaccines. It is almost impossible to achieve complete HCV elimination without a vaccine, but the real problem is that we cannot have a vaccine, at least not for the time being. An excellent review on the reasons why HCV cannot be eradicated without an efficient vaccine has been recently published[25].

A model based on 167 countries showed that only between 0 and 48 countries could achieve an 80% HCV incidence reduction without a vaccine. The number went up to 15–113 countries with a 75% effective vaccine and 10-year duration of protection, while billions of United States dollars could be saved across 78 countries at a cost of 50 United States dollars per vaccination[103].

Spontaneous clearance of HCV has been correlated with the development of neutralizing antibodies[104] targeting the E2 envelope protein of the virus[105]. An earlier study showed that induction of neutralizing antibodies was feasible in chimpanzees and human volunteers[106]. CD4 T cell responses against envelope proteins E1 and E2 were also observed in humans[106,107]**.** For the time being vaccines based on proteins of the E2 hypervariable region are not producing satisfactory results[108].

A different vaccine based on the use of a replication defective adenovirus containing the entire non-structural proteins was also developed[109,110]. This vaccine elicited a broad and durable CD4/CD8 T cell response, IFN-g production and memory cell development in humans. The same group developed and tried in a phase 1 human trial a vaccine based on a replication defective simian adenoviral vector and a modified vaccinia Ankara vector containing the NS3, NS4, NS5A and NS5B proteins of the genotype 1b. An effector and T cell memory response were developed[111].

However, a randomized, double-blind, placebo-controlled phase I and II clinical study mostly on PWIDs who received either the vaccine or placebo did not show a protective effect against the development of viral persistence. The protection provided was no greater than that provided by the placebo[112]. Recent investigation on HCV vaccine adjuvants demonstrated that the induction of a strong T and B cell immunity is enhanced by choosing the right adjuvant[113]. The subject of vaccines producing neutralizing antibodies has also been briefly reviewed in two recent editorials[114,115].

**HCV INFECTION: HOW DANGEROUS IS IT REALLY?**

It is estimated that 5%–20% of patients with chronic HCV will develop liver cirrhosis[116,117], while approximately 25% of subjects will clear the virus after the initial infection[118]. It is also stated that approximately 27% of liver cirrhosis and 25% of HCC cases are attributable to chronic HCV[119]. This estimate is based on studies of patients with advanced liver disease.

Efforts to determine the natural history of HCV are not easy because of the inherent characteristics of the disease. Its onset cannot be verified with certainty and its course may be unusually prolonged. Disease outcome reports were mainly based on retrospective studies concluding that at least 20% of chronic infections develop cirrhosis within 20 years of the disease onset. By contrast, studies that used a retrospective/prospective approach have produced different results at least in certain population groups. Among young people, particularly young women, spontaneous resolution was more common than previously thought, and cirrhosis developed in only 5%of infections or less. The major drawback of most studies is that natural history studies rarely exceed the first 20 years so that evolution beyond this time is usually the result of predictions through models. An additional problem is that many confounding factors that influence outcome are not taken into account[120].

The first paper that raised questions about the real natural course of HCV was reported almost 30 years ago. An accurate infection time was ascertained for over 94% of the 568 patients, as participants were infected by transfusion. More importantly, two control groups (526 first controls and 458 second controls) were also included. After an average of 18 years, life-table analysis showed that all-cause mortality was 51% for those with transfusion-associated non A non B hepatitis compared to 52% and 50% for the control groups. The survival curves for the three groups were almost identical. Liver-related mortality was 3.3%, 1.1% and 2.0%, respectively. (*P* = 0.033 between hepatitis and the combined control group). Most importantly, 71% of liver-related deaths occurred in patients with chronic alcoholism. There is no specific mention of the causes of non-liver mortality in all groups, but one can assume that controls had more cerebrovascular accidents than the hepatitis group[121].

As a result of this study, one could further assume that if a curative treatment was given leading to a reduction of liver-related deaths in the hepatitis group, then survival would be more than the general population, which is rather odd**.** However, there may be a plausible explanation after the demonstration of changes in the lipid profile of HCV patients[122,123]. HCV-infected patients show significantly lower levels of cholesterol with a reduction of low-density lipoprotein levels compared to healthy controls irrespective of the degree of hepatic fibrosis[124,125]. Viral clearance increases levels of low-density lipoprotein and total cholesterol[126]. Therefore, it is reasonable to assume that after treatment more cerebrovascular accidents will equate the overall mortality of patients with general population mortality.

Mortality and morbidity data of the same patients and controls after approximately 25 years of follow-up were presented. All-cause mortality was 67% among 222 HCV cases and 65% among 377 controls. Yet again, liver-related mortality was 4.1% and 1.3%, respectively (*P* = 0.05). Interestingly, among the 129 living persons with transfusion-associated hepatitis, 70% had proven HCV and 30%, non-A-G hepatitis. In addition, 17% of all those originally HCV infected had cirrhosis[127].

There have been more studies verifying the fact that HCV may be a rather benign condition unless a harmful confounding factor like alcohol is added. Thus, many children acquired HCV infection after cardiac surgery before blood donors were screened for HCV in Germany. After about 20 years, the virus had spontaneously cleared in many patients, and the clinical course in those with chronic infection was more benign than expected when compared to infected adults[128].

A very long follow-up of 45 years was reported in a group of military recruits. HCV-positive persons had very low liver-related morbidity and mortality rates suggesting that healthy HCV-positive persons may be at low risk for progressive liver disease[129].

Older patients with tuberculosis sequelae, transfused at a younger age, entered a study approximately 30 years after the infection and were followed up for an average of 5.7 years after entry. Overall, 64% of HCV-infected and 57% of non-infected people had died. The main cause of death was tuberculosis sequelae in 42% and 46% of patients, respectively. Although liver-related deaths during follow-up were higher in HCV-infected patients, the overall mortality was similar between the two groups[130].

Similar findings were reported in a group of transfusion recipients from Denmark. After 22 years of follow-up no difference was found in all-cause mortality between HCV-exposed and non-exposed patients, but liver-related mortality was higher in the HCV group[131]. Even in specific high risk groups similar results have been reported. In a cohort of community-acquired HCV among mostly PWIDs, only 8% had overt cirrhosis, while no HCC cases were identified after 25 years of follow-up. Moreover, HCV-infected individuals were 8 times more likely to have committed suicide or die from drug overdose than from liver-related disease[132].

In a cohort of 1667 PWID with HCV infection for a mean of 14 years and followed up for an additional mean of 8.8 years, a low incidence of liver-related mortality of 3/1000 years was found. The risk of end-stage liver disease was higher for persons who ingested more than 260 g of alcohol per week. Two hundred and ten of these patients without advanced liver disease were randomly selected to have a liver biopsy. Only 2 had cirrhosis (1%)[133].

In another PWID cohort, an all-cause high mortality rate of 1.85/100 person-years after 33 years of follow-up was found, but it was not related to persisting HCV infection. Intoxication and suicide were the main causes of death[134].

Using statistical models for untreated HCV-infected PWIDs, the time to cirrhosis was estimated to be 46 years, and estimations for the time required to reach the F3 fibrosis stage was 38 years using stage-specific estimates[135].

Nine hundred and twenty-four patients with a known date of transfusion-acquired HCV were followed up for 16 years after infection in the United Kingdom. They were compared to 475 not infected transfusion recipients. All-cause mortality was not different between cases and controls, but the risk of liver-related mortality was higher among cases. It should be noted that nearly 30% of the HCV-infected cases that died directly from liver disease had also reported excessive alcohol consumption[136].

Almost identical data were reported from a cohort of East German women who were also exposed to HCV *via* contaminated Rh immunoglobulin. Clinical cirrhosis was identified in 4 (0.4%) of 917 infected women, 2 of whom died, 1 from HBV coinfection and 1 as a result of heavy alcohol use. Among the 403 chronically infected women in this study who underwent liver biopsy after a mean duration of infection of 20 years, only 3% exhibited bridging fibrosis, and none had cirrhosis[137].

Interestingly, more women of the initial group were later identified and followed up for 25 years. In total, 1980 women representing 70% of the total cohort were re-examined; 46% were positive for HCV RNA. Only 0.5% had overt liver cirrhosis, 1.5% developed pre-cirrhotic stages and only one HCC was diagnosed. Ten died of HCV-related complications, but in five of those an additional comorbidity was present[138].

Since this was an ideal homogeneous population to investigate the course of HCV infection, 718 patients were further evaluated at 35 years after inoculation. Four groups were compared for liver disease and mortality: self-limited HCV, untreated chronic HCV and treated condition with or without SVR. Overall, 9.3% of patients had clinical signs of cirrhosis. End stage liver disease was higher in the non-SVR group (15.3%), whereas the overall survival was significantly higher after SVR compared to untreated patients or non-SVR. However, looking at the details of the study, it is obvious that the survival probability is significantly decreased only in overweight women and even more so in cases of obesity. The same is true for the development of extensive fibrosis or cirrhosis[139].

A similar study from Ireland included 376 women with anti-D contamination, infected with HCV and followed up for about 17 years. Liver biopsies showed inflammation in 356 of 363 women (98%). The inflammation was mild (41%) or moderate (52%). Only 7 women (2%) had probable or definite cirrhosis, and of those only two reported excessive alcohol consumption[140].

After 5 additional years of follow-up, inflammatory scores were increased in 18% and decreased in 28% of patients. Forty-nine percent of patients had no change in fibrosis, 24% showed regression and only 27% showed progression, while 4 patients (2.1%) developed cirrhosis. Given the age of these women, currently in their fifth decade, some may still be at risk for more advanced liver disease, but for most of these patients it appears unlikely[141].

A third follow-up paper appeared presenting data from 36 years after contamination. In total, 682 patients were studied, including the 374 women chronically infected with HCV. Nineteen percent of them had developed cirrhosis, while all-cause mortality was 13% (4.9% died from liver-related causes) as opposed to 6.8% of the non-infected women. Liver-related, but not all-cause mortality, was significantly higher between the two groups. At face value, the results indicate that cirrhosis and liver-related deaths had increased during the last 5 years of follow-up. However, when factors associated with cirrhosis were examined, high alcohol intake, diabetes mellitus and obesity were present in the majority of cirrhotic women. It should also be noted that over two-thirds of cirrhotic patients were still alive[142].

Hemophiliacs were a group of patients heavily infected with HCV prior to the introduction of viral inactivation of factor concentrates and blood screening. Only hemophiliacs with HCV/HIV coinfection had a lower survival compared with HCV mono-infected who had a similar mortality with non-infected hemophiliacs over 10 years. There was no survival gain from anti-HCV treatment (IFN) or from achievement of an SVR[143].

One hundred and six HCV RNA positive hemophiliacs were followed up for approximately 30 years, and 34% were HIV coinfected. All-cause mortality was 44% in HIV positive patients and 29% in HIV negative patients. Liver-related mortality was 12.5% and was not different between the two groups. In this cohort as well the probability of cirrhosis was significantly increased when either HBV coinfection or substantial alcohol consumption were present[144].

There have been studies indicating that HCV infection is associated with both a high rate of cirrhosis and/or high mortality. However, these are in disagreement with studies where the contamination time point can be ascertained. Most mortality studies report on cirrhotic patients, *i.e.* the final stage of HCV infection usually comparing mortality without and with viral elimination. Thus, an Italian study showed that patients with compensated HCV cirrhosis achieving SVR by IFN obtained a significant benefit as they level their survival curve to that of the general population. But the controls were based on the standardized mortality ratio of the age and sex matched general population. Importantly, no mention of drinking or metabolic syndrome was made[145].

Higher mortality rates compared to the general population even after SVR were reported from Denmark. The time point of contamination was not ascertained. Half of the patients were heavy drinkers[146]. Similar results were also reported in 1824 patients from Scotland, followed up for an average of 5.2 years after SVR. In total, all-cause mortality was 1.9 times more frequent for SVR patients than the general population. Characteristics associated with increased mortality were markers either of heavy alcohol consumption or intravenous drug use. Without these behavioral markers an equivalent survival to the general population was noted[147].

A reduction in serious liver-related events was also noted in a prospective study of patients with HCV-compensated cirrhosis who achieved an SVR. SVR reduced overall mortality and risk of liver-related deaths. However, metabolic features were associated with a higher risk of HCC in patients with SVR. No alcohol consumption was reported[148].

In a study from Japan, the presence of HCV viremia increased mortality, mainly due to liver-related deaths. There were no biopsies at the beginning of the study, and the cause of death was based on death certificates[149].

Paid blood or plasma donors were studied after a median of 27 years from the last blood donation to the time of survey. HCV RNA was detected in 592 individuals. A high 27.2% of them were considered to have cirrhosis by liver stiffness measurement.Almost 50% of the total were overweight. No intravenous drug use was mentioned, and insulin resistance (IR) was significantly higher in HCV-infected blood donors compared to the non-infected ones. More importantly, the time point of infection was not known[150].

In another study of paid plasma donors with HCV infection from China, liver cirrhosis or HCC developed in 10.00% of individuals, with a liver-related mortality of 8.18% after 12-19 years of follow-up. Alcohol was again a risk factor involved in the outcome of HCV infection[151].

In a recent study, age-sex standardized mortality ratios for patients with an HCV infection were calculated and compared to the general population. All-cause age-sex standardized mortality ratio were 2.3 times higher. No confounding factors like alcohol, obesity or HIV coinfection were reportedin detail[152].

The significance of confounding factors is clearly exemplified in a recent study by the same group where the median age of death was lower in persons with evidence of HCV than the general population (53 years *vs* 81 years). A significant proportion of persons with HCV died of external causes, liver disease and HIV compared to the general population[153].

A recent investigation reported on the natural history of HCV in children and young adults after a median follow-up of 33 years. The modes of transmission were intravenous drug use (53%), blood product exposure (24%) and perinatal infection (11%); 55% of them were treated with IFN and the rest with DAAs. SVR was obtained in 75%. Mortality rate was higher in patients without SVR *vs* those with SVR, but SVR did not abolish mortality altogether. Almost 40% of patients consumed alcohol heavily or were HIV coinfected. No mention of the presence of metabolic syndrome was reported[154].

Mortality is not high even in patients with advanced/decompensated HCV cirrhosis with Model for End-Stage Liver Disease (MELD) > 10. In a recent long-term follow-up after initiation of treatment with DAAs, a meaningful decrease of 3 or more in MELD occurred in 29% of patients, while a final MELD score of < 10 was obtained in 25%. Only 11% died after a median follow-up of 4 years. In view of the marginal changes that were achieved, the authors concluded that the low mortality was certainly not due to the favoring effect of DAAs[155].

HCV cirrhotic patients survived longer than those with alcoholic cirrhosis, while HBV patients were over twice at risk of dying compared with HCV patients. Patients with alcoholic cirrhosis had a higher risk of decompensation compared to those with HCV, while patients with HCV plus alcohol use had a significantly higher rate of decompensation compared with HCV alone. The highest median decompensation-free time was noted in the HCV patient group[156].

A large recent meta-analysis updated prognostic estimations of important patient subpopulations. Findings indicate that HCV’s natural course is influenced by factors like infection, age, duration of infection and population studied. Fibrosis progression is grossly heterogeneous across study populations. It is suggested that HCV prognosis should be examined in homogeneous populations[157].

**WHAT SVR REALLY REPRESENTS**

SVR is a marker of viral eradication in HCV infection. The all-oral,] DAAs have drastically increased SVR rates compared to IFN-based treatment[158,159]. In addition, SVR achieved after DAAs treatment hasbeen shown to persist long term[63,160]. SVR is indiscriminately characterized as a surrogate marker of clinical cure.

The National Institutes of Health (United States) defined surrogate endpoint or surrogate marker as a biomarker intended to substitute for a clinical endpoint. A first step for establishing a new surrogate marker is the investigation of the degree to which the candidate biomarker can explain or predict the effect of treatments on clinical endpoints measured in randomized clinical trials[161].

A Cochrane systematic review published in 2017 evaluated 51 trials comparing DAAs with placebo and/or no interventions. Most trials primarily reported on sustained virologic response and provided relatively limited data on clinically important outcomes and none at all on long-term effects. Meta-analysis of the effects of all DAAs showed no evidence of a difference in all-cause mortality between DAA recipients and controls with very low-quality evidence. Furthermore, all trials and outcome results were at high risk of bias.

It has been suggested that DAAs may reduce the number of patients with detectable virus in their blood, but no sufficient evidence from randomized trials exists that could allow us to understand how SVR affects long-term clinical outcomes. Therefore, SVR was considered to be an outcome that needs proper validation in randomized clinical trials. A laboratory measurement cannot be characterized as a surrogate marker without solid proof of a clinical outcome[162]. Within a month, an unusual response to the Cochrane review appeared with EASL as both the author and the corresponding author! No names were mentioned, although they should have since EASL is a scientific society and cannot certainly write papers[163]. At about the same time, the Cochrane review was fiercely criticized, but the critics admitted that the end point for most clinical trials of DAA therapies conducted has been SVR. They also pointed out that there were a few DAA trials that have examined clinical outcomes in decompensated patients with cirrhosis[164].

The Cochrane team in fact substantiated their argument on both SVR and on the effect of DAAs on mortality[165]. They correctly pointed out that SVR had never been validated and even failed such validation in one analysis of long-term IFN intervention[166]. Moreover, it was pointed out that quality of life is a completely subjective outcome, and its assessment needs blinded random controlled trials with unbiased patients[167]. This is very difficult to be implemented in the case of DAAs as advertisements have promised a cure even for asymptomatic patients. It was also pointed out that the use of the word ‘cure’ was inappropriate. They argued that although SVR is a good prognostic sign, it has no validation as a surrogate outcome[168].

There are two critical points that require further analysis. The first is the question of randomized controlled trials, and the second is the use of the word ‘cure.’ The second is easier to answer as patients who achieve SVR can relapse years later with genetically identical viruses, suggesting that the virus possibly existed in a latent form inside the body, and so patients who achieve SVR can still progress to end-stage liver disease[169,170]. A certain number of patients with compensated or decompensated cirrhosis show a deterioration of liver function[43,171,172] or display persistent hepatic inflammation or progress to cirrhosis despite SVR[173]. Not only fibrosis or inflammation but also the development of HCC in patients with advanced fibrosis or cirrhosis may continue in the presence of SVR[174,175] and in non-cirrhotic patients with a FIB-4 score ≥ 3.25[176].

In addition, achievement of SVR, characterized as ‘cure,’ has indeed been associated with reduced mortality among cirrhotic patients, but nonetheless it remains higher than general population mortality[146]. Recent reports indicate that HCV patients may also die from liver-related complications even after SVR[154,177]. Likewise, all-cause mortality is still high after SVR in cirrhotic patients[178]. SVR after IFN-based treatment offered no survival benefit after 10 years of follow-up even in the specific group of hemophiliacs[142].

The other question is more difficult to answer, as prospective randomized controlled studies are extremely difficult, if not impossible, to organize in the case of DAAs. The very existence of many confounding factors intervening in the progress and outcome of HCV infection makes the whole project very difficult indeed. Two recent follow-up studies may exemplify the situation. In patients studied for the incidence of HCC, age, gender, cirrhosis and aspartate aminotransferase to platelet ratio index were predictors of HCC in multivariate analysis, while SVR was not[179]. In the same group of patients, diabetes proved to be a significant risk factor for disease progression in certain subgroups of patients without cirrhosis or compensated cirrhosis. Moreover, the absence of SVR was not an important risk factor[180].

A beneficial effect of SVR after DAA treatment on diabetes prevention and the short-term outcome of metabolic alterations has been reported by some studies. A recent review however argued that this effect may not be maintained in the long term, or more importantly this effect may not have any real clinical impact in liver disease[181].

The best conclusions that can be presented so far come from a recent prospective study but not a randomized trial comparing patients who achieve SVR with those that fail. After an extensive adjustment for a large number of variables, administration of DAAs was associated with a decrease in all-cause mortality and HCC but not with decompensated cirrhosis[182].

Data from the extensive Italian RESIST-HCV cohort similarly indicated that in patients with Child-Pugh B cirrhosis, the rate of liver decompensation was not associated with SVR[183]. The need for extensive adjustments in different groups of patients may produce conflicting results. In a different study of patients with HCC from the same group, SVR was also a significant predictor of hepatic decompensation apart from being a predictor of survival and HCC recurrence[184].

SVR was a favorable prognostic marker of fibrosis decrease in a study based on liver elasticity measurements. However, progression of liver stiffness despite viral clearance was observed in 17% of patients[185].

Similarly, despite improvements in MELD score with DAA treatment that allowed the removal of almost a fifth of candidates from the transplantation list, many HCV-infected patients with SVR and decompensated cirrhosis still die or have a liver transplantation[186]. In a longer follow-up of the same delisted patients due to their clinical improvement after DAAs, approximately 4% were either relisted because of disease progression or died due to the development of HCC[187].

In another study of HCV cirrhosis, SVR was associated with an improved MELD score in 37% of patients, but MELD was aggravated in 22% and stayed unchanged in the remaining 41%[38]. These results were verified in another real world study of patients with advanced/decompensated cirrhosis treated with DAAs and a median follow-up of 4 years. After SVR, only marginal improvements in MELD at a clinically meaningful decrease were found in 29% of patients who might still remain at high risk of decompensation[155]. These are examples of SVR use as a surrogate marker of a laboratory index rather than a specific clinical outcome.

Despite the previous reservations as to the use of SVR as a surrogate marker, recent guidelines of the two major liver disease associations equate SVR with successful clinical treatment[89,188]. In accordance to these guidelines, investigators concluded that successful treatment of HCV translates into a significant mortality benefit in a very large study of HCV mono-infected patients without advanced fibrosis. Patients were stratified according to FIB-4 measurements. SVR patients with FIB-4 < 1.45 had a 46% reduction in mortality compared to no SVR patients, while patients with a FIB-4 between 1.45 and 3.25 had a 63.2% reduction in mortality rates. However, data were not based on liver biopsies as a basal stratification point, and this is a serious disadvantage. Another finding is that patients with no SVR die less compared to untreated patients, which is hard to explain[189]. Conversely, SVR was associated with a reduction in fibrosis, but no association of fibrosis with mortality was reported. Finally, since only 14% of patients were re-biopsied, steatosis was not assessed[190].

A review on the reinfection rates after SVR with DAAs clearly states that SVR corresponds to a definitive cure of HCV infection as the incidence of late recurrent viremia is low[61]. This is clearly different from another recent review stating that DAAs have been efficient in curing patients with chronic hepatitis C[191]. A recent report on long-term results of DAAs avoids the words cure and surrogate marker, stating that despite excellent SVR rates there was a considerable overall mortality and liver-related mortality as well as decompensation incidence after 28 mo of follow-up[192]. Even those supporting that SVR has been proven to be associated with reduced liver events and reduced overall mortality cannot support that SVR is a surrogate marker of the clinical cure of the patient[193].

The advent of liver stiffness measurements with the resultant substantial reduction of liver biopsies has not allowed for an accurate estimation of the effects of DAAs in patients with F1-F2 fibrosis. As rightly pointed out in a very recent review, only after long-term follow-up of large real-life cohorts of patients with mild to moderate fibrosis will we be able to confirm the real impact of SVR[194].

A very recent prospective multicenter study of 226 patients with HCV-related cirrhosis and clinically significant portal hypertension has shown that liver stiffness markedly decreased after SVR but did not correlate with hepatic venous pressure gradient changes. Ninety-six weeks after SVR, clinically significant portal hypertension may persist in up to 53%–65% of patients indicating a persistent risk of decompensation[195]. These findings verify previous reports from the same group, also confirmed by other investigators, indicating that hepatic venous pressure gradient measurement is a better prognostic factor than SVR in advanced liver disease[196,197].

The conclusion is that no randomized trials exist so far, and only a few trials are actually prospective. Furthermore, it is clear that a considerable number of liver-related incidents may occur despite SVR. We feel therefore that there is no justification of referring to SVR as a surrogate marker or as an equivalent to clinical cure for HCV patients. SVR should only be used as a favorable prognostic marker or as a marker of viral cure for HCV.

As mentioned before, HCV infection may have a relatively benign outcome without the presence of harmful confounding factors, namely alcohol, metabolic syndrome, HCV/HIV coinfection and liver iron.

**EFFECT OF ALCOHOL CONSUMPTION IN HCV-RELATED FIBROSIS AND CIRRHOSIS**

Earlier studies have shown that the prevalence of HCV is 3-30 times higher in alcoholics than the general population. Alcohol abuse is an independent factor of HCV progression. Advanced fibrosis and higher probability of developing cirrhosis and HCC have been reported for those with heavy alcohol consumption compared with non-drinkers[198-203].

In Dionysos, an extensive study of HCV in the general population in Northern Italy reported an association between alcohol and severity of HCV-associated liver disease. Alcohol consumption higher than 30 g/d aggravated the natural course of the disease significantly[204]. Overall, at least in Western countries, approximately 60% of HCV patients have a past history of alcohol use. Chronic consumption of more than five drinks per day increases the rate of liver fibrosis[205].

Even lower alcohol intake increases HCV viremia and hepatic fibrosis[206]. An interesting report of HCV patients was based on pairs of liver biopsies with a median time of 6.3 years between them. Alcohol consumption during the period between the biopsies was low (median 4.8 g ethanol/d. Deterioration of fibrosis was associated with higher total alcohol intake and higher drinking frequency between the biopsies[207]. The fact that even low amounts of alcohol intake may lead to fibrosis progression has been recently reviewed[208].

An early study of HCV patients with elevated alanine aminotransferase has convincingly demonstrated that these patients had severe fibrosis associated with high alcohol consumption. Interestingly, all 3 patients who had cirrhosis and persistently normal alanine aminotransferase were also heavy drinkers[209]*.* Other studies have also confirmed that total life-time alcohol consumption was independently associated with cirrhosis[210].A large observational study in five European countries confirmed the reports on the detrimental effects of alcohol on liver fibrosis irrespective of differences in biopsy use and preferred scoring systems[211].There was a 2-3-fold greater risk of liver cirrhosis and decompensated liver disease in the alcohol-consuming group. Progression to cirrhosis and decompensation was much faster in alcoholics with HCV compared to non-drinkers[212].A liver biopsy was performed on 86 heavy alcohol drinkers (80 g or more of ethanol/d for at least 10 years) with or without HCV infection. Higher intralobular necrosis and periportal inflammation was found on the liver histology of drinkers. Importantly, the development of cirrhosis was related more to the amount of alcohol intake than to the presence of HCV infection[213].Among 1620 HCV patients, the fraction of cirrhosis attributable to heavy alcohol intake was 36.1% and exceeded 50.0% among those who had engaged in heavy alcohol use at some point. AUDs contributed to approximately 70% of liver-related complications in young and middle-aged adults with HCV infection. An additional 15% was attributed to metabolic syndrome. Importantly, alcohol rehabilitation and abstinence reduced liver complications by 60% and 78%, respectively[214].

In addition to fibrosis and cirrhosis the risk of decompensation is also increased after alcohol. Data suggested that heavy, but not moderate, alcohol intake was associated with a higher risk for hepatic decompensation in patients with cirrhosis than HCV infection was[215], a finding confirmed in a population study of HCV-infected individuals. Age-adjusted decompensated cirrhosis incidence was considerably higher in people with AUDs in British Columbia, New South Wales and Scotland; AUD was present in 28%, 32% and 50% of those with decompensated cirrhosis, respectively[216]. A very recent meta-analysis also verified that alcohol is strongly associated with HCV cirrhosis decompensation. Data from 286641 people with chronic HCV infections, of whom 22.3% with AUDs, showed that AUD diagnosis was associated with a 3.3-fold risk for progression of liver disease. Almost 4 out of 10 decompensated liver cirrhosis cases were attributable to an AUD[217]. Interestingly, similar findings were reported in a very recent study on the effects of alcohol in patients with HBV[218].

The effect of alcohol on response to treatment with DAAs was recently reported*.* The baseline risk factors related to the success of DAAs were studied in 4946 HCV patients. They found that obesity, diabetes and alcohol consumption were associated with persistent liver enzyme elevation after SVR[219].

Earlier research also showed that HCC development increased as a result of the combined effect of alcohol and HCV infection[220]. Alcohol intake was almost universally considered as a critical factor in the still unresolved dispute of HCC occurrence and recurrence after treatment with DAAs[221,222].

Τhe most important aspect of the involvement of alcohol consumption in the natural history of chronic HCV infection is its effect on mortality. Τhe risk of death in HCV patients is increased by 40% if alcohol abuse is also present[223]. HCV patients admitted to the hospital with alcohol-related problems have doubled in-hospital mortality rates[224]. Mortality rate was worst for alcoholic cirrhosis with concomitant HCV even after adjustment for age and gender[225]. In a long-term study of cirrhosis of different etiologies from Sweden, the lowest 10-year transplantation-free survival was found in cryptogenic cirrhosis (11%) and in alcoholic cirrhosis combined with hepatitis C (12%)[226]. The attributable risk of AUDs was 68.8% of 6677 liver deaths of patients infected by HCV. Moreover, liver-related mortality increased faster for individuals with AUDs[214].

The all-cause mortality was 1.9 times higher compared to the general population in patients with HCV followed up for an average of 5.2 years after SVR. Increased mortality was associated with either heavy alcohol use or injection of drugs. Patients without these behavioral markers had equal survival to the general population[146]. Similar findings were also reported in a very recent study from the United States. Survival analysis demonstrated that there was a significant association between unhealthy drinking and lower survival compared with non-drinking[227].

Conclusions are similar when patients with AUDs were evaluated for the effects of the concomitant presence of HCV infection. In a small study of hospitalized alcoholic hepatitis patients, the presence of HCV was a significant risk factor for a poor outcome at 6 mo, even after adjustment for disease severity and treatment[228]. The same group reported that patients with alcoholic hepatitis had a higher prevalence of HCV compared with the general population and that the presence of HCV infection also predicted a higher mortality[229]. In a more recent investigation, the overall mortality rate was significantly higher among HCV-positive alcoholic patients than among HCV-negative patients, and the same was true for their respective liver-related mortality. Survival time for the HCV-infected patients was 34% less[230]. These findings are usually not taken into account in Markov models of cost-effectiveness, and therefore estimates may be exaggerated[86].

Research has focused on the mechanism ofthe synergistic effect of alcohol and HCV in view of the above findings.An increase of apoptotic cell death in hepatocytes of HCV-infected patients has been demonstrated. Apoptosis was further upregulated by active ethanol consumption[231]. Another critical mechanism of HCV-alcohol synergy is the effect both have on innate immunity. Dendritic cells, the critical cell type in antigen presentation, have shown to be a major target for HCV and ethanol with a resultant dysfunction of CD4 and CD8 T cells[232,233]. The common molecular mechanisms of the synergy between alcohol and HCV also include the interference with cytokine production, lipopolysaccharide-TLR4 signaling and reactive oxygen species production. Increased oxidative stress seems to be the dominant mechanism for this synergism between alcohol and HCV[203,234]. Recently, the synergistic effect of alcohol and HCV on alcohol-induced ‘leaky gut’ as well as their effects on miR-122 and immune dysregulation have been investigated[235].

An important mechanism still under intense investigation is autophagy. Both alcohol and HCV infection could induce cellular autophagy in liver cells, a process that is considered to be essential for productive HCV replication. It would seem, at least from experimental studies, that alcohol promotes HCV replication through activation of autophagy[236].

The problem of HCV-alcohol interconnections has been extensively reviewed[237,238].

**HCV AND METABOLIC SYNDROME**

Other factors that might interfere with the outcome of HCV infection are related to metabolic syndrome**.**

Previous reports have indicated that obesity and diabetes occur more frequently in HCV patients. Both conditions result in fatty liver. Steatosis is associated with either metabolic alterations like IR and visceral obesity (metabolic steatosis) or a direct cytopathic effect of the virus mostly genotype 3(viral steatosis),which is strongly related to serum viral load[239-243].

There is evidence that metabolic syndrome is directly linked to HCV infection[244]. Visceral adiposity index is a marker of adipose dysfunction in HCV patients. It is associated with steatosis and necro-inflammatory activity and has a direct correlation with viral load and SVR. In fact, visceral adiposity index represents a measure of the metabolic syndrome[245,246].

There is also indirect evidence connecting metabolic syndrome with HCV. Hyperuricemia is associated with the metabolic syndrome. Its association with HCV infection is additional indirect evidence of their relationship. As expected, body mass index (BMI) is also a factor associated with hyperuricemia in HCV patients[247]. Hyperuricemia has been independently associated with severity of steatosis, indirectly affecting liver damage[248]. There are conflicting recent reports on the effect of DAA treatment on hyperuricemia. Uric acid levels were significantly decreased in chronic HCV patients after viral eradication. The improvement was particularly enhanced in patients with mild liver disease[249]. On the contrary, uric acid levels were moderately increased after HCV eradication in patients with hyperuricemia. Thus, it was considered an adverse effect to DAAs containing ribavirin, potentially leading to side effects such as renal impairment[250]. The reason for this discrepancy is unknown.

Carotid plaques are also an indirect indication of metabolic syndrome, although other pathophysiological mechanisms may be involved. The risk of a person with HCV infection developing carotid plaques is approximately 3.94 times the risk of an uninfected person[251]. More importantly, metabolic syndrome is an independent risk factor of HCV mortality[252,253]. An extensive review on the association between HCV and metabolic syndrome has recently been published[254].

***Obesity-steatosis***

According to the WHO, obesity is an excessive or abnormal accumulation of fat. It has been suggested that this condition is a 21st century pandemic, with a prevalence of 1.9 billion cases worldwide, while almost 40% of the adult population in industrialized countries is overweight[255].

Liver steatosis affects up to 80% of patients with HCV infection[256]. In a recent cross-sectional study, 66% of HCV patients were obese and almost one-third fulfilled the criteria of metabolic syndrome. Of note is the fact that 67% of them were either current or past heavy drinkers[257]. HCV has been closely associated with obesity and steatosis. Obese HCV patients had higher grades of steatosis and advanced fibrosis[258]. Earlier and more recent studies have proven beyond any doubt that obesity, steatosis and liver inflammation are interconnected[240,259-262]. At the same time, the fibrosis progression rate was higher when excessive steatosis was present in the first liver biopsy[263]. The association between steatosis and fibrosis was dependent on a simultaneous association between steatosis and liver inflammation[264].

The association of BMI with steatosis and fibrosis may have important therapeutic implications[265] because weight reduction improved both biochemistry and the Knodell fibrosis score[266]. In the era of IFN-based treatments, obesity and steatosis were associated with reduced SVR[267-271].

***Cirrhosis-HCC***

A recent Swedish population-based study of cirrhosis identified that irrespective of etiology the most common comorbidities at diagnosis were arterial hypertension (33%), type 2 diabetes (T2DM) (29%) and obesity (24%)[272]. The metabolic syndrome and liver stiffness measurements were independent risk factors of HCV progression to cirrhosis[273]. Indirect evidence that cirrhosis in HCV infection is related to metabolic syndrome comes from a prospective study indicating that dysregulation of various metabolic profiles preceded the ultimate development of cirrhosis[274].

There are data connecting the appearance of HCC with components of metabolic syndrome. The risk of HCC in HCV patients increases in proportion to their BMI, from underweight to obese[275]. Individuals with a high BMI (≥ 25.0 kg/m2) accompanied by low triglyceride levels (< 160 mg/dL) had a significantly increased risk for liver cancer related mortality[276]. In the DAA era, increase in HCC incidence after treatment has been associated with higher BMI and cirrhosis[277]. A systematic review demonstrated a significant association between BMI and HCC risk. As expected steatosis was also associated with a higher risk of HCC[278].

In IFN-based treatment, response was diminished in overweight patients without other comorbidities. The group included children and teenagers[279]. This however is not the case with DAAs as reported recently but is worth noting that the separation between obese and non-obese patients was set at a rather high BMI of 30[280].

***Diabetes mellitus and IR***

Several studies have verified that T2DM, IR and hepatic steatosis are highly prevalent in patients with genotype 1 HCV infection[246,278,281-283]. In a large study of 710 patients with a known duration of infection, both overt diabetes and high serum glucose levels were associated with advanced fibrosis and a high fibrosis progression rate independent of alcohol consumption and other risk factors such as the duration of infection[244]. IR was also associated with fibrosis[284]. HOMA-IR was higher in advanced fibrosis than in mild. The number of lipid laden hepatocytes was also higher in cases of advanced fibrosis with increased HOMA-IR and BMI > 25.0 kg/m2[285,286]. IR is associated with HCV infection in up to 80% of cases, and the risk of developing T2DM is twice as high compared to subjects without HCV[287].

Not only is HCV natural course aggravated by diabetes, butHCV infection is a significant risk factor for developing T2DM as well. Spontaneous or treatment-induced HCV clearance may reduce the risk of the onset of T2DM[288].

Another important aspect of the interaction between T2DM and HCV is the association with HCC development. Diabetics with HCV has a 2-3-fold increase in HCC risk[289-291]. Maintenance of glycated hemoglobin level below 7.0% reduced the development of HCC[292]. Diabetes was independently associated with both de novo HCC occurrence and HCC recurrence after DAA treatment[178,293]. A systematic review of seven cohort and two case-control studies has confirmed the significant contribution of T2DM in the development of HCC in HCV-infected patients[278].

The presence of IR or overt diabetes has implications in the treatment of HCV[242] as it adversely affects the response to treatment with IFN-based therapies[294-296]. However, HCV patients who achieved SVR after IFN-based therapy had an improvement of both HOMA-IR and HOMA-b[297]. SVR12 rates are not affected by the presence of T2DM in DAA treated HCV patients[298]. Recent evidence indicates that viral elimination by DAAs improves the increased IR and T2DM incidence by restoring alterations of glucose homeostasis induced by HCV. It should be noted however that IR may persist after SVR, particularly in patients with high BMI[299,300].

HCV patients have an altered serum lipid profile characterized by a reduction of total cholesterol, low‐density lipoproteins and very‐low‐density lipoproteins[301]. Viral eradication with DAAs may have improved HOMA-IR, but serum lipids were increased and the lipid profile worsened in a follow-up study of 24 wk after SVR. BMI did not change in this study[302]. This was not the case in a larger study of 343 HCV patients with the same follow-up. In addition to increased serum cholesterol and low-density lipoprotein cholesterol, an increase in BMI was also observed. Serum glucose, HOMA-IR and HOMA-b were decreased. More importantly, one-third of patients with fasting hyperglycemia normalized serum glucose values, and almost half of diabetics improved glycemic control[303]. A temporary IR increase during treatment with DAAs that went back to normal after treatment was reported, in contrast to lipids that remained increased[304].

In general, HCV steatosis occurs in association with multiple metabolic abnormalities like hyperuricemia, hypocholesterolemia, IR, arterial hypertension and expansion of visceral adipose tissue referred to as “HCV-associated dysmetabolic syndrome” and shares many underlying abnormalities with nonalcoholic liver disease[305].

There are somemechanistic explanations for the aforementioned findings. HCV-associated metabolic steatosis accelerates liver fibrosis progression and development of HCC by inducing liver inflammation and oxidative stress[306]. Both pathways lead to increased fibrosis through induction of the connective tissue growth factor[307,308]. HCV core protein and nonstructural protein 5A are implicated in the disturbance of lipid and glucose pathways that lead to steatosis, lipid abnormalities and metabolic syndrome[309]. Moreover, HCV interferes directly and indirectly with insulin signaling that results in the production of proinflammatory cytokines[310].

**HCV/HIV COINFECTION**

HIV patients are very often coinfected with HCV. Prevalence of coinfection varies in different countries and among different subpopulations like PWID or hemophiliacs[311-313]. HCV/HIV coinfection may interfere with some aspects of HCV natural course[314,315]. HIV antiretroviral therapy (HAART) alonedid not fully correct the adverse effect of HIV infection on HCV progress[316].

***Mortality***

In the HAART era, HCV coinfection increased the risk of mortality compared with HIV mono-infection possibly due to a more rapid progression of HCV in the coinfection group[317].

In a long-term follow-up study of HCV-infected hemophiliacs, HIV coinfected patients were compared to non-HIV patients for mortality after an average of 24 years. The adjusted risk ratio for death was significantly greater among HIV-positive than among HIV-negative patients after adjustment for alcohol use and HAART use was applied, indicating that HIV accelerates HCV disease progression[318]. Failure to clear HCV led from rapid progression to decompensation in HCV/HIV coinfected patients[319]. These findings were confirmed as HCV infection was independently associated with all-cause and liver-related mortality in HIV patients with alcohol problems, even when adjusting for alcohol and other drug use[320]. In a very large retrospective study, a higher mortality of HCV/HIV coinfection compared to HCV mono-infection was reported. Moreover, the presence of HCV cirrhosis or complications from it were associated with four times greater mortality risk in HIV patients[321]. A very recent study of people living with HIV (PLWH) and of those injecting drugs demonstrated the highest odds of HCV-positivity, which was an independent predictor of greater mortality[322].

An individual-based model of disease progression in HIV/HCV coinfected MSM has been developed. There was a gradual increase of liver-related deaths according to fibrosis state and the time treatment was initiated. Two percent of treated patients would die if treatment was initiated at stage F0 and 22% if treatment was deferred until F4. Similar gradual mortality increments were associated with the length of time individuals replicate HCV[323].

HCC development is associated with increased HCV mortality rates. Older age, cirrhosis and low current CD4 cell count were associated with a higher incidence of HCC in HCV/HIV coinfection[324,325]. Furthermore, a recent prospective study demonstrated that HCV/HIV patients with compensated cirrhosis have similar risks for further end-stage liver disease and HCC with HCV mono-infected patients[15] provided they receive both HAART and DAA treatment[326].

***Fibrosis***

In the pre-DAA era, many studies based on paired liver biopsies demonstrated that hepatic fibrosis progressed more rapidly in HCV/HIV coinfection than in HCV mono-infected patients even after adjustment for alcohol consumption or duration of HCV infection[327-331]. In a retrospective cohort study focusing on a PWID group of patients, HIV coinfection worsened the outcome of chronic HCV infection, increasing liver damage and decreasing sustained SVR after IFN therapy. Age and alcohol were cofactors associated with cirrhosis and mortality[332]. Fibrosis progressed in a significant number of HCV/HIV coinfected patients even after DAA-induced SVR[333].

Not all studies agree with the above findings. After adjustment for daily alcohol use, HIV patients with HCV coinfection and BMI greater than 25 kg/m2 had equal liver fibrosis to those without HIV but at an average onset of 9.2 years earlier[334]. Hepatic steatosis increased faster and was associated with fibrosis progression only in HIV mono-infected patients but not in HIV/HCV coinfected ones. Diagnosis was based on liver stiffness measurements for fibrosis and controlled attenuation parameter for steatosis without histological documentation[335]. Histological abnormalities were usually significantly milder in HCV/HIV coinfection with persistently normal alanine aminotransferase levels than those found in patients with high alanine aminotransferase, but this was not always the case as patients with persistently normal alanine aminotransferase levels also developed significant fibrosis[336].

The risk of advanced fibrosis increased at high levels of alcohol consumption[337]. In this group of patients even low alcohol consumption was associated with advanced hepatic fibrosis[338]. The impact of alcohol was recently verified. HIV/HCV coinfected patients had a higher prevalence of intermediate and advanced liver disease markers than HIV mono-infected patients. Advanced markers of liver disease were strongly connected to hazardous drinking for both men and women[339].

Genetic factors are also involved. Cirrhosis was more prevalent in IL28B CC genotype HCV/HIV infected patients than in patients with CT/TT genotypes, possibly indicating that IL28B CC carriers have a more rapid progression of HCV-related fibrosis[340].

A number of studies have reported on the achievement of SVR in either observational studies or clinical trials, and the results were conflicting. A statistically significant difference in SVR12 response was observed between HCV mono-infection and HCV/HIV coinfection after DAAs (94% and 84%, respectively)[341]. HCV/HIV coinfection response to DAAs was worse (86%) compared to HCV mono-infection (95%). This was possibly due to a higher rate of relapses among HCV/HIV coinfected subjects[342].

A high SVR12 was similar in a review of 11 real-world observational studies (90.8%) and 8 clinical trials (93.1%). There was no control group of HCV-mono-infection[343]. A recent multicenter study of SOF/DCV from Brazil showed an SVR12 rate of 92.8% in an intention-to-treat analysis. There was no comparison with HCV mono-infected patients[344]. A similar SVR12 of 94% was reported in a retrospective study from the United States. Substance abuse and diabetes, but not obesity, had a negative effect on treatment[345]. Importantly, a recent paper stressed the fact that both adherence to HAART treatment and alcohol consumption should be carefully monitored in this group of patients. Furthermore, higher alcohol consumption per day was positively associated with HAART non-adherence[346]. Interestingly, high coffee intake is probably associated with reduced liver fibrosis even in HCV/HIV coinfected patients with high alcohol abuse[347].

Clinical consequences after successful treatment with IFN-free regimens are limited. A Spanish group reported that successful SVR in HCV/HIV coinfected patients led to the same probability of liver complications with HCV mono-infection after a median follow-up of 21 mo[348]. In addition, the same group reported that only successful SVR patients with > 14 kPa on liver stiffness measurement are among the few who develop a liver-related complication[349].

Strangely enough, HCV/HIV coinfected patients had a lower risk of HCC development compared to HCV-mono-infection after successful SVR in a follow-up study from the same group. This is hard to explain particularly because alcohol consumption and diabetes were the same, and the HIV-positive group included significantly more PWID[350]. This is in slight disagreement with another study where HCV/HIV coinfected patients had a greater mortality risk and a similar risk of HCC development indicating that DAAs do not produce complete resolution of inflammatory and profibrogenic stimuli[326].

Similar SVR rates, as well as risk of liver-related deaths and events, were also reported between HCV-mono-infected and HCV/HIV coinfected individuals, but a higher risk of all-cause and non-liver related cancers were observed in HIV coinfected patients[351].

There are some mechanistic explanations to account for the discrepancies mentioned before. An opposite effect between HCV mono-infected and HCV/HIV coinfected patients was observed after an increase in HCV viral load and CD4+ T cell count. HCV viral load in HAART-treated patients was associated with greater natural killer cell dysfunction than the same HCV viral load alone in HCV mono-infection. This may influence HCV disease progression in these patients[352]. Advanced liver fibrosis in coinfected individuals is associated with reduced numbers and a defective function of natural killer cells, along with an increased expression of the exhaustion/senescence marker PD-1[353]. In addition, HIV-positive patients have a persistent CD4+ T cell depletion in the gut, which increases gut permeability. A greater microbe translocation leads Kupffer cells to produce more proinflammatory and profibrotic cytokines[354].

Despite differences, it seems that coinfected patients have a higher mortality risk compared to HCV mono-infected patients even after DAA administration. This implies the existence of unique pathways that continue to promote accelerated liver disease in these patients compared with those with HCV mono-infection. An article on the pathobiology of liver disease in HCV-HIV coinfection in the DAA era was very recently published[355].

There are some recent reports addressing the final question that needs to be answered: can we eliminate HCV/HIV in the real world?

A model analysis from Spainshowed that screening and treating all PLWH every year from 2020 onwards would probably lead to an increase of the number of new HCV infections among PLWH by 28% as the majority belong to the PWID and MSM groups with ongoing infection and reinfection. As for the general population, only a reduction of new HCV infections by 39% will be achieved by 2030[356].

A program of HCV elimination among PLWH has been reported from Scotland. As in Spain, the most common mode of HCV transmission was injection of drugs. DAAs increased the number of treated patients and produced higher SVR12 results compared to pegylated IFN. However, the number of the patients involved was small[357]. Rather disappointing results came from Austria where despite the fact that HCV testing was successful in the Viennese HIV-positive patients, HCV prevalence was stable in HIV-positive PWIDs and even doubled in HIV-positive MSMs. New HCV infections occurred mostly in MSM and HCV, while reinfections were mostly observed in PWIDs. HCV treatment adherence was not adequate since 42.8% remained HCV-RNA positive at follow-up[358].

The last findings lead to the problem of PWIDs. Can we eliminate HCV in PWIDs in the real world?

Efforts to reach PWIDs are unsuccessful in many countries. Better organized interventions are urgently needed since additional factors, like HIV infection and alcohol abuse that contribute to the progress of fibrosis, are commonly involved[359,360]. This is exemplified by a longitudinal study of 501 patients from an opioid agonist therapy program. Prevalence of HCV and HIV infection was 70% and 34%, respectively. Almost half of those infected with HCV used alcohol, cannabis and cocaine. Current drug use was a strong independent risk factor for not receiving treatment against HCV[361]. Treatment costs and reduced treatment uptake are additional prohibitive factors. Screening and treatment for high-risk populations like PWIDs and MSMs are considered cost-effective in high-income countries, but DAAs remain expensive and a barrier worldwide despite lower prices in many of the low-income countries. Although universal DAA availability led to a 50% reduction in acute HCV incidence among HIV + MSM in the Netherlands, this cannot be achieved in low-income countries. Close monitoring for HCV reinfection, harm reduction and behavioral interventions are also required among others[35]. In a large French study of 27127 individuals, DAA treatment uptake was still lower in women despite an increased uptake after DAA introduction compared with IFN[362]. Alcohol, HIV and PWID interactions were extensively reviewed[363].

Frequent testing has been suggested as a means to achieve HCV elimination in PWIDs. If the prevalence of HCV approaches 75% or more, like it does in Indonesia, Iran, Italy, Malaysia, Mexico and Pakistan[364], it is possible that even a frequency of one HCV test every 3 mo would not contribute to major reductions in incidence[365]. In low-middle income countries the situation would be much worse.

HCV-infected PWIDs may achieve high SVR12 rates with DAAs, but their response rates are lower compared to patients who have never used drugs. This is because they are more frequently lost to follow-up[366]. This was verified in an Austrian study where GLE/PIB was administered under direct observation by doctors as part of an opioid substitution therapy. Similar high SVR rates (94.6%) as in patients with excellent compliance were obtained[367].

Left untreated, PWIDs with chronic HCV infection will develop serious liver disease (including HCC) in mid to late adulthood. Models estimate the average time to cirrhosis to be between 36 years and 46 years after infection[135]. Strangely enough, a notable exception was the reported lower incidence of HCC in users of illicit drugs. In fact, while cirrhosis, male gender and diabetes are risk factors for HCC development in both SVR and non-SVR patients, the use of illicit drugs seemed to be a protective factor in both SVR and non-SVR patients. Moreover, despite the fact that HCC incidence after IFN treatment was significantly less in SVR patients, deaths were twice more frequent after SVR compared with non-SVR (4.9% *vs* 2.0%)[368].

Reinfection is another serious problem in this group of patients. Reinfection rates were higher among recent and former PWIDs than among non-PWIDs. Among recent PWIDs, reinfection rates were higher among those born after 1975 and those coinfected with HIV[369]. These findings are in agreement with a previous study where higher reinfection risk was found in HIV coinfection and PWID. Both opioid-substitution therapy and engagement with mental health counselling services were negatively associated with risk of reinfection[63]. An analysis of reinfection rates in PWIDs from seven middle-income countries was recently reported. The follow-up time from cure to reinfection ranged from 12 wk to 6.6 years. The pooled reinfection rate was 2.8 cases/100 person-years that dropped to 1 case/100 person-years when differentiation between relapse and reinfection was feasible[370].

**HCV AND IRON**

The presence of iron in the liver may interfere with the natural course of HCV infection.Chimpanzees on high iron diets had histological abnormalities only if coinfected with HCV[371].Minor increases in iron stores in heterozygous carriers of C282Y or H63D mutations for hemochromatosis are associated with more fibrosis in chronic HCV[372,373].HCV patients have low serum hepcidin levels, a fact leading to enhanced necro-inflammation and fibrosis[374].Increased serum aminotransferases were found only in HCV patients with stainable iron in the Kupffer cells but not in those with hepatocyte iron[375].Genotype 3-infected patients had more frequently elevated liver iron, and this condition was related to viral-induced hepatic steatosis[376].

Thalassemia patients coinfected with HCV prove that iron is indeed harmful. Liver iron overload affects the prognosis of liver disease negatively, leading to severe hepatic inflammation and fibrosis[377].

Some studies however do not support the linkage between advanced fibrosis and increased iron in hepatocytes[378]. Iron overload was not common in HCV patients, and hepatic-iron content was not related to the liver damage process[379]. Others reported that the presence of high serum ferritin and stainable liver iron had no significant role in the progression of liver disease[380].

Whatever the differences may have been, there is a uniform agreement that liver iron stores adversely affect the response to IFN-based treatments[381-383]. This is not the case with DAAs. Thus, in IFN-treated patients, ferritin levels increased 24 wk after treatment regardless of SVR. Ferritin levels decreased at about 3 years post-treatment. Conversely, among DAA-treated SVR patients, ferritin levels were permanently decreased and remained stable thereafter[384]. Now that treatment with DAAs seems to be effective, achieving SVR 90%-98% irrespective of iron status, long-term follow-up studies will delineate the role of iron and HCV in the progress of liver disease[385-388].

Many studies have addressed the reasons for iron overload in certain patients with HCV as well as the possible detrimental effect it may have on the disease progress. A possible direct mechanism for iron overload has been proposed based on experiments in transgenic mice harboring the HCV polyprotein. The presence of HCV proteins led to reduced hepcidin transcription and increased ferroportin expression, leading to hepatic iron accumulation[389]. Another explanation is that extravascular hemolysis may play a role in the development of secondary iron overload since alterations in red blood cell indices indicate hemolysis in end-stage liver disease[390].Some studies found that iron favors HCV replication and more specifically HCV translation due to increased expression of factors involved with HCV internal ribosome entry sites[391]. Alternatively, HCV alters expression of the iron uptake receptor transferrin receptor 1. Transferrin receptor 1 is possibly involved in HCV particle internalization at the level of glycoprotein-mediated entry[392,393]. Increased iron can feed the Fenton reaction to produce excess amounts of free radicals that cause serious cellular and tissue damage and contribute to fibrosis[394].

As a general rule, intracellular iron overload, induced by upregulation of hepcidin, promotes the progression of viral infections[395]. Seemingly, HCV infections represent a peculiar exception with a downregulation of hepcidin, which following antiviral therapy is then upregulated again[374,396]. Low levels of hepcidin have been attributed to reactive oxygen species-mediated decrease in *HAMP* gene expression. On the other hand, HCV-driven inflammation may counteract reactive oxygen species-induced hepcidin reduction, as elevated IL-6 stimulates *HAMP* gene transcription. Details have been presented in an extensive review[397].

An additional, mechanistic explanation of the role of iron in HCV viral persistence has been reported. HCV may or may not upregulate *HAMP* gene expression and hepcidin levels depending on infection acuteness and viral load. Enhanced hepcidin expression led to enhanced HCV translation and replication. Apart from intracellular iron sequestration through hepcidin, an intercellular mobilization of iron through ferritin was also required for efficient viral replication[398]. A recent review emphasized the role of low levels of hepcidin in various liver diseases, including HCV, as hepcidin is further implicated in both iron deposition in hepatocytes and participation in stellate cell activation and liver fibrosis[399].

Recently, ferroptosis has been investigated as a type of non-apoptotic cell death in different pathological conditions, including viral hepatitis. The molecular hallmark of ferroptosis is iron-driven lipid peroxidation that interacts with cellular antioxidant systems and may play a critical role in HCV’s natural course[400].

However, other studies reported opposing results stating that supra-physiological, intracellular iron damages HCV. A knockdown of hepcidin increased intracellular ferritin and inhibited HCV replication[401]. A recent review argued that iron overload is weakly fibrogenic in experimental animals, rarely causing serious liver damage in patients and only if its action is potentiated by a coexisting inflammation. However, this is exactly the situation in HCV-iron coexistence[402].

**WHO REALLY NEEDS TREATMENT: THE PROPOSED POLICY**

There are two reasons for a global elimination of HCV. The most important is to prevent the progression to cirrhosis, then to HCC and finally to death. Once cirrhosis has been developed, these objectives are no longer feasible as both HCC and all-mortality continue despite treatment with DAAs[403,404]. An additional reason for treating HCV infection is that even subjects with a low progression of disease are still capable of transmitting HCV, a problem of major interest for PWIDs and MSMs but also for hemodialysis patients or health care employees performing invasive procedures. As previously detailed, comorbidities such as diabetes, obesity, metabolic syndrome and alcohol consumption may play a critical role in the outcome of liver disease in SVR patients without cirrhosis[405] (Table 2).

We live in the severe acute respiratory syndrome coronavirus 2 era. All cost-effectiveness studies are based on Markov models. Such mathematical models, however accurate they may be, rely on various assumptions that may or may not be true, like the real mortality of HCV or the real outcome of HCV cirrhosis. In fact, the accepted cost of quality-adjusted life-years may be seriously reconsidered in many countries in view of the COVID-19 pandemic.

Since it is very doubtful that screening and treatment programs will be feasible even in high-income countries, the idea of micro-elimination programs has been proposed. A micro-elimination program is a concept that breaks down the national elimination targets into easier-to-accomplish, smaller tasks[406]. So far, there have been programs applied to either special populations or to small, geographically-restricted communities. Currently successful efforts are being made in Egypt[407,408]where a follow-up study of 2.4 years after the first evaluation with a re-test of the initially non-infected individuals demonstrated a significant reduction in the incidence of new cases of HCV infection. Infections through surgery or dental procedures were independent predictors of incident new cases[409].A different approach was reported from the United States. They estimated cost effectiveness comparing screening programs targeting PWIDs with the universal screening of United States adults. They concluded that HCV screening for PWIDs could potentially decrease the risk of untreated HCV infection and liver-related mortality and may thus be cost effective[410].

New tools must be developed to implement micro-elimination. This is obviously harder in high-prevalence, low-income countries than in Western countries[411]. One of the most difficult parts of such a program would be to engage as many patients as possible in alcohol abuse treatment programs provided by liver clinics. It should also be kept in mind that successful abstinence will be limited to a minority of those treated anyway[412].

Current literature, as detailed above, has clearly identified certain subpopulations that should definitely be treated as they are prone to develop cirrhosis or HCC and may therefore have increased mortality. On the other hand, prospective studies have shown that HCV infection without an additional confounding factor will have very limited consequences. Even cirrhotic patients have a much better survival rate compared to those with cirrhosis of other etiologies. Present data allow for the proposition of a different micro-elimination program based on groups that are likely to either progress towards cirrhosis or are at risk of reinfection.

We believe that screening and treatment should be reserved only for people with AUDs, obesity or other aspects of metabolic syndrome, compromised immune system including HIV coinfection, cancer and hemodialysis patients and cirrhosis patients. Additional groups should include PWID, MSM, hemophiliacs and thalassemia patients. These are the groups that should be treated with DAAs, not necessarily those DAAs recommended by the EASL or the American Association for the Study of Liver Diseases.

Approaching these subpopulations is easier compared with approaching the entirety of the general population and obviously more cost-effective in every country irrespective of income. The proposition remains valid even after the development of an effective vaccine as these are the groups that should be vaccinated to avoid waste of valuable resources.

**CONCLUSION**

It is highly unlikely that the WHO target will be achieved by 2030, as among other reasons, there is only one known example of a chronic human infection that is near eradication in the absence of a vaccine: yaws, caused by *Treponema pallidum pertenue*, a spirochete bacterium. However, this disease is geographically localized and can be effectively treated with conventional inexpensive antibiotics[413].

The ambitious WHO goal can be achieved only after the development of a highly efficient, low-cost vaccine or by treating all carriers of HCV with DAAs. Both however are unlikely to be achieved in the foreseeable future, particularly in the era of the severe acute respiratory syndrome coronavirus 2 pandemic. Moreover, HCV is a disease with two main characteristics. First, its transmission is difficult since sexual transmission is negligible. Second, the deadly consequences are not frequent and take a very long time to appear even after cirrhosis development.

On the other hand, practically all studies indicate that in the vast majority of patients cirrhosis is associated with one or more of the following: alcohol, the presence of metabolic syndrome (including obesity, diabetes, IR and hyperuricemia), intravenous drug use or immune compromise (including HIV coinfection).

A micro-elimination program should therefore be implemented focusing on screening and treatment of people who belong to the above high-risk groups. Such a program may altogether eradicate morbidity and mortality of HCV even in the COVID-19 era. This program can still be used after any future vaccine development.

**REFERENCES**

1 **Smith DB**, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. *Hepatology* 2014; **59**: 318-327 [PMID: 24115039 DOI: 10.1002/hep.26744]

2 **Forns X**, Purcell RH, Bukh J. Quasispecies in viral persistence and pathogenesis of hepatitis C virus. *Trends Microbiol* 1999; **7**: 402-410 [PMID: 10498948 DOI: 10.1016/s0966-842x(99)01590-5]

3 **Farci P**, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. *Science* 2000; **288**: 339-344 [PMID: 10764648 DOI: 10.1126/science.288.5464.339]

4 **Pierce BG**, Keck ZY, Foung SK. Viral evasion and challenges of hepatitis C virus vaccine development. *Curr Opin Virol* 2016; **20**: 55-63 [PMID: 27657659 DOI: 10.1016/j.coviro.2016.09.004]

5 **Tsukiyama-Kohara K**, Kohara M. Hepatitis C Virus: Viral Quasispecies and Genotypes. *Int J Mol Sci* 2017; **19** [PMID: 29271914 DOI: 10.3390/ijms19010023]

6 **World Health Organization**. WHO Fact sheets Hepatitis C. [cited 4 May 2020]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c

7 **Zibbell JE**, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, Holtzman D. Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014. *Am J Public Health* 2018; **108**: 175-181 [PMID: 29267061 DOI: 10.2105/AJPH.2017.304132]

8 **Chhatwal J**, Sussman NL. Universal Screening for Hepatitis C: An Important Step in Virus Elimination. *Clin Gastroenterol Hepatol* 2019; **17**: 835-837 [PMID: 30528843 DOI: 10.1016/j.cgh.2018.12.002]

9 **Kandeel AM**, Talaat M, Afifi SA, El-Sayed NM, Abdel Fadeel MA, Hajjeh RA, Mahoney FJ. Case control study to identify risk factors for acute hepatitis C virus infection in Egypt. *BMC Infect Dis* 2012; **12**: 294 [PMID: 23145873 DOI: 10.1186/1471-2334-12-294]

10 **Kouyoumjian SP**, Chemaitelly H, Abu-Raddad LJ. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. *Sci Rep* 2018; **8**: 1661 [PMID: 29374178 DOI: 10.1038/s41598-017-17936-4]

11 **Omar MZ**, Metwally MA, El-Feky HM, Ahmed IA, Ismail MA, Idris A. Role of intrafamilial transmission in high prevalence of hepatitis C virus in Egypt. *Hepat Med* 2017; **9**: 27-33 [PMID: 28652827 DOI: 10.2147/HMER.S129681]

12 **Lionis C**, Vlachonikolis IG, Skliros S, Symeonidis A, Merkouris BP, Kouroumalis E. Do undefined sources of hepatitis C transmission exist? The Greek study in General Practice. *J Viral Hepat* 2000; **7**: 218-224 [PMID: 10849264 DOI: 10.1046/j.1365-2893.2000.00217.x]

13 **Wu J**, Zhou Y, Fu X, Deng M, Zheng Y, Tian G, Li Y, Wang C, Ding C, Ruan B, Yang S, Li L. The Burden of Chronic Hepatitis C in China From 2004 to 2050: An Individual-Based Modeling Study. *Hepatology* 2019; **69**: 1442-1452 [PMID: 30561833 DOI: 10.1002/hep.30476]

14 **Hatzakis A**, Lazarus JV, Cholongitas E, Baptista-Leite R, Boucher C, Busoi CS, Deuffic-Burban S, Chhatwal J, Esmat G, Hutchinson S, Malliori MM, Maticic M, Mozalevskis A, Negro F, Papandreou GA, Papatheodoridis GV, Peck-Radosavljevic M, Razavi H, Reic T, Schatz E, Tozun N, Younossi Z, Manns MP. Securing sustainable funding for viral hepatitis elimination plans. *Liver Int* 2020; **40**: 260-270 [PMID: 31808281 DOI: 10.1111/liv.14282]

15 **World Health Organization**. Draft global health sector strategies. Viral hepatitis. [cited 4 May 2020]. Available from: http://apps.who.int/gb/ebwha/pdf\_files/WHA69/A6 9\_32-en.pdf?ua=1

16 **Cox AL**. Medicine. Global control of hepatitis C virus. *Science* 2015; **349**: 790-791 [PMID: 26293940 DOI: 10.1126/science.aad1302]

17 **Calvaruso V**, Petta S, Craxì A. Is global elimination of HCV realistic? *Liver Int* 2018; **38 Suppl 1**: 40-46 [PMID: 29427499 DOI: 10.1111/liv.13668]

18 **Spearman CW**, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. *Lancet* 2019; **394**: 1451-1466 [PMID: 31631857 DOI: 10.1016/S0140-6736(19)32320-7]

19 **Razavi H,** Sanchez Y, Pangerl A, Cornberg M. Global timing of hepatitis C virus elimination: Estimating the year countries will achieve the World Health Organization elimination targets. *J Hepatol* 2019; **70** Suppl 1: e748 [DOI:10.1016/S0618-8278(19)31493-8]

20 **Sulkowski M**, Cheng WH, Marx S, Sanchez Gonzalez Y, Strezewski J, Reau N. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis C. *Adv Ther* 2021; **38**: 423-440 [PMID: 33145648 DOI: 10.1007/s12325-020-01535-3]

21 **Popping S**, Bade D, Boucher C, van der Valk M, El-Sayed M, Sigurour O, Sypsa V, Morgan T, Gamkrelidze A, Mukabatsinda C, Deuffic-Burban S, Ninburg M, Feld J, Hellard M, Ward J. The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. *J Virus Erad* 2019; **5**: 60-66 [PMID: 30800429]

22 **Umutesi G**, Shumbusho F, Kateera F, Serumondo J, Kabahizi J, Musabeyezu E, Ngwije A, Gupta N, Nsanzimana S. Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa. *J Hepatol* 2019; **70**: 1043-1045 [PMID: 30948269 DOI: 10.1016/j.jhep.2019.03.011]

23 **Feld JJ**. HCV elimination: It will take a village and then some. *J Hepatol* 2020; **72**: 601-603 [PMID: 32057492 DOI: 10.1016/j.jhep.2020.01.002]

24 **Blach S**, Kondili LA, Aghemo A, Cai Z, Dugan E, Estes C, Gamkrelidze I, Ma S, Pawlotsky JM, Razavi-Shearer D, Razavi H, Waked I, Zeuzem S, Craxi A. Impact of COVID-19 on global HCV elimination efforts. *J Hepatol* 2021; **74**: 31-36 [PMID: 32777322 DOI: 10.1016/j.jhep.2020.07.042]

25 **Roingeard P**, Beaumont E. Hepatitis C Vaccine: 10 Good Reasons for Continuing. *Hepatology* 2020; **71**: 1845-1850 [PMID: 32060946 DOI: 10.1002/hep.31182]

26 **Sepulveda-Crespo D**, Resino S, Martinez I. Hepatitis C virus vaccine design: focus on the humoral immune response. *J Biomed Sci* 2020; **27**: 78 [PMID: 32631318 DOI: 10.1186/s12929-020-00669-4]

27 **Holmberg SD**, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. *N Engl J Med* 2013; **368**: 1859-1861 [PMID: 23675657 DOI: 10.1056/NEJMp1302973]

28 **Kim NG**, Kullar R, Khalil H, Saab S. Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics. *J Viral Hepat* 2020; **27**: 762-769 [PMID: 32386099 DOI: 10.1111/jvh.13317]

29 **Tordrup D**, Hutin Y, Stenberg K, Lauer JA, Hutton DW, Toy M, Scott N, Bulterys M, Ball A, Hirnschall G. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30. *Lancet Glob Health* 2019; **7**: e1180-e1188 [PMID: 31353061 DOI: 10.1016/S2214-109X(19)30272-4]

30 **Rodríguez-Tajes S**, Pocurull A, Castillo J, Casanova G, Vega L, Lens S, Mariño Z, Londoño MC, Forner A, Torres F, Forns X. Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. *J Hepatol* 2020; **73**: 1360-1367 [PMID: 32697948 DOI: 10.1016/j.jhep.2020.07.018]

31 **Hill AM**, Nath S, Simmons B. The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries. *J Virus Erad* 2017; **3**: 117-123 [PMID: 28758018]

32 **Heffernan A**, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. *Lancet* 2019; **393**: 1319-1329 [PMID: 30704789 DOI: 10.1016/S0140-6736(18)32277-3]

33 **Chhatwal J**, Chen Q, Wang X, Ayer T, Zhuo Y, Janjua NZ, Kanwal F. Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan. *JAMA Netw Open* 2019; **2**: e193613 [PMID: 31074817 DOI: 10.1001/jamanetworkopen.2019.3613]

34 **Matičič M**, Lombardi A, Mondelli MU, Colombo M; ESCMID Study Group for Viral Hepatitis (ESGVH). Elimination of hepatitis C in Europe: can WHO targets be achieved? *Clin Microbiol Infect* 2020; **26**: 818-823 [PMID: 31978546 DOI: 10.1016/j.cmi.2020.01.014]

35 **Martin NK**, Boerekamps A, Hill AM, Rijnders BJA. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it? *J Int AIDS Soc* 2018; **21** Suppl 2: e25062 [PMID: 29633560 DOI: 10.1002/jia2.25062]

36 **Di Maio VC**, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. *Liver Int* 2017; **37**: 514-528 [PMID: 28105744 DOI: 10.1111/liv.13327]

37 **Ji F**, Yeo YH, Wei MT, Ogawa E, Enomoto M, Lee DH, Iio E, Lubel J, Wang W, Wei B, Ide T, Preda CM, Conti F, Minami T, Bielen R, Sezaki H, Barone M, Kolly P, Chu PS, Virlogeux V, Eurich D, Henry L, Bass MB, Kanai T, Dang S, Li Z, Dufour JF, Zoulim F, Andreone P, Cheung RC, Tanaka Y, Furusyo N, Toyoda H, Tamori A, Nguyen MH. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. *J Hepatol* 2019; **71**: 473-485 [PMID: 31096005 DOI: 10.1016/j.jhep.2019.04.017]

38 **Steinebrunner N**, Stein K, Sandig C, Bruckner T, Stremmel W, Pathil A. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort. *World J Gastroenterol* 2018; **24**: 852-861 [PMID: 29467555 DOI: 10.3748/wjg.v24.i7.852]

39 **Valerio H**, Alavi M, Law M, Tillakeratne S, Amin J, Janjua NZ, Krajden M, George J, Matthews GV, Hajarizadeh B, Degenhardt L, Grebely J, Dore GJ. High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia. *J Hepatol* 2021; **74**: 293-302 [PMID: 32931879 DOI: 10.1016/j.jhep.2020.08.038]

40 **Barré T**, Marcellin F, Di Beo V, Delorme J, Rojas Rojas T, Mathurin P, Protopopescu C, Bailly F, Coste M, Authier N, Carrieri MP, Rolland B. Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study). *Addiction* 2020; **115**: 573-582 [PMID: 31595554 DOI: 10.1111/add.14820]

41 **Laskus T**, Wilkinson J, Gallegos-Orozco JF, Radkowski M, Adair DM, Nowicki M, Operskalski E, Buskell Z, Seeff LB, Vargas H, Rakela J. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. *Gastroenterology* 2004; **127**: 764-776 [PMID: 15362033 DOI: 10.1053/j.gastro.2004.06.005]

42 **Pawlotsky JM**. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. *Gastroenterology* 2016; **151**: 70-86 [PMID: 27080301 DOI: 10.1053/j.gastro.2016.04.003]

43 **Curry MP**, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RS Jr, Charlton M; ASTRAL-4 Investigators. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. *N Engl J Med* 2015; **373**: 2618-2628 [PMID: 26569658 DOI: 10.1056/NEJMoa1512614]

44 **Wei L**, Lim SG, Xie Q, Văn KN, Piratvisuth T, Huang Y, Wu S, Xu M, Tang H, Cheng J, Le Manh H, Gao Y, Mou Z, Sobhonslidsuk A, Dou X, Thongsawat S, Nan Y, Tan CK, Ning Q, Tee HP, Mao Y, Stamm LM, Lu S, Dvory-Sobol H, Mo H, Brainard DM, Yang YF, Dao L, Wang GQ, Tanwandee T, Hu P, Tangkijvanich P, Zhang L, Gao ZL, Lin F, Le TTP, Shang J, Gong G, Li J, Su M, Duan Z, Mohamed R, Hou JL, Jia J. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. *Lancet Gastroenterol Hepatol* 2019; **4**: 127-134 [PMID: 30555048 DOI: 10.1016/S2468-1253(18)30343-1]

45 **Li DK**, Chung RT. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. *Methods Mol Biol* 2019; **1911**: 3-32 [PMID: 30593615 DOI: 10.1007/978-1-4939-8976-8\_1]

46 **Smith D**, Magri A, Bonsall D, Ip CLC, Trebes A, Brown A, Piazza P, Bowden R, Nguyen D, Ansari MA, Simmonds P, Barnes E; STOP-HCV Consortium. Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. *Hepatology* 2019; **69**: 1861-1872 [PMID: 29425396 DOI: 10.1002/hep.29837]

47 **Fourati S**, Rodriguez C, Hézode C, Soulier A, Ruiz I, Poiteau L, Chevaliez S, Pawlotsky JM. Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r. *Hepatology* 2019; **69**: 513-523 [PMID: 30125371 DOI: 10.1002/hep.30225]

48 **Gupta N**, Mbituyumuremyi A, Kabahizi J, Ntaganda F, Muvunyi CM, Shumbusho F, Musabeyezu E, Mukabatsinda C, Ntirenganya C, Van Nuil JI, Kateera F, Camus G, Damascene MJ, Nsanzimana S, Mukherjee J, Grant PM. Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial. *Lancet Gastroenterol Hepatol* 2019; **4**: 119-126 [PMID: 30552056 DOI: 10.1016/S2468-1253(18)30382-0]

49 **Nguyen D**, Smith D, Vaughan-Jackson A, Magri A; STOP-HCV Consortium, Barnes E, Simmonds P. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. *J Hepatol* 2020; **73**: 794-799 [PMID: 32470499 DOI: 10.1016/j.jhep.2020.05.029]

50 **Childs K**, Davis C, Cannon M, Montague S, Filipe A, Tong L, Simmonds P, Smith D, Thomson EC, Dusheiko G, Agarwal K. Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C. *J Hepatol* 2019; **71**: 1099-1105 [PMID: 31400349 DOI: 10.1016/j.jhep.2019.07.025]

51 **Pawlotsky JM**. DAA failures in African patients with "unusual" HCV subtypes: Hey! Didn't you know there was another world? *J Hepatol* 2019; **71**: 1070-1072 [PMID: 31648816 DOI: 10.1016/j.jhep.2019.09.021]

52 **Pawlotsky JM**. About the absolute need to keep active research on the efficacy of direct-acting antiviral drugs against the hepatitis C virus. *J Hepatol* 2020; **73**: 752-754 [PMID: 32732060 DOI: 10.1016/j.jhep.2020.06.029]

53 **Austria A**, Wu GY. Occult Hepatitis C Virus Infection: A Review. *J Clin Transl Hepatol* 2018; **6**: 155-160 [PMID: 29951360 DOI: 10.14218/JCTH.2017.00053]

54 **Jamshidi S**, Bokharaei-Salim F, Esghaei M, Bastani MN, Garshasbi S, Chavoshpour S, Dehghani-Dehej F, Fakhim S, Khanaliha K. Occult HCV and occult HBV coinfection in Iranian human immunodeficiency virus-infected individuals. *J Med Virol* 2020 [PMID: 32232978 DOI: 10.1002/jmv.25808]

55 **Lotfi AA**, Mohamed AE, Shalaby NA, Eissa DS, El-Dabaa E, Sallam AM, Kamel MM, Abdelaziz H, El-Afifi AM, Abdel-Moneim AS. Occult hepatitis C virus infection in patients with malignant lymphoproliferative disorders. *Int J Immunopathol Pharmacol* 2020; **34**: 2058738420961202 [PMID: 33045856 DOI: 10.1177/2058738420961202]

56 **Yousif MM**, Elsadek Fakhr A, Morad EA, Kelani H, Hamed EF, Elsadek HM, Zahran MH, Fahmy Afify A, Ismail WA, Elagrody AI, Ibrahim NF, Amer FA, Zaki AM, Sadek AMEM, Shendi AM, Emad G, Farrag HA. Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response to direct-acting antiviral agents. *Infez Med* 2018; **26**: 237-243 [PMID: 30246766]

57 **Dennin RH**, Wo JE. DNA sequences homologous to hepatitis C virus (HCV) in the extrachromosomal circular DNA in peripheral blood mononuclear cells of HCV-negative subjects. *J Zhejiang Univ Sci B* 2019; **20**: 637-646 [PMID: 31273961 DOI: 10.1631/jzus.B1800453]

58 **Simmons B**, Saleem J, Hill A, Riley RD, Cooke GS. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. *Clin Infect Dis* 2016; **62**: 683-694 [PMID: 26787172 DOI: 10.1093/cid/civ948]

59 **Nelson PK**, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. *Lancet* 2011; **378**: 571-583 [PMID: 21802134 DOI: 10.1016/S0140-6736(11)61097-0]

60 **Hajarizadeh B**, Cunningham EB, Valerio H, Martinello M, Law M, Janjua NZ, Midgard H, Dalgard O, Dillon J, Hickman M, Bruneau J, Dore GJ, Grebely J. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. *J Hepatol* 2020; **72**: 643-657 [PMID: 31785345 DOI: 10.1016/j.jhep.2019.11.012]

61 **Sarrazin C**, Isakov V, Svarovskaia ES, Hedskog C, Martin R, Chodavarapu K, Brainard DM, Miller MD, Mo H, Molina JM, Sulkowski MS. Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies. *Clin Infect Dis* 2017; **64**: 44-52 [PMID: 27737953 DOI: 10.1093/cid/ciw676]

62 **Hayashi K**, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hirooka Y, Toyoda H, Kumada T, Hattori M, Katano Y, Goto H. Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy. *J Viral Hepat* 2018; **25**: 1446-1451 [PMID: 29993164 DOI: 10.1111/jvh.12967]

63 **Islam N**, Krajden M, Shoveller J, Gustafson P, Gilbert M, Buxton JA, Wong J, Tyndall MW, Janjua NZ; British Columbia Hepatitis Testers Cohort (BC-HTC) team. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study. *Lancet Gastroenterol Hepatol* 2017; **2**: 200-210 [PMID: 28404135 DOI: 10.1016/S2468-1253(16)30182-0]

64 **Thimme R**. T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine. *J Hepatol* 2021; **74**: 220-229 [PMID: 33002569 DOI: 10.1016/j.jhep.2020.09.022]

65 **Blach S**, Schaetti C, Bruggmann P, Negro F, Razavi H. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland. *Swiss Med Wkly* 2019; **149**: w20026 [PMID: 30905063 DOI: 10.4414/smw.2019.20026]

66 **Chhatwal J**, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. *Ann Intern Med* 2015; **162**: 397-406 [PMID: 25775312 DOI: 10.7326/M14-1336]

67 **Gordon S**, Lee J, Smith N, Dieterich D. Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States. *Expert Rev Pharmacoecon Outcomes Res* 2020; **20**: 251-257 [PMID: 31204882 DOI: 10.1080/14737167.2019.1629291]

68 **Yuen MF**, Liu SH, Seto WK, Mak LY, Corman SL, Hsu DC, Lee MYK, Khan TK, Puenpatom A. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. *Dig Dis Sci* 2021; **66**: 1315-1326 [PMID: 32385703 DOI: 10.1007/s10620-020-06281-8]

69 **Chugh Y**, Dhiman RK, Premkumar M, Prinja S, Singh Grover G, Bahuguna P. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India. *PLoS One* 2019; **14**: e0221769 [PMID: 31465503 DOI: 10.1371/journal.pone.0221769]

70 **Kawaguchi I**, Chayama K, Gonzalez YS, Virabhak S, Mitchell D, Yuen C, Kumada H. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan. *Adv Ther* 2020; **37**: 457-476 [PMID: 31808054 DOI: 10.1007/s12325-019-01166-3]

71 **Due OT**, Thakkinstian A, Thavorncharoensap M, Sobhonslidsuk A, Wu O, Phuong NK, Chaikledkaew U. Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam. *Value Health* 2020; **23**: 1180-1190 [PMID: 32940236 DOI: 10.1016/j.jval.2020.03.018]

72 **Yun H**, Zhao G, Sun X, Shi L. Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China. *BMJ Open* 2020; **10**: e035224 [PMID: 32819983 DOI: 10.1136/bmjopen-2019-035224]

73 **Ruggeri M**, Romano F, Basile M, Coretti S, Rolli FR, Drago C, Cicchetti A. Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy. *Appl Health Econ Health Policy* 2018; **16**: 711-722 [PMID: 30039348 DOI: 10.1007/s40258-018-0410-x]

74 **Marcellusi A**, Viti R, Kondili LA, Rosato S, Vella S, Mennini FS; PITER Collaborating group available at www.progettopiter.it. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. *Pharmacoeconomics* 2019; **37**: 255-266 [PMID: 30378086 DOI: 10.1007/s40273-018-0733-3]

75 **Gountas I**, Sypsa V, Papatheodoridis G, Souliotis K, Athanasakis K, Razavi H, Hatzakis A. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals. *World J Gastroenterol* 2019; **25**: 1327-1340 [PMID: 30918426 DOI: 10.3748/wjg.v25.i11.1327]

76 **Ledesma F**, Buti M, Domínguez-Hernández R, Casado MA, Esteban R. Is the universal population Hepatitis C virus screening a cost-effective strategy? A systematic review of the economic evidence. *Rev Esp Quimioter* 2020; **33**: 240-248 [PMID: 32510188 DOI: 10.37201/req/030.2020]

77 **Ogilvie JW**. Determination of the free-energy coupling between ATP and an affinity label attached to rabbit muscle phosphofructokinase. *Biochemistry* 1985; **24**: 317-321 [PMID: 3156632 DOI: 10.1021/bi00323a012]

78 **Krauth C**, Rossol S, Ortsäter G, Kautz A, Krüger K, Herder B, Stahmeyer JT. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies. *BMC Infect Dis* 2019; **19**: 1019 [PMID: 31791253 DOI: 10.1186/s12879-019-4524-z]

79 **Kim DY**, Wong G, Lee J, Kim MH, Smith N, Blissett R, Kim HJ. Cost-effectiveness of increased screening and treatment of chronic hepatitis C in Korea. *Curr Med Res Opin* 2020; **36**: 993-1002 [PMID: 32295431 DOI: 10.1080/03007995.2020.1756232]

80 **Wiktor S**. How feasible is the global elimination of HCV infection? *Lancet* 2019; **393**: 1265-1267 [PMID: 30704788 DOI: 10.1016/S0140-6736(18)32750-8]

81 **Iyengar S**, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, Hill S. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. *PLoS Med* 2016; **13**: e1002032 [PMID: 27243629 DOI: 10.1371/journal.pmed.1002032]

82 **Chhatwal J**, Chen Q, Bethea ED, Hur C, Spaulding AC, Kanwal F. The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. *Aliment Pharmacol Ther* 2019; **50**: 66-74 [PMID: 31115920 DOI: 10.1111/apt.15291]

83 **Duchesne L**, Hejblum G, Njouom R, Touré Kane C, Toni TD, Moh R, Sylla B, Rouveau N, Attia A, Lacombe K. Model-based cost-effectiveness estimates of testing strategies for diagnosing hepatitis C virus infection in Central and Western Africa. *PLoS One* 2020; **15**: e0238035 [PMID: 32833976 DOI: 10.1371/journal.pone.0238035]

84 **Zhuo Y**, Hayashi T, Chen Q, Aggarwal R, Hutin Y, Chhatwal J. Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan. *Sci Rep* 2020; **10**: 4089 [PMID: 32139872 DOI: 10.1038/s41598-020-60986-4]

85 **Sweeney S**, Ward Z, Platt L, Guinness L, Hickman M, Hope V, Maher L, Iversen J, Hutchinson SJ, Smith J, Ayres R, Hainey I, Vickerman P. Evaluating the cost-effectiveness of existing needle and syringe programmes in preventing hepatitis C transmission in people who inject drugs. *Addiction* 2019; **114**: 560-570 [PMID: 30674091 DOI: 10.1111/add.14519]

86 **Innes HA**, Hutchinson SJ, Barclay S, Cadzow E, Dillon JF, Fraser A, Goldberg DJ, Mills PR, McDonald SA, Morris J, Stanley A, Hayes P; Hepatitis C Clinical Database Monitoring Committee. Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. *Hepatology* 2013; **57**: 451-460 [PMID: 22961861 DOI: 10.1002/hep.26051]

87 **European Association for the Study of the Liver**. EASL Recommendations on Treatment of Hepatitis C 2016. *J Hepatol* 2017; **66**: 153-194 [PMID: 27667367 DOI: 10.1016/j.jhep.2016.09.001]

88 **European Association for the Study of the Liver**. EASL Recommendations on Treatment of Hepatitis C 2018. *J Hepatol* 2018; **69**: 461-511 [PMID: 29650333 DOI: 10.1016/j.jhep.2018.03.026]

89 **European Association for the Study of the Liver**; Clinical Practice Guidelines Panel: Chair; EASL Governing Board representative; Panel members. EASL recommendations on treatment of hepatitis C: Final update of the series. *J Hepatol* 2020; **73**: 1170-1218 [PMID: 32956768 DOI: 10.1016/j.jhep.2020.08.018]

90 **Dahari H**, Canini L, Graw F, Uprichard SL, Araújo ES, Penaranda G, Coquet E, Chiche L, Riso A, Renou C, Bourliere M, Cotler SJ, Halfon P. HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. *J Hepatol* 2016; **64**: 1232-1239 [PMID: 26907973 DOI: 10.1016/j.jhep.2016.02.022]

91 **Goel A**, Chen Q, Chhatwal J, Aggarwal R. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment. *J Gastroenterol Hepatol* 2018; **33**: 2029-2036 [PMID: 29864213 DOI: 10.1111/jgh.14301]

92 **Mushtaq S**, Akhter TS, Khan A, Sohail A, Khan A, Manzoor S. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan. *Front Pharmacol* 2020; **11**: 550205 [PMID: 32982753 DOI: 10.3389/fphar.2020.550205]

93 **Belperio PS**, Shahoumian TA, Loomis TP, Mole LA, Backus LI. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3. *J Hepatol* 2019; **70**: 15-23 [PMID: 30266283 DOI: 10.1016/j.jhep.2018.09.018]

94 **Cheng TS**, Liang PC, Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Huang JF, Dai CY, Hsieh PH, Chuang WL, Yu ML. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment. *Kaohsiung J Med Sci* 2021; **37**: 334-345 [PMID: 33151016 DOI: 10.1002/kjm2.12315]

95 **Soria A**, Fava M, Bernasconi DP, Lapadula G, Colella E, Valsecchi MG, Migliorino GM, D'Ambrosio R, Landonio S, Schiavini M, Spinetti A, Carriero C, Degasperi E, Cologni G, Gatti F, Viganò P, Hasson H, Uberti-Foppa C, Pasulo L, Baiguera C, Rossotti R, Vinci M, Puoti M, Giorgini A, Menzaghi B, Lombardi A, Pan A, Aghemo A, Grossi PA, Boldizzoni R, Colombo S, Viganò M, Rumi MG, Del Poggio P, Valenti L, Giglio O, De Bona A, d'Arminio Monforte A, Colombo A, Spinelli O, Pigozzi MG, Molteni C, Bonfanti P, Terreni N, Perini P, Capretti A, Bella D, Liani C, Polo S, Aimo G, Pagnucco L, Bhoori S, Centenaro R, Graffeo M, Ciaccio A, Dionigi E, Lazzaroni S, Carderi I, Di Marco M, Rizzardini G, Noventa F, Lampertico P, Fagiuoli S. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort. *Liver Int* 2020; **40**: 769-777 [PMID: 31970845 DOI: 10.1111/liv.14386]

96 **Nguyen E**, Trinh S, Trinh H, Nguyen H, Nguyen K, Do A, Levitt B, Do S, Nguyen M, Purohit T, Shieh E, Nguyen MH. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir. *Aliment Pharmacol Ther* 2019; **49**: 99-106 [PMID: 30467877 DOI: 10.1111/apt.15043]

97 **Buggisch P**, Wursthorn K, Stoehr A, Atanasov PK, Supiot R, Lee J, Ting J, Petersen J. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. *PLoS One* 2019; **14**: e0214795 [PMID: 30946776 DOI: 10.1371/journal.pone.0214795]

98 **Zhuang L**, Li J, Zhang Y, Ji S, Li Y, Zhao Y, Li B, Li W, Quan M, Duan Y, Zhao H, Cheng D, Wang X, Ou W, Xing H. Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis. *Ann Hepatol* 2021; **23**: 100268 [PMID: 33059055 DOI: 10.1016/j.aohep.2020.09.012]

99 **Janjua NZ**, Darvishian M, Wong S, Yu A, Rossi C, Ramji A, Yoshida EM, Butt ZA, Samji H, Chong M, Chapinal N, Cook D, Alvarez M, Tyndall M, Krajden M; British Columbia Hepatitis Testers Cohort Team. Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy. *Hepatol Commun* 2019; **3**: 478-492 [PMID: 30976739 DOI: 10.1002/hep4.1307]

100 **Naggie S**, Ramers CB. Sustained Virologic Response in People Who Inject Drugs and/or Who Are on Opioid Agonist Therapy: Is 90% Enough? *Hepatol Commun* 2019; **3**: 453-455 [PMID: 30976736 DOI: 10.1002/hep4.1347]

101 **Young J**, Wong S, Janjua NZ, Klein MB. Comparing direct acting antivirals for hepatitis C using observational data - Why and how? *Pharmacol Res Perspect* 2020; **8**: e00650 [PMID: 32894643 DOI: 10.1002/prp2.650]

102 **Roelens M**, Bertisch B, Moradpour D, Cerny A, Semmo N, Schmid P, Müllhaupt B, Clerc O, Semela D, Junker C, Negro F, Keiser O; Swiss Hepatitis C Cohort Study. All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS). *Open Forum Infect Dis* 2020; **7**: ofaa308 [PMID: 32855989 DOI: 10.1093/ofid/ofaa308]

103 **Scott N**, Wilson DP, Thompson AJ, Barnes E, El-Sayed M, Benzaken AS, Drummer HE, Hellard ME. The case for a universal hepatitis C vaccine to achieve hepatitis C elimination. *BMC Med* 2019; **17**: 175 [PMID: 31530275 DOI: 10.1186/s12916-019-1411-9]

104 **Osburn WO**, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, Cox AL, Ray SC. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. *Hepatology* 2014; **59**: 2140-2151 [PMID: 24425349 DOI: 10.1002/hep.27013]

105 **Kinchen VJ**, Zahid MN, Flyak AI, Soliman MG, Learn GH, Wang S, Davidson E, Doranz BJ, Ray SC, Cox AL, Crowe JE Jr, Bjorkman PJ, Shaw GM, Bailey JR. Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. *Cell Host Microbe* 2018; **24**: 717-730.e5 [PMID: 30439341 DOI: 10.1016/j.chom.2018.10.012]

106 **Meunier JC**, Gottwein JM, Houghton M, Russell RS, Emerson SU, Bukh J, Purcell RH. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. *J Infect Dis* 2011; **204**: 1186-1190 [PMID: 21917891 DOI: 10.1093/infdis/jir511]

107 **Frey SE**, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, Hill H, Wolff MC, Schultze V, Han JH, Scharschmidt B, Belshe RB. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. *Vaccine* 2010; **28**: 6367-6373 [PMID: 20619382 DOI: 10.1016/j.vaccine.2010.06.084]

108 **Law JLM**, Logan M, Wong J, Kundu J, Hockman D, Landi A, Chen C, Crawford K, Wininger M, Johnson J, Mesa Prince C, Dudek E, Mehta N, Tyrrell DL, Houghton M. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine. *J Virol* 2018; **92** [PMID: 29540595 DOI: 10.1128/JVI.02141-17]

109 **Folgori A**, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, Pezzanera M, Tafi R, Arcuri M, Fattori E, Lahm A, Luzzago A, Vitelli A, Colloca S, Cortese R, Nicosia A. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. *Nat Med* 2006; **12**: 190-197 [PMID: 16462801 DOI: 10.1038/nm1353]

110 **Barnes E**, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O'Hara G, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y, Adams D, Hill A, Colloca S, Nicosia A, Cortese R, Klenerman P. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. *Sci Transl Med* 2012; **4**: 115ra1 [PMID: 22218690 DOI: 10.1126/scitranslmed.3003155]

111 **Swadling L**, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, Halliday J, Kelly C, Bowen D, Fergusson J, Kurioka A, Ammendola V, Del Sorbo M, Grazioli F, Esposito ML, Siani L, Traboni C, Hill A, Colloca S, Davis M, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. *Sci Transl Med* 2014; **6**: 261ra153 [PMID: 25378645 DOI: 10.1126/scitranslmed.3009185]

112 **Cox AL,** Page K, Melia M, Veenhuis R, Massaccesi G, Osburn W. A randomized, double-blind, placebo-controlled efficacy trial of a vaccine to prevent chronic hepatitis C virus infection in an at-risk population. *Open Forum Infect Dis* 2019; **6** Suppl 2: S997 [DOI:10.1093/ofid/ofz415.2493]

113 **Sepulveda-Crespo D**, Resino S, Martinez I. Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants. *Vaccines (Basel)* 2020; **8** [PMID: 32560440 DOI: 10.3390/vaccines8020313]

114 **Wrensch F**, Keck ZY, Foung SKH, Baumert TF. Learning from a clinical cohort for HCV vaccine development. *J Hepatol* 2019; **71**: 9-11 [PMID: 30992137 DOI: 10.1016/j.jhep.2019.03.030]

115 **Skinner NE**, Bailey JR. Broadly neutralizing antibodies against hepatitis C virus: location, location, location. *J Hepatol* 2020; **72**: 604-606 [PMID: 32019681 DOI: 10.1016/j.jhep.2020.01.005]

116 **Lingala S**, Ghany MG. Natural History of Hepatitis C. *Gastroenterol Clin North Am* 2015; **44**: 717-734 [PMID: 26600216 DOI: 10.1016/j.gtc.2015.07.003]

117 **Morozov VA**, Lagaye S. Hepatitis C virus: Morphogenesis, infection and therapy. *World J Hepatol* 2018; **10**: 186-212 [PMID: 29527256 DOI: 10.4254/wjh.v10.i2.186]

118 **Westbrook RH**, Dusheiko G. Natural history of hepatitis C. *J Hepatol* 2014; **61**: S58-S68 [PMID: 25443346 DOI: 10.1016/j.jhep.2014.07.012]

119 **Perz JF**, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. *J Hepatol* 2006; **45**: 529-538 [PMID: 16879891 DOI: 10.1016/j.jhep.2006.05.013]

120 **Seeff LB**. Natural history of chronic hepatitis C. *Hepatology* 2002; **36**: S35-S46 [PMID: 12407575 DOI: 10.1053/jhep.2002.36806]

121 **Seeff LB**, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. *N Engl J Med* 1992; **327**: 1906-1911 [PMID: 1454085 DOI: 10.1056/NEJM199212313272703]

122 **Carvalho JR**, Velosa J, Serejo F. Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens. *Scand J Gastroenterol* 2018; **53**: 857-863 [PMID: 29779403 DOI: 10.1080/00365521.2018.1473486]

123 **Inoue T**, Goto T, Iio E, Matsunami K, Fujiwara K, Shinkai N, Matsuura K, Matsui T, Nojiri S, Tanaka Y. Changes in serum lipid profiles caused by three regimens of interferon-free direct-acting antivirals for patients infected with hepatitis C virus. *Hepatol Res* 2018; **48**: E203-E212 [PMID: 28834042 DOI: 10.1111/hepr.12970]

124 **Corey KE**, Kane E, Munroe C, Barlow LL, Zheng H, Chung RT. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. *Hepatology* 2009; **50**: 1030-1037 [PMID: 19787818 DOI: 10.1002/hep.23219]

125 **Adinolfi LE**, Restivo L, Zampino R, Lonardo A, Loria P. Metabolic alterations and chronic hepatitis C: treatment strategies. *Expert Opin Pharmacother* 2011; **12**: 2215-2234 [PMID: 21883025 DOI: 10.1517/14656566.2011.597742]

126 **Hashimoto S**, Yatsuhashi H, Abiru S, Yamasaki K, Komori A, Nagaoka S, Saeki A, Uchida S, Bekki S, Kugiyama Y, Nagata K, Nakamura M, Migita K, Nakao K. Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. *PLoS One* 2016; **11**: e0163644 [PMID: 27680885 DOI: 10.1371/journal.pone.0163644]

127 **Seeff LB**, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, Ishak KG, Iber FL, Toro D, Samanta A, Koretz RL, Perrillo RP, Goodman ZD, Knodell RG, Gitnick G, Morgan TR, Schiff ER, Lasky S, Stevens C, Vlahcevic RZ, Weinshel E, Tanwandee T, Lin HJ, Barbosa L. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. *Hepatology* 2001; **33**: 455-463 [PMID: 11172349 DOI: 10.1053/jhep.2001.21905]

128 **Vogt M**, Lang T, Frösner G, Klingler C, Sendl AF, Zeller A, Wiebecke B, Langer B, Meisner H, Hess J. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. *N Engl J Med* 1999; **341**: 866-870 [PMID: 10498458 DOI: 10.1056/NEJM199909163411202]

129 **Seeff LB**, Miller RN, Rabkin CS, Buskell-Bales Z, Straley-Eason KD, Smoak BL, Johnson LD, Lee SR, Kaplan EL. 45-year follow-up of hepatitis C virus infection in healthy young adults. *Ann Intern Med* 2000; **132**: 105-111 [PMID: 10644270 DOI: 10.7326/0003-4819-132-2-200001180-00003]

130 **Kamitsukasa H**, Harada H, Tanaka H, Yagura M, Tokita H, Ohbayashi A. Late liver-related mortality from complications of transfusion-acquired hepatitis C. *Hepatology* 2005; **41**: 819-825 [PMID: 15793849 DOI: 10.1002/hep.20648]

131 **Just SA**, Grau K, Georgsen J, Weis N, Cowan S, Groenbaek K, Krarup H, Christensen PB; Danish HCV Lookback Group. Long-term follow-up among Danish transfusion recipients identified in the national hepatitis C lookback. *Transfusion* 2012; **52**: 582-588 [PMID: 21883266 DOI: 10.1111/j.1537-2995.2011.03309.x]

132 **Rodger AJ**, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. *Hepatology* 2000; **32**: 582-587 [PMID: 10960453 DOI: 10.1053/jhep.2000.9714]

133 **Thomas DL**, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D. The natural history of hepatitis C virus infection: host, viral, and environmental factors. *JAMA* 2000; **284**: 450-456 [PMID: 10904508 DOI: 10.1001/jama.284.4.450]

134 **Kielland KB**, Skaug K, Amundsen EJ, Dalgard O. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. *J Hepatol* 2013; **58**: 31-37 [PMID: 22960427 DOI: 10.1016/j.jhep.2012.08.024]

135 **Smith DJ**, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. *Int J Drug Policy* 2015; **26**: 911-921 [PMID: 26298331 DOI: 10.1016/j.drugpo.2015.07.004]

136 **Harris HE**, Ramsay ME, Andrews NJ; HCV National Register Steering Group. Survival of a national cohort of hepatitis C virus infected patients, 16 years after exposure. *Epidemiol Infect* 2006; **134**: 472-477 [PMID: 16255834 DOI: 10.1017/S0950268805005340]

137 **Wiese M**, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. *Hepatology* 2000; **32**: 91-96 [PMID: 10869294 DOI: 10.1053/jhep.2000.8169]

138 **Wiese M**, Grüngreiff K, Güthoff W, Lafrenz M, Oesen U, Porst H; East German Hepatitis C Study Group. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study. *J Hepatol* 2005; **43**: 590-598 [PMID: 16237783 DOI: 10.1016/j.jhep.2005.04.007]

139 **Wiese M**, Fischer J, Löbermann M, Göbel U, Grüngreiff K, Güthoff W, Kullig U, Richter F, Schiefke I, Tenckhoff H, Zipprich A, Berg T, Müller T; East German HCV Study Group. Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. *Hepatology* 2014; **59**: 49-57 [PMID: 23929603 DOI: 10.1002/hep.26644]

140 **Kenny-Walsh E**. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. *N Engl J Med* 1999; **340**: 1228-1233 [PMID: 10210705 DOI: 10.1056/NEJM199904223401602]

141 **Levine RA**, Sanderson SO, Ploutz-Snyder R, Murray F, Kay E, Hegarty J, Nolan N, Kelleher D, McDonald G, O'Keane JC, Crowe J. Assessment of fibrosis progression in untreated irish women with chronic hepatitis C contracted from immunoglobulin anti-D. *Clin Gastroenterol Hepatol* 2006; **4**: 1271-1277 [PMID: 16901770 DOI: 10.1016/j.cgh.2006.05.028]

142 **Garvey P**, Murphy N, Flanagan P, Brennan A, Courtney G, Crosbie O, Crowe J, Hegarty J, Lee J, McIver M, McNulty C, Murray F, Nolan N, O'Farrelly C, Stewart S, Tait M, Norris S, Thornton L. Disease outcomes in a cohort of women in Ireland infected by hepatitis C-contaminated anti-D immunoglobulin during 1970s. *J Hepatol* 2017; **67**: 1140-1147 [PMID: 28843656 DOI: 10.1016/j.jhep.2017.07.034]

143 **Maor Y**, Schapiro JM, Bashari D, Martinowitz U. Survival of hepatitis C-infected haemophilia patients is predicted by presence of cirrhosis but not by anti-viral treatment. *Ann Hepatol* 2014; **13**: 753-761 [PMID: 25332261]

144 **Murphy N**, O'Mahony B, Flanagan P, Noone D, White B, Bergin C, Norris S, Thornton L; National Hepatitis C Database Scientific and Technical Committee. Progression of hepatitis C in the haemophiliac population in Ireland, after 30 years of infection in the pre-DAA treatment era. *Haemophilia* 2017; **23**: 712-720 [PMID: 28752601 DOI: 10.1111/hae.13244]

145 **Bruno S**, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, Aghemo A, Cabibbo G, Viganò M, Boccaccio V, Craxí A, Colombo M, Maisonneuve P. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. *J Hepatol* 2016; **64**: 1217-1223 [PMID: 27059129 DOI: 10.1016/j.jhep.2016.01.034]

146 **Hallager S**, Brehm Christensen P, Ladelund S, Rye Clausen M, Lund Laursen A, Møller A, Schlicthting P, Galmstrup Madsen L, Gerstoft J, Lunding S, Elmegaard Grønbæk K, Bygum Krarup H, Weis N. Mortality Rates in Patients With Chronic Hepatitis C and Cirrhosis Compared With the General Population: A Danish Cohort Study. *J Infect Dis* 2017; **215**: 192-201 [PMID: 27803168 DOI: 10.1093/infdis/jiw527]

147 **Innes H**, McDonald S, Hayes P, Dillon JF, Allen S, Goldberg D, Mills PR, Barclay ST, Wilks D, Valerio H, Fox R, Bhattacharyya D, Kennedy N, Morris J, Fraser A, Stanley A, Bramley P, Hutchinson SJ. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. *J Hepatol* 2017; **66**: 19-27 [PMID: 27545496 DOI: 10.1016/j.jhep.2016.08.004]

148 **Nahon P**, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, Guyader D, Fontaine H, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Leroy V, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Dharancy S, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Thibaut V, Salmon D, Ziol M, Sutton A, Pol S, Roudot-Thoraval F; ANRS CO12 CirVir Group. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. *Gastroenterology* 2017; **152**: 142-156.e2 [PMID: 27641509 DOI: 10.1053/j.gastro.2016.09.009]

149 **Uto H**, Stuver SO, Hayashi K, Kumagai K, Sasaki F, Kanmura S, Numata M, Moriuchi A, Hasegawa S, Oketani M, Ido A, Kusumoto K, Hasuike S, Nagata K, Kohara M, Tsubouchi H. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. *Hepatology* 2009; **50**: 393-399 [PMID: 19585614 DOI: 10.1002/hep.23002]

150 **Tan YW**, Tao Y, Liu LG, Ye Y, Zhou XB, Chen L, He C. Epidemiological features of chronic hepatitis C infection caused by remunerated blood donors: A nearly 27-year period survey. *World J Gastroenterol* 2018; **24**: 1250-1258 [PMID: 29568205 DOI: 10.3748/wjg.v24.i11.1250]

151 **Rao HY**, Sun DG, Yang RF, Liu F, Wang J, Feng B, Wu N, Fang JL, Song GJ, Ma H, Guo F, Wang JH, Li XB, Jin Q, Qin H, Zhuang H, Wei L. Outcome of hepatitis C virus infection in Chinese paid plasma donors: a 12-19-year cohort study. *J Gastroenterol Hepatol* 2012; **27**: 526-532 [PMID: 21871021 DOI: 10.1111/j.1440-1746.2011.06880.x]

152 **Ireland G**, Mandal S, Hickman M, Ramsay M, Harris R, Simmons R. Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016. *Euro Surveill* 2019; **24** [PMID: 31362807 DOI: 10.2807/1560-7917.ES.2019.24.30.1800695]

153 **Simmons R**, Ireland G, Ijaz S, Ramsay M, Mandal S; National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Blood Borne, Sexually Transmitted Infections. Causes of death among persons diagnosed with hepatitis C infection in the pre- and post-DAA era in England: A record linkage study. *J Viral Hepat* 2019; **26**: 873-880 [PMID: 30896055 DOI: 10.1111/jvh.13096]

154 **Modin L**, Arshad A, Wilkes B, Benselin J, Lloyd C, Irving WL, Kelly DA. Epidemiology and natural history of hepatitis C virus infection among children and young people. *J Hepatol* 2019; **70**: 371-378 [PMID: 30496763 DOI: 10.1016/j.jhep.2018.11.013]

155 **Verna EC**, Morelli G, Terrault NA, Lok AS, Lim JK, Di Bisceglie AM, Zeuzem S, Landis CS, Kwo P, Hassan M, Manns MP, Vainorius M, Akushevich L, Nelson DR, Fried MW, Reddy KR. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. *J Hepatol* 2020; **73**: 540-548 [PMID: 32243960 DOI: 10.1016/j.jhep.2020.03.031]

156 **Samonakis DN**, Koulentaki M, Coucoutsi C, Augoustaki A, Baritaki C, Digenakis E, Papiamonis N, Fragaki M, Matrella E, Tzardi M, Kouroumalis EA. Clinical outcomes of compensated and decompensated cirrhosis: A long term study. *World J Hepatol* 2014; **6**: 504-512 [PMID: 25068002 DOI: 10.4254/wjh.v6.i7.504]

157 **Erman A**, Krahn MD, Hansen T, Wong J, Bielecki JM, Feld JJ, Wong WWL, Grootendorst P, Thein HH. Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update. *BMJ Open* 2019; **9**: e027491 [PMID: 31719068 DOI: 10.1136/bmjopen-2018-027491]

158 **Kudo M**. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. *Liver Cancer* 2015; **4**: 39-50 [PMID: 26020028 DOI: 10.1159/000367727]

159 **Morio K**, Imamura M, Kawakami Y, Nakamura Y, Hatooka M, Morio R, Fujino H, Nakahara T, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Miki D, Ochi H, Katamura Y, Arataki K, Moriya T, Ito H, Tsuji K, Kohno H, Waki K, Tamura T, Nakamura T, Chayama K; Hiroshima Liver Study Group. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C. *J Med Virol* 2018; **90**: 1834-1840 [PMID: 30016555 DOI: 10.1002/jmv.25267]

160 **Kozbial K**, Moser S, Al-Zoairy R, Schwarzer R, Datz C, Stauber R, Laferl H, Strasser M, Beinhardt S, Stättermayer AF, Gschwantler M, Zoller H, Maieron A, Graziadei I, Trauner M, Steindl-Munda P, Hofer H, Ferenci P. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment. *Liver Int* 2018; **38**: 1028-1035 [PMID: 29136329 DOI: 10.1111/liv.13629]

161 **De Gruttola VG**, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, Gail MH, Prentice R, Wittes J, Zeger SL. Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. *Control Clin Trials* 2001; **22**: 485-502 [PMID: 11578783 DOI: 10.1016/s0197-2456(01)00153-2]

162 **Jakobsen JC**, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. *Cochrane Database Syst Rev* 2017; **9**: CD012143 [PMID: 28922704 DOI: 10.1002/14651858.CD012143.pub3]

163 **European Association for the Study of the Liver**. Response to the Cochrane systematic review on DAA-based treatment of chronic hepatitis C. *J Hepatol* 2017; **67**: 663-664 [PMID: 28669753 DOI: 10.1016/j.jhep.2017.06.022]

164 **Kwo PY**, Shiffman ML, Bernstein DE. The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong. *Am J Gastroenterol* 2018; **113**: 2-4 [PMID: 29134963 DOI: 10.1038/ajg.2017.420]

165 **Koretz RL**, Jakobsen JC, Djurisic S, Poropat G, Hauser G, Bjelakovic M, Bjelakovic G, Gluud C. Who is wrong? Responses to Kwo et al. *Am J Gastroenterol* 2018; **113**: 779-780 [PMID: 29487409 DOI: 10.1038/s41395-018-0029-4]

166 **Koretz RL**, Pleguezuelo M, Arvaniti V, Barrera Baena P, Ciria R, Gurusamy KS, Davidson BR, Burroughs AK. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C. *Cochrane Database Syst Rev* 2013: CD003617 [PMID: 23440791 DOI: 10.1002/14651858.CD003617.pub2]

167 **Dusheiko G**. The impact of antiviral therapy for hepatitis C on the quality of life: a perspective. *Liver Int* 2017; **37** Suppl 1: 7-12 [PMID: 28052638 DOI: 10.1111/liv.13292]

168 **Koretz RL**, Gurusamy K, Davidson B, Burroughs A. Evidence recommending antiviral therapy in hepatitis C. *J Hepatol* 2014; **60**: 1101-1102 [PMID: 24445221 DOI: 10.1016/j.jhep.2013.12.031]

169 **Koretz RL**, Lin KW, Ioannidis JP, Lenzer J. Is widespread screening for hepatitis C justified? *BMJ* 2015; **350**: g7809 [PMID: 25587052 DOI: 10.1136/bmj.g7809]

170 **Jakobsen JC**, Nielsen EE, Koretz RL, Gluud C. Do direct acting antivirals cure chronic hepatitis C? *BMJ* 2018; **361**: k1382 [PMID: 29748173 DOI: 10.1136/bmj.k1382]

171 **Charlton M**, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N; SOLAR-1 Investigators. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. *Gastroenterology* 2015; **149**: 649-659 [PMID: 25985734 DOI: 10.1053/j.gastro.2015.05.010]

172 **Foster GR**, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson WT, MacDonald DC, Agarwal K; HCV Research, UK. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. *J Hepatol* 2016; **64**: 1224-1231 [PMID: 26829205 DOI: 10.1016/j.jhep.2016.01.029]

173 **Lee YA**, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? *Antiviral Res* 2014; **107**: 23-30 [PMID: 24726738 DOI: 10.1016/j.antiviral.2014.03.012]

174 **Piñero F**, Mendizabal M, Ridruejo E, Herz Wolff F, Ameigeiras B, Anders M, Schinoni MI, Reggiardo V, Palazzo A, Videla M, Alonso C, Santos L, Varón A, Figueroa S, Vistarini C, Adrover R, Fernández N, Perez D, Tanno F, Hernández N, Sixto M, Borzi S, Bruno A, Cocozzella D, Soza A, Descalzi V, Estepo C, Zerega A, de Araujo A, Cheinquer H, Silva M; LALREAN. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. *Liver Int* 2019; **39**: 1033-1043 [PMID: 30636361 DOI: 10.1111/liv.14041]

175 **Pons M**, Rodríguez-Tajes S, Esteban JI, Mariño Z, Vargas V, Lens S, Buti M, Augustin S, Forns X, Mínguez B, Genescà J. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. *J Hepatol* 2020; **72**: 472-480 [PMID: 31629779 DOI: 10.1016/j.jhep.2019.10.005]

176 **Ioannou GN**, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, Sterling RK, Feld JJ, Kaplan DE, Taddei TH, Berry K. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. *Gastroenterology* 2019; **157**: 1264-1278.e4 [PMID: 31356807 DOI: 10.1053/j.gastro.2019.07.033]

177 **Butt AA**, Yan P, Shaikh OS, Lo Re V 3rd, Abou-Samra AB, Sherman KE. Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study. *J Hepatol* 2020; **73**: 277-284 [PMID: 32145260 DOI: 10.1016/j.jhep.2020.02.022]

178 **Søholm J**, Hansen JF, Mössner B, Røge BT, Lauersen A, Hansen JB, Weis N, Barfod TS, Lunding S, Øvrehus A, Mohey R, Thielsen P, Christensen PB. Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs. *PLoS One* 2020; **15**: e0243725 [PMID: 33301499 DOI: 10.1371/journal.pone.0243725]

179 **Yang M**, Parikh ND, Liu H, Wu E, Rao H, Feng B, Lin A, Wei L, Lok AS. Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States. *Sci Rep* 2020; **10**: 20922 [PMID: 33262356 DOI: 10.1038/s41598-020-77515-y]

180 **Rao H**, Liu H, Wu E, Yang M, Feng B, Lin A, Fei R, Fontana RJ, Wei L, Lok AS. Comparison of clinical outcomes and impact of SVR in American and Chinese patients with chronic hepatitis C. *JHEP Rep* 2020; **2**: 100136 [PMID: 32715286 DOI: 10.1016/j.jhepr.2020.100136]

181 **Ribaldone DG**, Sacco M, Saracco GM. The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm. *J Clin Med* 2020; **9** [PMID: 32092892 DOI: 10.3390/jcm9020563]

182 **Carrat F**, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki JP, Zoulim F, Asselah T, Marcellin P, Thabut D, Leroy V, Tran A, Habersetzer F, Samuel D, Guyader D, Chazouilleres O, Mathurin P, Metivier S, Alric L, Riachi G, Gournay J, Abergel A, Cales P, Ganne N, Loustaud-Ratti V, D'Alteroche L, Causse X, Geist C, Minello A, Rosa I, Gelu-Simeon M, Portal I, Raffi F, Bourliere M, Pol S; French ANRS CO22 Hepather cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. *Lancet* 2019; **393**: 1453-1464 [PMID: 30765123 DOI: 10.1016/S0140-6736(18)32111-1]

183 **Calvaruso V,** Petta S, Cacciola I, Cabibbo G, Cartabellotta F, Di Rosolini MA, Davì A, Cannavò MR, RusselloM , Di Stefano M, Scifo G, DI Lorenzo F, Tullio P, Larocca LN, Montineri A, Fuduli G, DI Giacomo A, Cannizzaro M, Madonia S, Licata A, Malizia G, Alaimo G, Bertino G, Cacopardo B, Iacobello C, Averna A, Guarneri L, Scalisi I, Mazzola G, Mondello L, Vincenzo P, Squadrito G, Camma C, Raimondo G, Craxi A, DI Marco V. Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort. *J Hepatol* 2018; **68** Suppl: S83 [DOI: 10.1016/S0168-8278(18)30385-4]

184 **Cabibbo G**, Celsa C, Calvaruso V, Petta S, Cacciola I, Cannavò MR, Madonia S, Rossi M, Magro B, Rini F, Distefano M, Larocca L, Prestileo T, Malizia G, Bertino G, Benanti F, Licata A, Scalisi I, Mazzola G, Di Rosolini MA, Alaimo G, Averna A, Cartabellotta F, Alessi N, Guastella S, Russello M, Scifo G, Squadrito G, Raimondo G, Trevisani F, Craxì A, Di Marco V, Cammà C; Rete Sicilia Selezione Terapia – HCV (RESIST-HCV) and Italian Liver Cancer (ITA.LI.CA.) Group. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. *J Hepatol* 2019; **71**: 265-273 [PMID: 30959157 DOI: 10.1016/j.jhep.2019.03.027]

185 **Pietsch V**, Deterding K, Attia D, Ringe KI, Heidrich B, Cornberg M, Gebel M, Manns MP, Wedemeyer H, Potthoff A. Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. *United European Gastroenterol J* 2018; **6**: 1188-1198 [PMID: 30288281 DOI: 10.1177/2050640618786067]

186 **Belli LS**, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, Donato F, Volpes R, Pageaux GP, Coilly A, Fagiuoli S, Amaddeo G, Perricone G, Vinaixa C, Berlakovich G, Facchetti R, Polak W, Muiesan P, Duvoux C; European Liver and Intestine Association (ELITA). Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. *J Hepatol* 2016; **65**: 524-531 [PMID: 27212241 DOI: 10.1016/j.jhep.2016.05.010]

187 **Perricone G**, Duvoux C, Berenguer M, Cortesi PA, Vinaixa C, Facchetti R, Mazzarelli C, Rockenschaub SR, Martini S, Morelli C, Monico S, Volpes R, Pageaux GP, Fagiuoli S, Belli LS; European Liver and Intestine Transplant Association (ELITA). Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. *Liver Int* 2018; **38**: 2170-2177 [PMID: 29750389 DOI: 10.1111/liv.13878]

188 **AASLD-IDSA HCV Guidance Panel**. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. *Clin Infect Dis* 2018; **67**: 1477-1492 [PMID: 30215672 DOI: 10.1093/cid/ciy585]

189 **Backus LI,** Belperio PS, Shahoumian TA, Mole LA. Direct-Acting Antiviral Sustained Virologic Response: Impact on Mortality in Patients without Advanced Liver Disease. *Hepatology* 2018; **68**: 827-838 [DOI: 10.1002/hep.29811]

190 **Chen Yi Mei SLG**, Thompson AJ, Christensen B, Cunningham G, McDonald L, Bell S, Iser D, Nguyen T, Desmond PV. Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection. *PLoS One* 2017; **12**: e0185609 [PMID: 29065124 DOI: 10.1371/journal.pone.0185609]

191 **Laursen TL**, Sandahl TD, Kazankov K, George J, Grønbæk H. Liver-related effects of chronic hepatitis C antiviral treatment. *World J Gastroenterol* 2020; **26**: 2931-2947 [PMID: 32587440 DOI: 10.3748/wjg.v26.i22.2931]

192 **Pereira Guedes T**, Fragoso P, Lemos C, Garrido M, Silva J, Falcão D, Maia L, Moreira T, Manuel Ferreira J, Pedroto I. Long-Term Follow-Up of Advanced Liver Disease after Sustained Virological Response to Treatment of Hepatitis C with Direct-Acting Antivirals: Outcomes from a Real-World Portuguese Cohort. *GE Port J Gastroenterol* 2020; **27**: 149-159 [PMID: 32509920 DOI: 10.1159/000503074]

193 **Maan R**, van der Meer AJ. Outcome of direct-acting antiviral treatment for patients with chronic hepatitis C virus infection: clinical benefit proven? *Hepatobiliary Surg Nutr* 2020; **9**: 257-259 [PMID: 32355697 DOI: 10.21037/hbsn.2019.10.04]

194 **Calvaruso V**, Craxì A. Hepatic benefits of HCV cure. *J Hepatol* 2020; **73**: 1548-1556 [PMID: 32777323 DOI: 10.1016/j.jhep.2020.08.006]

195 **Lens S**, Baiges A, Alvarado-Tapias E, LLop E, Martinez J, Fortea JI, Ibáñez-Samaniego L, Mariño Z, Rodríguez-Tajes S, Gallego A, Bañares R, Puente Á, Albillos A, Calleja JL, Torras X, Hernández-Gea V, Bosch J, Villanueva C, García-Pagán JC, Forns X. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. *J Hepatol* 2020; **73**: 1415-1424 [PMID: 32535060 DOI: 10.1016/j.jhep.2020.05.050]

196 **Lens S**, Alvarado-Tapias E, Mariño Z, Londoño MC, LLop E, Martinez J, Fortea JI, Ibañez L, Ariza X, Baiges A, Gallego A, Bañares R, Puente A, Albillos A, Calleja JL, Torras X, Hernández-Gea V, Bosch J, Villanueva C, Forns X, García-Pagán JC. Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. *Gastroenterology* 2017; **153**: 1273-1283.e1 [PMID: 28734831 DOI: 10.1053/j.gastro.2017.07.016]

197 **Mandorfer M**, Kozbial K, Schwabl P, Chromy D, Semmler G, Stättermayer AF, Pinter M, Hernández-Gea V, Fritzer-Szekeres M, Steindl-Munda P, Trauner M, Peck-Radosavljevic M, García-Pagán JC, Ferenci P, Reiberger T. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. *Hepatology* 2020; **71**: 1023-1036 [PMID: 31365764 DOI: 10.1002/hep.30885]

198 **Noda K**, Yoshihara H, Suzuki K, Yamada Y, Kasahara A, Hayashi N, Fusamoto H, Kamada T. Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma--its relationship to alcohol drinking and the age of transfusion. *Alcohol Clin Exp Res* 1996; **20**: 95A-100A [PMID: 8659701 DOI: 10.1111/j.1530-0277.1996.tb01739.x]

199 **Wiley TE**, McCarthy M, Breidi L, McCarthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. *Hepatology* 1998; **28**: 805-809 [PMID: 9731576 DOI: 10.1002/hep.510280330]

200 **Frieden TR**, Ozick L, McCord C, Nainan OV, Workman S, Comer G, Lee TP, Byun KS, Patel D, Henning KJ. Chronic liver disease in central Harlem: the role of alcohol and viral hepatitis. *Hepatology* 1999; **29**: 883-888 [PMID: 10051493 DOI: 10.1002/hep.510290308]

201 **Corrao G**, Aricò S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. *Hepatology* 1998; **27**: 914-919 [PMID: 9537428 DOI: 10.1002/hep.510270404]

202 **Freeman AJ**, Law MG, Kaldor JM, Dore GJ. Predicting progression to cirrhosis in chronic hepatitis C virus infection. *J Viral Hepat* 2003; **10**: 285-293 [PMID: 12823595 DOI: 10.1046/j.1365-2893.2003.00436.x]

203 **Singal AK**, Anand BS. Mechanisms of synergy between alcohol and hepatitis C virus. *J Clin Gastroenterol* 2007; **41**: 761-772 [PMID: 17700425 DOI: 10.1097/MCG.0b013e3180381584]

204 **Bellentani S**, Pozzato G, Saccoccio G, Crovatto M, Crocè LS, Mazzoran L, Masutti F, Cristianini G, Tiribelli C. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. *Gut* 1999; **44**: 874-880 [PMID: 10323892 DOI: 10.1136/gut.44.6.874]

205 **Jamal MM**, Morgan TR. Liver disease in alcohol and hepatitis C. *Best Pract Res Clin Gastroenterol* 2003; **17**: 649-662 [PMID: 12828960 DOI: 10.1016/s1521-6918(03)00018-0]

206 **Westin J**, Lagging LM, Spak F, Aires N, Svensson E, Lindh M, Dhillon AP, Norkrans G, Wejstål R. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. *J Viral Hepat* 2002; **9**: 235-241 [PMID: 12010513 DOI: 10.1046/j.1365-2893.2002.00356.x]

207 **Pessione F**, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, Degott C, Valla D, Erlinger S, Rueff B. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. *Hepatology* 1998; **27**: 1717-1722 [PMID: 9620348 DOI: 10.1002/hep.510270635]

208 **Hagström H**. Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much? *Curr Hepatol Rep* 2017; **16**: 152-157 [PMID: 28706775 DOI: 10.1007/s11901-017-0343-0]

209 **Mathurin P**, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, Cazier A, Huraux JM, Devergie B, Vidaud M, Opolon P, Poynard T. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. *Hepatology* 1998; **27**: 868-872 [PMID: 9500720 DOI: 10.1002/hep.510270333]

210 **Ostapowicz G**, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. *Hepatology* 1998; **27**: 1730-1735 [PMID: 9620350 DOI: 10.1002/hep.510270637]

211 **Marcellin P**, Grotzinger K, Theodore D, Demuth D, Manns M, Bañares Cañizares R, Pike J, Forssen UM. Severity of liver disease among chronic hepatitis C patients: an observational study of 4594 patients in five European countries. *J Gastroenterol Hepatol* 2015; **30**: 364-371 [PMID: 25088088 DOI: 10.1111/jgh.12698]

212 **Harris DR**, Gonin R, Alter HJ, Wright EC, Buskell ZJ, Hollinger FB, Seeff LB; National Heart, Lung, and Blood Institute Study Group. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. *Ann Intern Med* 2001; **134**: 120-124 [PMID: 11177315 DOI: 10.7326/0003-4819-134-2-200101160-00012]

213 **Anderson S**, Nevins CL, Green LK, El-Zimaity H, Anand BS. Assessment of liver histology in chronic alcoholics with and without hepatitis C virus infection. *Dig Dis Sci* 2001; **46**: 1393-1398 [PMID: 11478489 DOI: 10.1023/a:1010671300507]

214 **Schwarzinger M**, Baillot S, Yazdanpanah Y, Rehm J, Mallet V. Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008-2013: A nationwide retrospective cohort study. *J Hepatol* 2017; **67**: 454-461 [PMID: 28396173 DOI: 10.1016/j.jhep.2017.03.031]

215 **Mankal PK**, Abed J, Aristy JD, Munot K, Suneja U, Engelson ES, Kotler DP. Relative effects of heavy alcohol use and hepatitis C in decompensated chronic liver disease in a hospital inpatient population. *Am J Drug Alcohol Abuse* 2015; **41**: 177-182 [PMID: 25320839 DOI: 10.3109/00952990.2014.964358]

216 **Alavi M**, Janjua NZ, Chong M, Grebely J, Aspinall EJ, Innes H, Valerio HM, Hajarizadeh B, Hayes PC, Krajden M, Amin J, Law MG, George J, Goldberg DJ, Hutchinson SJ, Dore GJ. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study. *J Hepatol* 2018; **68**: 393-401 [PMID: 29107152 DOI: 10.1016/j.jhep.2017.10.019]

217 **Llamosas-Falcón L**, Shield KD, Gelovany M, Manthey J, Rehm J. Alcohol use disorders and the risk of progression of liver disease in people with hepatitis C virus infection - a systematic review. *Subst Abuse Treat Prev Policy* 2020; **15**: 45 [PMID: 32605584 DOI: 10.1186/s13011-020-00287-1]

218 **Choi HSJ**, Brouwer WP, Zanjir WMR, de Man RA, Feld JJ, Hansen BE, Janssen HLA, Patel K. Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B. *Hepatology* 2020; **71**: 539-548 [PMID: 31309589 DOI: 10.1002/hep.30857]

219 **Tacke F**, Boeker KHW, Klinker H, Heyne R, Buggisch P, Pathil A, Wiegand J, Cornberg M, Lange C, Berg T, Zeuzem S, Mauss S. Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. *Liver Int* 2020; **40**: 539-548 [PMID: 31241820 DOI: 10.1111/liv.14186]

220 **Donato F**, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. *Am J Epidemiol* 2002; **155**: 323-331 [PMID: 11836196 DOI: 10.1093/aje/155.4.323]

221 **Mariño Z**, Darnell A, Lens S, Sapena V, Díaz A, Belmonte E, Perelló C, Calleja JL, Varela M, Rodriguez M, Rodriguez de Lope C, Llerena S, Torras X, Gallego A, Sala M, Morillas RM, Minguez B, Llaneras J, Coll S, Carrion JA, Iñarrairaegui M, Sangro B, Vilana R, Sole M, Ayuso C, Ríos J, Forns X, Bruix J, Reig M. Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. *J Hepatol* 2019; **70**: 874-884 [PMID: 30684506 DOI: 10.1016/j.jhep.2019.01.005]

222 **Sangiovanni A**, Alimenti E, Gattai R, Filomia R, Parente E, Valenti L, Marzi L, Pellegatta G, Borgia G, Gambato M, Terreni N, Serio I, Belli L, Oliveri F, Maimone S, Brunacci M, D'Ambrosio R, Forzenigo LV, Russo FP, Rumi M, Barone M, Fracanzani AL, Raimondo G, Giannini EG, Brunetto MR, Villa E, Biganzoli E, Colombo M, Lampertico P. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. *J Hepatol* 2020; **73**: 593-602 [PMID: 32243959 DOI: 10.1016/j.jhep.2020.03.030]

223 **Kim WR**, Gross JB Jr, Poterucha JJ, Locke GR 3rd, Dickson ER. Outcome of hospital care of liver disease associated with hepatitis C in the United States. *Hepatology* 2001; **33**: 201-206 [PMID: 11124837 DOI: 10.1053/jhep.2001.20798]

224 **Tsui JI**, Pletcher MJ, Vittinghoff E, Seal K, Gonzales R. Hepatitis C and hospital outcomes in patients admitted with alcohol-related problems. *J Hepatol* 2006; **44**: 262-266 [PMID: 16226823 DOI: 10.1016/j.jhep.2005.07.027]

225 **Chen CM**, Yoon YH, Yi HY, Lucas DL. Alcohol and hepatitis C mortality among males and females in the United States: a life table analysis. *Alcohol Clin Exp Res* 2007; **31**: 285-292 [PMID: 17250621 DOI: 10.1111/j.1530-0277.2006.00304.x]

226 **Nilsson E**, Anderson H, Sargenti K, Lindgren S, Prytz H. Incidence, clinical presentation and mortality of liver cirrhosis in Southern Sweden: a 10-year population-based study. *Aliment Pharmacol Ther* 2016; **43**: 1330-1339 [PMID: 27091240 DOI: 10.1111/apt.13635]

227 **Kim NJ**, Pearson M, Vutien P, Su F, Moon AM, Berry K, Green PK, Williams EC, Ioannou GN. Alcohol Use and Long-Term Outcomes Among U.S. Veterans Who Received Direct-Acting Antivirals for Hepatitis C Treatment. *Hepatol Commun* 2020; **4**: 314-324 [PMID: 32025613 DOI: 10.1002/hep4.1464]

228 **Singal AK**, Sagi S, Kuo YF, Weinman S. Impact of hepatitis C virus infection on the course and outcome of patients with acute alcoholic hepatitis. *Eur J Gastroenterol Hepatol* 2011; **23**: 204-209 [PMID: 21258239 DOI: 10.1097/MEG.0b013e328343b085]

229 **Singal AK**, Kuo YF, Anand BS. Hepatitis C virus infection in alcoholic hepatitis: prevalence patterns and impact on in-hospital mortality. *Eur J Gastroenterol Hepatol* 2012; **24**: 1178-1184 [PMID: 22735607 DOI: 10.1097/MEG.0b013e328355cce0]

230 **Muga R**, Sanvisens A, Jarrin I, Fuster D, Bolao F, Tor J, Muñoz A. Hepatitis C infection substantially reduces survival of alcohol-dependent patients. *Clin Epidemiol* 2018; **10**: 897-905 [PMID: 30123002 DOI: 10.2147/CLEP.S162308]

231 **Pianko S**, Patella S, Ostapowicz G, Desmond P, Sievert W. Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. *J Viral Hepat* 2001; **8**: 406-413 [PMID: 11703571 DOI: 10.1046/j.1365-2893.2001.00316.x]

232 **Siu L**, Foont J, Wands JR. Hepatitis C virus and alcohol. *Semin Liver Dis* 2009; **29**: 188-199 [PMID: 19387918 DOI: 10.1055/s-0029-1214374]

233 **Osna NA**, Ganesan M, Kharbanda KK. Hepatitis C, innate immunity and alcohol: friends or foes? *Biomolecules* 2015; **5**: 76-94 [PMID: 25664450 DOI: 10.3390/biom5010076]

234 **Szabo G**, Wands JR, Eken A, Osna NA, Weinman SA, Machida K, Joe Wang H. Alcohol and hepatitis C virus--interactions in immune dysfunctions and liver damage. *Alcohol Clin Exp Res* 2010; **34**: 1675-1686 [PMID: 20608905 DOI: 10.1111/j.1530-0277.2010.01255.x]

235 **Punzalan CS**, Bukong TN, Szabo G. Alcoholic hepatitis and HCV interactions in the modulation of liver disease. *J Viral Hepat* 2015; **22**: 769-776 [PMID: 25754333 DOI: 10.1111/jvh.12399]

236 **Ran M**, Chen H, Liang B, Liao W, Jiang J, Huang J, Ning C, Zang N, Zhou B, Liao Y, Liu H, Qin F, Yang Q, Li J, Ho W, Liang H, Ye L. Alcohol-induced autophagy via upregulation of PIASy promotes HCV replication in human hepatoma cells. *Cell Death Dis* 2018; **9**: 898 [PMID: 30185779 DOI: 10.1038/s41419-018-0845-x]

237 **Shoreibah M**, Anand BS, Singal AK. Alcoholic hepatitis and concomitant hepatitis C virus infection. *World J Gastroenterol* 2014; **20**: 11929-11934 [PMID: 25232227 DOI: 10.3748/wjg.v20.i34.11929]

238 **Novo-Veleiro I**, Alvela-Suárez L, Chamorro AJ, González-Sarmiento R, Laso FJ, Marcos M. Alcoholic liver disease and hepatitis C virus infection. *World J Gastroenterol* 2016; **22**: 1411-1420 [PMID: 26819510 DOI: 10.3748/wjg.v22.i4.1411]

239 **Ratziu V**, Trabut JB, Poynard T. Fat, diabetes, and liver injury in chronic hepatitis C. *Curr Gastroenterol Rep* 2004; **6**: 22-29 [PMID: 14720450 DOI: 10.1007/s11894-004-0022-5]

240 **Adinolfi LE**, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. *Hepatology* 2001; **33**: 1358-1364 [PMID: 11391523 DOI: 10.1053/jhep.2001.24432]

241 **Hickman IJ**, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, Jonsson JR. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. *J Hepatol* 2003; **39**: 1042-1048 [PMID: 14642624 DOI: 10.1016/s0168-8278(03)00463-x]

242 **Zubair A**, Jamal S, Mubarik A. Morphometric analysis of hepatic steatosis in chronic hepatitis C infection. *Saudi J Gastroenterol* 2009; **15**: 11-14 [PMID: 19568548 DOI: 10.4103/1319-3767.45047]

243 **Hwang SJ**, Lee SD. Hepatic steatosis and hepatitis C: Still unhappy bedfellows? *J Gastroenterol Hepatol* 2011; **26** Suppl 1: 96-101 [PMID: 21199519 DOI: 10.1111/j.1440-1746.2010.06542.x]

244 **Ratziu V**, Munteanu M, Charlotte F, Bonyhay L, Poynard T; LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. *J Hepatol* 2003; **39**: 1049-1055 [PMID: 14642625 DOI: 10.1016/s0168-8278(03)00456-2]

245 **Yates FE**, Benton LA. Characteristics of ultradian and circadian rhythms of selected cardiovascular variables. Diagnostic and therapeutic implications. *Ann N Y Acad Sci* 1991; **618**: 38-56 [PMID: 2006797 DOI: 10.2337/dc09-1825]

246 **Petta S**, Amato M, Cabibi D, Cammà C, Di Marco V, Giordano C, Galluzzo A, Craxì A. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. *Hepatology* 2010; **52**: 1543-1552 [PMID: 20799355 DOI: 10.1002/hep.23859]

247 **Jang TY**, Yeh ML, Huang CI, Lin ZY, Chen SC, Hsieh MH, Dai CY, Huang JF, Huang CF, Chuang WL, Yu ML. Association of hyperuricemia with disease severity in chronic hepatitis C patients. *PLoS One* 2018; **13**: e0207043 [PMID: 30395654 DOI: 10.1371/journal.pone.0207043]

248 **Petta S**, Macaluso FS, Cammà C, Marco VD, Cabibi D, Craxì A. Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. *Liver Int* 2012; **32**: 1443-1450 [PMID: 22764879 DOI: 10.1111/j.1478-3231.2012.02842.x]

249 **Jang TY**, Huang CI, Yeh ML, Liang PC, Tsai PC, Lin YH, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Huang JF, Dai CY, Huang CF, Chuang WL, Yu ML. Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. *J Gastroenterol Hepatol* 2020; **35**: 473-481 [PMID: 31414504 DOI: 10.1111/jgh.14835]

250 **Elsayed A**, M Abdelraheem E, Hassan H, Abbas A, Hassnine A. Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect? *BMJ Open Gastroenterol* 2020; **7** [PMID: 33310750 DOI: 10.1136/bmjgast-2020-000533]

251 **Olubamwo OO**, Onyeka IN, Miettola J, Kauhanen J, Tuomainen TP. Hepatitis C as a risk factor for carotid atherosclerosis - a systematic review. *Clin Physiol Funct Imaging* 2016; **36**: 249-260 [PMID: 25620553 DOI: 10.1111/cpf.12229]

252 **Stepanova M**, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. *Gut* 2010; **59**: 1410-1415 [PMID: 20660697 DOI: 10.1136/gut.2010.213553]

253 **Yen YH**, Kee KM, Chen CH, Hu TH, Lu SN, Wang JH, Hung CH. Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C. *PLoS One* 2019; **14**: e0208858 [PMID: 30625158 DOI: 10.1371/journal.pone.0208858]

254 **Collins LF**, Adekunle RO, Cartwright EJ. Metabolic Syndrome in HIV/HCV Co-infected Patients. *Curr Treat Options Infect Dis* 2019; **11**: 351-371 [PMID: 32030090 DOI: 10.1007/s40506-019-00207-3]

255 **World Health Organization**. Obesity and overweight. WHO. [cited 5 November 2019]. Available from: https://www.who.int/news-room/fact-sheets/detail/ obesity-and-overweight

256 **Blonsky JJ**, Harrison SA. Review article: nonalcoholic fatty liver disease and hepatitis C virus--partners in crime. *Aliment Pharmacol Ther* 2008; **27**: 855-865 [PMID: 18315584 DOI: 10.1111/j.1365-2036.2008.03672.x]

257 **McPherson S**, Gosrani S, Hogg S, Patel P, Wetten A, Welton R, Hallsworth K, Campbell M. Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C. *BMJ Open Gastroenterol* 2020; **7** [PMID: 32847899 DOI: 10.1136/bmjgast-2020-000470]

258 **Younossi ZM**, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, Bringman D, Martin LM, Assmann J, Gramlich T, Mullen KD, O'Shea R, Carey WD, Ferguson R. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. *J Clin Gastroenterol* 2004; **38**: 705-709 [PMID: 15319656 DOI: 10.1097/01.mcg.0000135372.10846.2a]

259 **Bugianesi E**, Salamone F, Negro F. The interaction of metabolic factors with HCV infection: does it matter? *J Hepatol* 2012; **56** Suppl 1: S56-S65 [PMID: 22300466 DOI: 10.1016/S0168-8278(12)60007-5]

260 **Negro F**. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. *J Hepatol* 2014; **61**: S69-S78 [PMID: 25443347 DOI: 10.1016/j.jhep.2014.08.003]

261 **Reilly SM**, Saltiel AR. Adapting to obesity with adipose tissue inflammation. *Nat Rev Endocrinol* 2017; **13**: 633-643 [PMID: 28799554 DOI: 10.1038/nrendo.2017.90]

262 **Saltiel AR**, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. *J Clin Invest* 2017; **127**: 1-4 [PMID: 28045402 DOI: 10.1172/JCI92035]

263 **Westin J**, Nordlinder H, Lagging M, Norkrans G, Wejstål R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. *J Hepatol* 2002; **37**: 837-842 [PMID: 12445426 DOI: 10.1016/s0168-8278(02)00299-4]

264 **Leandro G**, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, Asselah T, Jonsson JR, Smedile A, Terrault N, Pazienza V, Giordani MT, Giostra E, Sonzogni A, Ruggiero G, Marcellin P, Powell EE, George J, Negro F; HCV Meta-Analysis (on) Individual Patients' Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. *Gastroenterology* 2006; **130**: 1636-1642 [PMID: 16697727 DOI: 10.1053/j.gastro.2006.03.014]

265 **Hourigan LF**, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. *Hepatology* 1999; **29**: 1215-1219 [PMID: 10094967 DOI: 10.1002/hep.510290401]

266 **Hickman IJ**, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, Jonsson JR, Powell EE. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. *Gut* 2002; **51**: 89-94 [PMID: 12077098 DOI: 10.1136/gut.51.1.89]

267 **Poynard T**, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. *Hepatology* 2003; **38**: 75-85 [PMID: 12829989 DOI: 10.1053/jhep.2003.50267]

268 **Fried MW**, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; **347**: 975-982 [PMID: 12324553 DOI: 10.1056/NEJMoa020047]

269 **Manns MP**, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; **358**: 958-965 [PMID: 11583749 DOI: 10.1016/s0140-6736(01)06102-5]

270 **Bressler BL**, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. *Hepatology* 2003; **38**: 639-644 [PMID: 12939590 DOI: 10.1053/jhep.2003.50350]

271 **Patton HM**, Patel K, Behling C, Bylund D, Blatt LM, Vallée M, Heaton S, Conrad A, Pockros PJ, McHutchison JG. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. *J Hepatol* 2004; **40**: 484-490 [PMID: 15123364 DOI: 10.1016/j.jhep.2003.11.004]

272 **Vaz J**, Eriksson B, Strömberg U, Buchebner D, Midlöv P. Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study. *BMC Gastroenterol* 2020; **20**: 84 [PMID: 32245414 DOI: 10.1186/s12876-020-01239-6]

273 **Sultanik P**, Kramer L, Soudan D, Bouam S, Meritet JF, Vallet-Pichard A, Fontaine H, Bousquet L, Boueyre E, Corouge M, Sogni P, Pol S, Mallet V. The relationship between liver stiffness measurement and outcome in patients with chronic hepatitis C and cirrhosis: a retrospective longitudinal hospital study. *Aliment Pharmacol Ther* 2016; **44**: 505-513 [PMID: 27407002 DOI: 10.1111/apt.13722]

274 **Yoo HJ**, Jung KJ, Kim M, Kim M, Kang M, Jee SH, Choi Y, Lee JH. Liver Cirrhosis Patients Who Had Normal Liver Function Before Liver Cirrhosis Development Have the Altered Metabolic Profiles Before the Disease Occurrence Compared to Healthy Controls. *Front Physiol* 2019; **10**: 1421 [PMID: 31803070 DOI: 10.3389/fphys.2019.01421]

275 **Ohki T**, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, Yamashiki N, Yoshida H, Kanai F, Kato N, Shiina S, Yoshida H, Kawabe T, Omata M. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. *Clin Gastroenterol Hepatol* 2008; **6**: 459-464 [PMID: 18387499 DOI: 10.1016/j.cgh.2008.02.012]

276 **Ukawa S**, Tamakoshi A, Murakami Y, Kiyohara Y, Yamada M, Nagai M, Satoh A, Miura K, Ueshima H, Okamura T, EPOCH-JAPAN Research Group. Pooled Analysis of the Associations between Body Mass Index, Total Cholesterol, and Liver Cancer-related Mortality in Japan. *Asian Pac J Cancer Prev* 2018; **19**: 2089-2095 [PMID: 30139206 DOI: 10.22034/APJCP.2018.19.8.2089]

277 **Lee HW**, Han DH, Shin HJ, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals. *Cancers (Basel)* 2020; **12** [PMID: 33217965 DOI: 10.3390/cancers12113414]

278 **Dyal HK**, Aguilar M, Bartos G, Holt EW, Bhuket T, Liu B, Cheung R, Wong RJ. Diabetes Mellitus Increases Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Virus Patients: A Systematic Review. *Dig Dis Sci* 2016; **61**: 636-645 [PMID: 26703125 DOI: 10.1007/s10620-015-3983-3]

279 **Delgado-Borrego A**, Healey D, Negre B, Christofi M, Sabharwal S, Ludwig DA, Chung RT, Jonas MM. Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. *J Pediatr Gastroenterol Nutr* 2010; **51**: 191-197 [PMID: 20531022 DOI: 10.1097/MPG.0b013e3181d32756]

280 **Lanini S**, Scognamiglio P, Mecozzi A, Lombardozzi L, Vullo V, Angelico M, Gasbarrini A, Taliani G, Attili AF, Perno CF, De Santis A, Puro V, Cerqua F, D'Offizi G, Pellicelli A, Armignacco O, Mennini FS, Siciliano M, Girardi E, Panella V, Ippolito G; members of the Lazio Region HCV treatment group. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study. *BMC Infect Dis* 2018; **18**: 223 [PMID: 29769038 DOI: 10.1186/s12879-018-3125-6]

281 **Allison ME**, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. *J Hepatol* 1994; **21**: 1135-1139 [PMID: 7699240 DOI: 10.1016/s0168-8278(05)80631-2]

282 **Wang CS**, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. *Am J Epidemiol* 2007; **166**: 196-203 [PMID: 17496314 DOI: 10.1093/aje/kwm061]

283 **Petta S**, Cammà C, Di Marco V, Alessi N, Cabibi D, Caldarella R, Licata A, Massenti F, Tarantino G, Marchesini G, Craxì A. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. *Am J Gastroenterol* 2008; **103**: 1136-1144 [PMID: 18477344 DOI: 10.1111/j.1572-0241.2008.01813.x]

284 **Padgham CR**, Paine AJ, Phillips IR, Shephard EA. Maintenance of cytochrome P-450IA2, IIB1 and IIB2 mRNAs by metyrapone in rat hepatocyte culture. *Biochem Soc Trans* 1990; **18**: 1203 [PMID: 2088866 DOI: 10.1016/j.jhep.2010.06.021]

285 **Stättermayer AF**, Rutter K, Beinhardt S, Scherzer TM, Stadlmayr A, Hofer H, Wrba F, Steindl-Munda P, Krebs M, Datz C, Trauner M, Ferenci P. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. *J Hepatol* 2012; **57**: 492-498 [PMID: 22634340 DOI: 10.1016/j.jhep.2012.04.036]

286 **Kawaguchi T**, Sata M. Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization. *World J Gastroenterol* 2010; **16**: 1943-1952 [PMID: 20419831 DOI: 10.3748/wjg.v16.i16.1943]

287 **Adinolfi LE**, Jacobson I, Bondin M, Cacoub P. Expert opinion on managing chronic HCV infection in patients with type 2 diabetes mellitus. *Antivir Ther* 2018; **23**: 11-21 [PMID: 30451154 DOI: 10.3851/IMP3255]

288 **Chen Y**, Ji H, Shao J, Jia Y, Bao Q, Zhu J, Zhang L, Shen Y. Different Hepatitis C Virus Infection Statuses Show a Significant Risk of Developing Type 2 Diabetes Mellitus: A Network Meta-Analysis. *Dig Dis Sci* 2020; **65**: 1940-1950 [PMID: 31758432 DOI: 10.1007/s10620-019-05918-7]

289 **Huang TS**, Lin CL, Lu MJ, Yeh CT, Liang KH, Sun CC, Shyu YC, Chien RN. Diabetes, hepatocellular carcinoma, and mortality in hepatitis C-infected patients: A population-based cohort study. *J Gastroenterol Hepatol* 2017; **32**: 1355-1362 [PMID: 27930829 DOI: 10.1111/jgh.13670]

290 **Li X**, Xu H, Gao Y, Pan M, Wang L, Gao P. Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis C patients in China. *Medicine (Baltimore)* 2017; **96**: e6508 [PMID: 28353605 DOI: 10.1097/MD.0000000000006508]

291 **Rao H**, Wu E, Fu S, Yang M, Feng B, Lin A, Fei R, Fontana RJ, Lok AS, Wei L. The higher prevalence of truncal obesity and diabetes in American than Chinese patients with chronic hepatitis C might contribute to more rapid progression to advanced liver disease. *Aliment Pharmacol Ther* 2017; **46**: 731-740 [PMID: 28833342 DOI: 10.1111/apt.14273]

292 **Arase Y**, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Kobayashi T. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. *Hepatology* 2013; **57**: 964-973 [PMID: 22991257 DOI: 10.1002/hep.26087]

293 **Degasperi E**, D'Ambrosio R, Iavarone M, Sangiovanni A, Aghemo A, Soffredini R, Borghi M, Lunghi G, Colombo M, Lampertico P. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection. *Clin Gastroenterol Hepatol* 2019; **17**: 1183-1191.e7 [PMID: 30613002 DOI: 10.1016/j.cgh.2018.10.038]

294 **Charlton MR**, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. *Hepatology* 2006; **43**: 1177-1186 [PMID: 16729327 DOI: 10.1002/hep.21239]

295 **Everhart JE**, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, Bonkovsky HL, Ghany MG; HALT-C Trial Group. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. *Gastroenterology* 2009; **137**: 549-557 [PMID: 19445938 DOI: 10.1053/j.gastro.2009.05.007]

296 **Ogawa E**, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, Hayashi J. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. *J Hepatol* 2012; **57**: 534-540 [PMID: 22613000 DOI: 10.1016/j.jhep.2012.04.027]

297 **Hu JH**, Chang ML, Liu NJ, Yeh CT, Huang TJ. Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis. *Exp Ther Med* 2019; **18**: 3568-3578 [PMID: 31602234 DOI: 10.3892/etm.2019.7995]

298 **Dong TS**, Aby ES, Benhammou JN, Kawamoto J, Han SH, May FP, Pisegna JR. Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c. *World J Hepatol* 2018; **10**: 612-621 [PMID: 30310539 DOI: 10.4254/wjh.v10.i9.612]

299 **Russo FP**, Zanetto A, Gambato M, Bortoluzzi I, Al Zoairy R, Franceschet E, De Marchi F, Marzi L, Lynch EN, Floreani A, Farinati F, Schaefer B, Burra P, Zoller H, Mega A. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. *J Viral Hepat* 2020; **27**: 188-194 [PMID: 31596996 DOI: 10.1111/jvh.13215]

300 **Adinolfi LE**, Petta S, Fracanzani AL, Nevola R, Coppola C, Narciso V, Rinaldi L, Calvaruso V, Pafundi PC, Lombardi R, Staiano L, Di Marco V, Solano A, Marrone A, Saturnino M, Rini F, Guerrera B, Troina G, Giordano M, Craxì A, Sasso FC. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. *Diabetes Obes Metab* 2020; **22**: 2408-2416 [PMID: 32761721 DOI: 10.1111/dom.14168]

301 **Bassendine MF**, Sheridan DA, Bridge SH, Felmlee DJ, Neely RD. Lipids and HCV. *Semin Immunopathol* 2013; **35**: 87-100 [PMID: 23111699 DOI: 10.1007/s00281-012-0356-2]

302 **Graf C**, Welzel T, Bogdanou D, Vermehren J, Beckel A, Bojunga J, Friedrich-Rust M, Dietz J, Kubesch A, Mondorf A, Fischer S, Lutz T, Stoffers P, Herrmann E, Poynard T, Zeuzem S, Dultz G, Mihm U. Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis. *J Clin Med* 2020; **9**: 2702 [PMID: 32825571 DOI: 10.3390/jcm9092702]

303 **Nevola R**, Rinaldi L, Zeni L, Sasso FC, Pafundi PC, Guerrera B, Marrone A, Giordano M, Adinolfi LE. Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals. *JGH Open* 2020; **4**: 713-721 [PMID: 32782961 DOI: 10.1002/jgh3.12324]

304 **Özdoğan O**, Yaraş S, Ateş F, Üçbilek E, Sezgin O, Altıntaş E. The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent? *Turk J Gastroenterol* 2020; **31**: 384-392 [PMID: 32519958 DOI: 10.5152/tjg.2020.19273]

305 **Lonardo A**, Adinolfi LE, Restivo L, Ballestri S, Romagnoli D, Baldelli E, Nascimbeni F, Loria P. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen. *World J Gastroenterol* 2014; **20**: 7089-7103 [PMID: 24966582 DOI: 10.3748/wjg.v20.i23.7089]

306 **Adinolfi LE**, Rinaldi L, Guerrera B, Restivo L, Marrone A, Giordano M, Zampino R. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. *Int J Mol Sci* 2016; **17**: 803 [PMID: 27231906 DOI: 10.3390/ijms17060803]

307 **Paradis V**, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, Conti M, Huet S, Ba N, Buffet C, Bedossa P. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. *Hepatology* 2001; **34**: 738-744 [PMID: 11584370 DOI: 10.1053/jhep.2001.28055]

308 **Lonardo A**, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. *Gastroenterology* 2004; **126**: 586-597 [PMID: 14762795 DOI: 10.1053/j.gastro.2003.11.020]

309 **Chang ML**. Metabolic alterations and hepatitis C: From bench to bedside. *World J Gastroenterol* 2016; **22**: 1461-1476 [PMID: 26819514 DOI: 10.3748/wjg.v22.i4.1461]

310 **Kralj D**, Virović Jukić L, Stojsavljević S, Duvnjak M, Smolić M, Čurčić IB. Hepatitis C Virus, Insulin Resistance, and Steatosis. *J Clin Transl Hepatol* 2016; **4**: 66-75 [PMID: 27047774 DOI: 10.14218/JCTH.2015.00051]

311 **Fotiou A**, Kanavou E, Antaraki A, Richardson C, Terzidou M, Kokkevi A; Drug Related Infectious Diseases (DRID) Medical Doctors Group of OKANA. HCV/HIV coinfection among people who inject drugs and enter opioid substitution treatment in Greece: prevalence and correlates. *Hepatol Med Policy* 2016; **1**: 9 [PMID: 30288313 DOI: 10.1186/s41124-016-0017-5]

312 **Rashti R**, Sharafi H, Alavian SM, Moradi Y, Mohamadi Bolbanabad A, Moradi G. Systematic Review and Meta-Analysis of Global Prevalence of HBsAg and HIV and HCV Antibodies among People Who Inject Drugs and Female Sex Workers. *Pathogens* 2020; **9** [PMID: 32486342 DOI: 10.3390/pathogens9060432]

313 **Zayedi E**, Makvandi M, Teimoori A, Samarbaf-Zadeh AR, Ghafari S, Seyedian SS, Azaran A. Prevalence of hepatitis C virus among HIV-infected patients. *Iran J Microbiol* 2020; **12**: 156-163 [PMID: 32494350]

314 **Graham CS**, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. *Clin Infect Dis* 2001; **33**: 562-569 [PMID: 11462196 DOI: 10.1086/321909]

315 **Thomas DL**. Hepatitis C and human immunodeficiency virus infection. *Hepatology* 2002; **36**: S201-S209 [PMID: 12407595 DOI: 10.1053/jhep.2002.36380]

316 **Thein HH**, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. *AIDS* 2008; **22**: 1979-1991 [PMID: 18784461 DOI: 10.1097/QAD.0b013e32830e6d51]

317 **Chen TY**, Ding EL, Seage Iii GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. *Clin Infect Dis* 2009; **49**: 1605-1615 [PMID: 19842982 DOI: 10.1086/644771]

318 **Ragni MV**, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. *J Infect Dis* 2001; **183**: 1112-1115 [PMID: 11237838 DOI: 10.1086/319273]

319 **Fierer DS**, Dieterich DT, Fiel MI, Branch AD, Marks KM, Fusco DN, Hsu R, Smith DM, Fierer J. Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. *Clin Infect Dis* 2013; **56**: 1038-1043 [PMID: 23264364 DOI: 10.1093/cid/cis1206]

320 **Fuster D**, Cheng DM, Quinn EK, Nunes D, Saitz R, Samet JH, Tsui JI. Chronic hepatitis C virus infection is associated with all-cause and liver-related mortality in a cohort of HIV-infected patients with alcohol problems. *Addiction* 2014; **109**: 62-70 [PMID: 24112091 DOI: 10.1111/add.12367]

321 **Ananthakrishnan AN**, McGinley EL, Fangman J, Saeian K. Hepatitis C/HIV co-infection is associated with higher mortality in hospitalized patients with hepatitis C or HIV. *J Viral Hepat* 2010; **17**: 720-729 [PMID: 20002558 DOI: 10.1111/j.1365-2893.2009.01232.x]

322 **Hall T**, Jenkins CA, Hulgan T, Furukawa S, Turner M, Pratap S, Sterling TR, Tabatabai M, Berthaud V. Hepatitis C Coinfection and Mortality in People Living with HIV in Middle Tennessee. *AIDS Res Hum Retroviruses* 2020; **36**: 193-199 [PMID: 31789047 DOI: 10.1089/AID.2019.0113]

323 **Zahnd C**, Salazar-Vizcaya L, Dufour JF, Müllhaupt B, Wandeler G, Kouyos R, Estill J, Bertisch B, Rauch A, Keiser O; Swiss HIV; Swiss Hepatitis C Cohort Studies. Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfected men who have sex with men. *J Hepatol* 2016; **65**: 26-32 [PMID: 26921687 DOI: 10.1016/j.jhep.2016.02.030]

324 **Kramer JR**, Kowalkowski MA, Duan Z, Chiao EY. The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection. *J Acquir Immune Defic Syndr* 2015; **68**: 456-462 [PMID: 25559606 DOI: 10.1097/QAI.0000000000000494]

325 **Gjærde LI**, Shepherd L, Jablonowska E, Lazzarin A, Rougemont M, Darling K, Battegay M, Braun D, Martel-Laferriere V, Lundgren JD, Rockstroh JK, Gill J, Rauch A, Mocroft A, Klein MB, Peters L. Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. *Clin Infect Dis* 2016; **63**: 821-829 [PMID: 27307505 DOI: 10.1093/cid/ciw380]

326 **Salmon-Ceron D**, Nahon P, Layese R, Bourcier V, Sogni P, Bani-Sadr F, Audureau E, Merchadou L, Dabis F, Wittkop L, Roudot-Thoraval F; ANRS CO12 CirVir and ANRS CO13 HEPAVIH study groups. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients. *Hepatology* 2019; **70**: 939-954 [PMID: 30569448 DOI: 10.1002/hep.30400]

327 **Benhamou Y**, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. *Hepatology* 1999; **30**: 1054-1058 [PMID: 10498659 DOI: 10.1002/hep.510300409]

328 **Schiavini M**, Angeli E, Mainini A, Zerbi P, Duca PG, Gubertini G, Vago L, Fociani P, Giorgi R, Cargnel A. Risk factors for fibrosis progression in HIV/HCV coinfected patients from a retrospective analysis of liver biopsies in 1985-2002. *HIV Med* 2006; **7**: 331-337 [PMID: 16945079 DOI: 10.1111/j.1468-1293.2006.00384.x]

329 **Sulkowski MS**, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, de Oca RM, Moore RD, Afdhal NH, Thomas DL. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. *AIDS* 2007; **21**: 2209-2216 [PMID: 18090048 DOI: 10.1097/QAD.0b013e3282f10de9]

330 **Bonnard P**, Lescure FX, Amiel C, Guiard-Schmid JB, Callard P, Gharakhanian S, Pialoux G. Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count. *J Viral Hepat* 2007; **14**: 806-811 [PMID: 17927617 DOI: 10.1111/j.1365-2893.2007.00874.x]

331 **Konerman MA**, Mehta SH, Sutcliffe CG, Vu T, Higgins Y, Torbenson MS, Moore RD, Thomas DL, Sulkowski MS. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. *Hepatology* 2014; **59**: 767-775 [PMID: 24436062 DOI: 10.1002/hep.26741]

332 **Di Martino V**, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, Matheron S, Le Moing V, Vachon F, Degott C, Valla D, Marcellin P. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. *Hepatology* 2001; **34**: 1193-1199 [PMID: 11732009 DOI: 10.1053/jhep.2001.29201]

333 **Labarga P**, Fernandez-Montero JV, de Mendoza C, Barreiro P, Pinilla J, Soriano V. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients. *Antivir Ther* 2015; **20**: 329-334 [PMID: 25372299 DOI: 10.3851/IMP2909]

334 **Kirk GD**, Mehta SH, Astemborski J, Galai N, Washington J, Higgins Y, Balagopal A, Thomas DL. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. *Ann Intern Med* 2013; **158**: 658-666 [PMID: 23440167 DOI: 10.7326/0003-4819-158-9-201305070-00604]

335 **Pembroke T**, Deschenes M, Lebouché B, Benmassaoud A, Sewitch M, Ghali P, Wong P, Halme A, Vuille-Lessard E, Pexos C, Klein MB, Sebastiani G. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. *J Hepatol* 2017; **67**: 801-808 [PMID: 28527666 DOI: 10.1016/j.jhep.2017.05.011]

336 **Sánchez-Conde M**, Berenguer J, Miralles P, Alvarez F, Carlos Lopez J, Cosin J, Pilar C, Ramirez M, Gutierrez I, Alvarez E. Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase. *Clin Infect Dis* 2006; **43**: 640-644 [PMID: 16886160 DOI: 10.1086/506440]

337 **Marcellin F**, Roux P, Loko MA, Lions C, Caumont-Prim A, Dabis F, Salmon-Ceron D, Spire B, Carrieri MP; HEPAVIH (ANRS CO13) Study Group. High levels of alcohol consumption increase the risk of advanced hepatic fibrosis in HIV/hepatitis C virus-coinfected patients: a sex-based analysis using transient elastography at enrollment in the HEPAVIH ANRS CO13 cohort. *Clin Infect Dis* 2014; **59**: 1190-1192 [PMID: 25015913 DOI: 10.1093/cid/ciu525]

338 **Lim JK**, Tate JP, Fultz SL, Goulet JL, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Rimland D, Goetz MB, Klein MB, Fiellin DA, Justice AC, Lo Re V 3rd. Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. *Clin Infect Dis* 2014; **58**: 1449-1458 [PMID: 24569533 DOI: 10.1093/cid/ciu097]

339 **Ferguson TF**, Rosen E, Carr R, Brashear M, Simon L, Theall KP, Ronis MJ, Welsh DA, Molina PE. Associations of Liver Disease with Alcohol Use among People Living with HIV and the Role of Hepatitis C: The New Orleans Alcohol Use in HIV Study. *Alcohol Alcohol* 2020; **55**: 28-36 [PMID: 31812989 DOI: 10.1093/alcalc/agz089]

340 **Barreiro P**, Pineda JA, Rallón N, Naggie S, Martín-Carbonero L, Neukam K, Rivero A, Benito JM, Caruz A, Vispo E, Camacho A, Medrano J, McHutchison J, Soriano V. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. *J Infect Dis* 2011; **203**: 1629-1636 [PMID: 21592993 DOI: 10.1093/infdis/jir113]

341 **Gayam V**, Hossain MR, Khalid M, Chakaraborty S, Mukhtar O, Dahal S, Mandal AK, Gill A, Garlapati P, Ramakrishnaiah S, Mowyad K, Sherigar J, Mansour M, Mohanty S. Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting. *Gut Liver* 2018; **12**: 694-703 [PMID: 29938459 DOI: 10.5009/gnl18004]

342 **Neukam K**, Morano-Amado LE, Rivero-Juárez A, Mancebo M, Granados R, Téllez F, Collado A, Ríos MJ, de Los Santos-Gil I, Reus-Bañuls S, Vera-Méndez F, Geijo-Martínez P, Montero-Alonso M, Suárez-Santamaría M, Pineda JA. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study. *HIV Clin Trials* 2017; **18**: 126-134 [PMID: 28599618 DOI: 10.1080/15284336.2017.1330801]

343 **Sikavi C**, Najarian L, Saab S. Similar Sustained Virologic Response in Real-World and Clinical Trial Studies of Hepatitis C/Human Immunodeficiency Virus Coinfection. *Dig Dis Sci* 2018; **63**: 2829-2839 [PMID: 30094623 DOI: 10.1007/s10620-018-5215-0]

344 **Machado SM**, Vigani AG, Leite AG, Diaz ACM, Ferreira PRA, Carnaúba-Júnior D, Tenore SB, Brandão-Mello CE, Gonzalez MP, Siroma F, Prado KD, Nunes DV, Lisboa-Neto G, Pinho JRR, Malta FM, Azevedo RS, Witkin SS, Mendes-Correa MC. Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study. *Medicine (Baltimore)* 2020; **99**: e21270 [PMID: 32791706 DOI: 10.1097/MD.0000000000021270]

345 **Patel SV**, Jayaweera DT, Althoff KN, Eron JJ, Radtchenko J, Mills A, Moyle G, Santiago S, Sax PE, Gillman J, Mounzer K, Elion RA, Huhn GD. Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV. *PLoS One* 2020; **15**: e0228847 [PMID: 32053682 DOI: 10.1371/journal.pone.0228847]

346 **Sims OT**, Chiu CY, Chandler R, Melton P, Wang K, Richey C, Odlum M. Alcohol Use and Ethnicity Independently Predict Antiretroviral Therapy Nonadherence Among Patients Living with HIV/HCV Coinfection. *J Racial Ethn Health Disparities* 2020; **7**: 28-35 [PMID: 31435855 DOI: 10.1007/s40615-019-00630-8]

347 **Yaya I**, Marcellin F, Costa M, Morlat P, Protopopescu C, Pialoux G, Santos ME, Wittkop L, Esterle L, Gervais A, Sogni P, Salmon-Ceron D, Carrieri MP; ANRS CO13-HEPAVIH Cohort Study Group. Impact of Alcohol and Coffee Intake on the Risk of Advanced Liver Fibrosis: A Longitudinal Analysis in HIV-HCV Coinfected Patients (ANRS HEPAVIH CO-13 Cohort). *Nutrients* 2018; **10**: 705 [PMID: 29857547 DOI: 10.3390/nu10060705]

348 **Corma-Gómez A**, Morano L, Téllez F, Rivero-Juárez A, Real LM, Alados JC, Ríos-Villegas MJ, Vera-Méndez FJ, Muñoz RP, Geijo P, Macías J, Pineda JA; RIS-HEP13 and GEHEP 011 study groups. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals. *AIDS* 2019; **33**: 1167-1174 [PMID: 30845068 DOI: 10.1097/QAD.0000000000002186]

349 **Corma-Gómez A**, Macías J, Téllez F, Freyre-Carrillo C, Morano L, Rivero-Juárez A, Ríos MJ, Alados JC, Vera-Méndez FJ, Merchante N, Palacios R, Granados R, Merino D, De Los Santos I, Pineda JA. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals. *Clin Infect Dis* 2020; **71**: 2354-2362 [PMID: 31754695 DOI: 10.1093/cid/ciz1140]

350 **Corma-Gómez A**, Macías J, Lacalle-Remigio JR, Téllez F, Morano L, Rivero A, Serrano M, Ríos MJ, Vera-Méndez FJ, Alados JC, Real LM, Palacios R, Santos IL, Imatz A, Pineda JA; RIS-HEP13 and GEHEP 011 study groups. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis. *Clin Infect Dis* 2021; **73**: e2109-e2116 [PMID: 32766891 DOI: 10.1093/cid/ciaa1111]

351 **Chalouni M**, Pol S, Sogni P, Fontaine H, Lacombe K, Marc-Lacombe J, Esterle L, Dorival C, Bourlière M, Bani-Sadr F, de Ledinghen V, Zucman D, Larrey D, Salmon D, Carrat F, Wittkop L; ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohort study groups. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death. *J Hepatol* 2021; **74**: 37-47 [PMID: 32798585 DOI: 10.1016/j.jhep.2020.08.008]

352 **Papasavvas E**, Azzoni L, Yin X, Liu Q, Joseph J, Mackiewicz A, Ross B, Lynn KM, Jacobson JM, Mounzer K, Kostman JR, Montaner LJ. HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects. *J Viral Hepat* 2017; **24**: 865-876 [PMID: 28419653 DOI: 10.1111/jvh.12714]

353 **Polo ML**, Ghiglione YA, Salido JP, Urioste A, Poblete G, Sisto AE, Martinez A, Rolón MJ, Ojeda DS, Cahn PE, Turk GJ, Laufer NL. Liver cirrhosis in HIV/HCV-coinfected individuals is related to NK cell dysfunction and exhaustion, but not to an impaired NK cell modulation by CD4+ T-cells. *J Int AIDS Soc* 2019; **22**: e25375 [PMID: 31536177 DOI: 10.1002/jia2.25375]

354 **Zhang L**, Bansal MB. Role of Kupffer Cells in Driving Hepatic Inflammation and Fibrosis in HIV Infection. *Front Immunol* 2020; **11**: 1086 [PMID: 32612603 DOI: 10.3389/fimmu.2020.01086]

355 **Jeyarajan AJ**, Chung RT. Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure? *J Infect Dis* 2020; **222**: S802-S813 [PMID: 33245355 DOI: 10.1093/infdis/jiaa279]

356 **Skaathun B**, Borquez A, Rivero-Juarez A, Mehta SR, Tellez F, Castaño-Carracedo M, Merino D, Palacios R, Macías J, Rivero A, Martin NK. What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis. *BMC Infect Dis* 2020; **20**: 588 [PMID: 32770955 DOI: 10.1186/s12879-020-05285-z]

357 **Byrne C**, Robinson E, Rae N, Dillon JF. Toward microelimination of hepatitis C and HIV coinfection in NHS Tayside, Scotland: Real-world outcomes. *Health Sci Rep* 2020; **3**: e191 [PMID: 33033752 DOI: 10.1002/hsr2.191]

358 **Schmidbauer C**, Chromy D, Schmidbauer V, Bauer D, Apata M, Nguyen D, Mandorfer M, Simbrunner B, Rieger A, Mayer F, Schmidt R, Holzmann H, Trauner M, Gschwantler M, Reiberger T. Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. *Liver Int* 2020; **40**: 787-796 [PMID: 32017359 DOI: 10.1111/liv.14399]

359 **Irvin R**, Chander G, Falade-Nwulia O, Astemborski J, Starbird L, Kirk GD, Sulkowski MS, Thomas DL, Mehta SH. Overlapping epidemics of alcohol and illicit drug use among HCV-infected persons who inject drugs. *Addict Behav* 2019; **96**: 56-61 [PMID: 31035079 DOI: 10.1016/j.addbeh.2019.04.023]

360 **Maticic M**, Pirnat Z, Leicht A, Zimmermann R, Windelinck T, Jauffret-Roustide M, Duffell E, Tammi T, Schatz E. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries. *Harm Reduct J* 2020; **17**: 89 [PMID: 33213481 DOI: 10.1186/s12954-020-00439-3]

361 **Sanvisens A**, Rivas I, Faure E, Espinach N, Hernandez-Rubio A, Majó X, Colom J, Muga R. Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study. *World J Gastroenterol* 2020; **26**: 5874-5883 [PMID: 33132641 DOI: 10.3748/wjg.v26.i38.5874]

362 **Rojas Rojas T**, Di Beo V, Delorme J, Barre T, Mathurin P, Protopopescu C, Bailly F, Coste M, Authier N, Carrieri MP, Rolland B, Marcellin F. Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project. *Int J Drug Policy* 2019; **72**: 61-68 [PMID: 31129024 DOI: 10.1016/j.drugpo.2019.05.013]

363 **Fuster D**, Sanvisens A, Bolao F, Rivas I, Tor J, Muga R. Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. *World J Hepatol* 2016; **8**: 1295-1308 [PMID: 27872681 DOI: 10.4254/wjh.v8.i31.1295]

364 **Degenhardt L**, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, Stone J, Cunningham EB, Trickey A, Dumchev K, Lynskey M, Griffiths P, Mattick RP, Hickman M, Larney S. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. *Lancet Glob Health* 2017; **5**: e1192-e1207 [PMID: 29074409 DOI: 10.1016/S2214-109X(17)30375-3]

365 **Scott N**, Sacks-Davis R, Pedrana A, Doyle J, Thompson A, Hellard M. Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings. *J Viral Hepat* 2018; **25**: 1472-1480 [PMID: 30047625 DOI: 10.1111/jvh.12975]

366 **Macías J**, Morano LE, Téllez F, Granados R, Rivero-Juárez A, Palacios R, Ríos M, Merino D, Pérez-Pérez M, Collado A, Figueruela B, Morano A, Freyre-Carrillo C, Martín JM, Rivero A, García F, Pineda JA; HEPAVIR group from the Sociedad Andaluza de Enfermedades Infecciosas (SAEI) and the GEHEP group from the Sociedad Española de Enfermedades Infecciosas y Microbiología (SEIMC). Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy. *J Hepatol* 2019; **71**: 45-51 [PMID: 30853642 DOI: 10.1016/j.jhep.2019.02.018]

367 **Schmidbauer C**, Schubert R, Schütz A, Schwanke C, Luhn J, Gutic E, Pirker R, Lang T, Reiberger T, Haltmayer H, Gschwantler M. Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria. *PLoS One* 2020; **15**: e0229239 [PMID: 32155165 DOI: 10.1371/journal.pone.0229239]

368 **Janjua NZ**, Chong M, Kuo M, Woods R, Wong J, Yoshida EM, Sherman M, Butt ZA, Samji H, Cook D, Yu A, Alvarez M, Tyndall M, Krajden M. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. *J Hepatol* 2017; **66**: 504-513 [PMID: 27818234 DOI: 10.1016/j.jhep.2016.10.028]

369 **Rossi C**, Butt ZA, Wong S, Buxton JA, Islam N, Yu A, Darvishian M, Gilbert M, Wong J, Chapinal N, Binka M, Alvarez M, Tyndall MW, Krajden M, Janjua NZ; BC Hepatitis Testers Cohort Team. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort. *J Hepatol* 2018; **69**: 1007-1014 [PMID: 30142429 DOI: 10.1016/j.jhep.2018.07.025]

370 **Muller A**, Vlahov D, Akiyama MJ, Kurth A. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis. *Int J Environ Res Public Health* 2020; **17**: 4951 [PMID: 32659974 DOI: 10.3390/ijerph17144951]

371 **Bassett SE**, Di Bisceglie AM, Bacon BR, Sharp RM, Govindarajan S, Hubbard GB, Brasky KM, Lanford RE. Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees. *Hepatology* 1999; **29**: 1884-1892 [PMID: 10347134 DOI: 10.1002/hep.510290623]

372 **Smith BC**, Gorve J, Guzail MA, Day CP, Daly AK, Burt AD, Bassendine MF. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. *Hepatology* 1998; **27**: 1695-1699 [PMID: 9620344 DOI: 10.1002/hep.510270631]

373 **Geier A**, Reugels M, Weiskirchen R, Wasmuth HE, Dietrich CG, Siewert E, Gartung C, Lorenzen J, Bosserhoff AK, Brügmann M, Gressner AM, Matern S, Lammert F. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C. *Liver Int* 2004; **24**: 285-294 [PMID: 15287851 DOI: 10.1111/j.1478-3231.2004.0928.x]

374 **Tsochatzis E**, Papatheodoridis GV, Koliaraki V, Hadziyannis E, Kafiri G, Manesis EK, Mamalaki A, Archimandritis AJ. Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. *J Viral Hepat* 2010; **17**: 800-806 [PMID: 20002304 DOI: 10.1111/j.1365-2893.2009.01244.x]

375 **Mitsuyoshi H**, Yasui K, Yamaguchi K, Minami M, Okanoue T, Itoh Y. Pathogenic Role of Iron Deposition in Reticuloendothelial Cells during the Development of Chronic Hepatitis C. *Int J Hepatol* 2013; **2013**: 686420 [PMID: 23653861 DOI: 10.1155/2013/686420]

376 **Sebastiani G**, Vario A, Ferrari A, Pistis R, Noventa F, Alberti A. Hepatic iron, liver steatosis and viral genotypes in patients with chronic hepatitis C. *J Viral Hepat* 2006; **13**: 199-205 [PMID: 16475996 DOI: 10.1111/j.1365-2893.2005.00662.x]

377 **Bou Daher H**, Sharara AI. Treatment of Chronic HCV Infection in Patients With Thalassemia. *Clin Liver Dis (Hoboken)* 2019; **14**: 199-202 [PMID: 32015868 DOI: 10.1002/cld.853]

378 **Sikorska K**, Stalke P, Izycka-Swieszewska E, Romanowski T, Bielawski KP. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C. *Med Sci Monit* 2010; **16**: CR137-CR143 [PMID: 20190684]

379 **Silva IS**, Perez RM, Oliveira PV, Cantagalo MI, Dantas E, Sisti C, Figueiredo-Mendes C, Lanzoni VP, Silva A, Ferraz ML. Iron overload in patients with chronic hepatitis C virus infection: clinical and histological study. *J Gastroenterol Hepatol* 2005; **20**: 243-248 [PMID: 15683427 DOI: 10.1111/j.1440-1746.2004.03549.x]

380 **D'Souza RF**, Feakins R, Mears L, Sabin CA, Foster GR. Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C. *Aliment Pharmacol Ther* 2005; **21**: 519-524 [PMID: 15740534 DOI: 10.1111/j.1365-2036.2005.02382.x]

381 **Van Thiel DH**, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon alpha therapy is influenced by the iron content of the liver. *J Hepatol* 1994; **20**: 410-415 [PMID: 8014455 DOI: 10.1016/s0168-8278(94)80017-0]

382 **Arber N**, Moshkowitz M, Konikoff F, Halpern Z, Hallak A, Santo M, Tiomny E, Baratz M, Gilat T. Elevated serum iron predicts poor response to interferon treatment in patients with chronic HCV infection. *Dig Dis Sci* 1995; **40**: 2431-2433 [PMID: 7587826 DOI: 10.1007/BF02063249]

383 **Di Bisceglie AM**, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, Killenberg P, Hunt C, Tamburro C, Tavill AS, Ferguson R, Krawitt E, Banner B, Bacon BR. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. *Hepatology* 2000; **32**: 135-138 [PMID: 10869301 DOI: 10.1053/jhep.2000.8700]

384 **Chang ML**, Hu JH, Yen CH, Chen KH, Kuo CJ, Lin MS, Lee CH, Chen SC, Chien RN. Evolution of ferritin levels in hepatitis C patients treated with antivirals. *Sci Rep* 2020; **10**: 19744 [PMID: 33184464 DOI: 10.1038/s41598-020-76871-z]

385 **Mangia A**, Sarli R, Gamberini R, Piga A, Cenderello G, Piazzolla V, Santoro R, Caruso V, Quarta A, Ganga R, Copetti M, Forni G. Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection. *Aliment Pharmacol Ther* 2017; **46**: 424-431 [PMID: 28660640 DOI: 10.1111/apt.14197]

386 **Sinakos E**, Kountouras D, Koskinas J, Zachou K, Karatapanis S, Triantos C, Vassiliadis T, Goulis I, Kourakli A, Vlachaki E, Toli B, Tampaki M, Arvaniti P, Tsiaoussis G, Bellou A, Kattamis A, Maragkos K, Petropoulou F, Dalekos GN, Akriviadis E, Papatheodoridis GV. Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease. *Br J Haematol* 2017; **178**: 130-136 [PMID: 28439915 DOI: 10.1111/bjh.14640]

387 **Nagral A**, Jhaveri A, Sawant S, Parikh NS, Nagral N, Merchant R, Gandhi M. Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major. *Indian J Pediatr* 2019; **86**: 148-153 [PMID: 30097845 DOI: 10.1007/s12098-018-2752-7]

388 **Sharara AI**, Rustom LBO, Marrache M, Rimmani HH, Bou Daher H, Koussa S, Taher A. Sofosbuvir/velpatasvir for chronic hepatitis C infection in patients with transfusion-dependent thalassemia. *Am J Hematol* 2019; **94**: E43-E45 [PMID: 30394575 DOI: 10.1002/ajh.25339]

389 **Nishina S**, Hino K, Korenaga M, Vecchi C, Pietrangelo A, Mizukami Y, Furutani T, Sakai A, Okuda M, Hidaka I, Okita K, Sakaida I. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. *Gastroenterology* 2008; **134**: 226-238 [PMID: 18166355 DOI: 10.1053/j.gastro.2007.10.011]

390 **Fierro-Fine A**, Guerin L, Hicsasmaz H, Brown KE. Clinical Factors Associated with Hepatocellular Iron Deposition in End-stage Liver Disease. *J Clin Transl Hepatol* 2020; **8**: 231-239 [PMID: 33083244 DOI: 10.14218/JCTH.2020.00022]

391 **Zou DM**, Sun WL. Relationship between Hepatitis C Virus Infection and Iron Overload. *Chin Med J (Engl)* 2017; **130**: 866-871 [PMID: 28345552 DOI: 10.4103/0366-6999.202737]

392 **Martin DN**, Uprichard SL. Identification of transferrin receptor 1 as a hepatitis C virus entry factor. *Proc Natl Acad Sci U S A* 2013; **110**: 10777-10782 [PMID: 23754414 DOI: 10.1073/pnas.1301764110]

393 **Wessling-Resnick M**. Crossing the Iron Gate: Why and How Transferrin Receptors Mediate Viral Entry. *Annu Rev Nutr* 2018; **38**: 431-458 [PMID: 29852086 DOI: 10.1146/annurev-nutr-082117-051749]

394 **Mehta KJ**, Farnaud SJ, Sharp PA. Iron and liver fibrosis: Mechanistic and clinical aspects. *World J Gastroenterol* 2019; **25**: 521-538 [PMID: 30774269 DOI: 10.3748/wjg.v25.i5.521]

395 **Schmidt SM**. The role of iron in viral infections. *Front Biosci (Landmark Ed)* 2020; **25**: 893-911 [PMID: 31585922 DOI: 10.2741/4839]

396 **Armitage AE**, Stacey AR, Giannoulatou E, Marshall E, Sturges P, Chatha K, Smith NM, Huang X, Xu X, Pasricha SR, Li N, Wu H, Webster C, Prentice AM, Pellegrino P, Williams I, Norris PJ, Drakesmith H, Borrow P. Distinct patterns of hepcidin and iron regulation during HIV-1, HBV, and HCV infections. *Proc Natl Acad Sci U S A* 2014; **111**: 12187-12192 [PMID: 25092293 DOI: 10.1073/pnas.1402351111]

397 **Georgopoulou U**, Dimitriadis A, Foka P, Karamichali E, Mamalaki A. Hepcidin and the iron enigma in HCV infection. *Virulence* 2014; **5**: 465-476 [PMID: 24626108 DOI: 10.4161/viru.28508]

398 **Foka P**, Dimitriadis A, Karamichali E, Kyratzopoulou E, Giannimaras D, Koskinas J, Varaklioti A, Mamalaki A, Georgopoulou U. Alterations in the iron homeostasis network: A driving force for macrophage-mediated hepatitis C virus persistency. *Virulence* 2016; **7**: 679-690 [PMID: 27058404 DOI: 10.1080/21505594.2016.1175700]

399 **Vela D**. Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker. *Mol Med* 2018; **24**: 5 [PMID: 30134796 DOI: 10.1186/s10020-018-0008-7]

400 **Macías-Rodríguez RU**, Inzaugarat ME, Ruiz-Margáin A, Nelson LJ, Trautwein C, Cubero FJ. Reclassifying Hepatic Cell Death during Liver Damage: Ferroptosis-A Novel Form of Non-Apoptotic Cell Death? *Int J Mol Sci* 2020; **21**: 1651 [PMID: 32121273 DOI: 10.3390/ijms21051651]

401 **Bartolomei G**, Cevik RE, Marcello A. Modulation of hepatitis C virus replication by iron and hepcidin in Huh7 hepatocytes. *J Gen Virol* 2011; **92**: 2072-2081 [PMID: 21593278 DOI: 10.1099/vir.0.032706-0]

402 **Bloomer SA**, Brown KE. Iron-Induced Liver Injury: A Critical Reappraisal. *Int J Mol Sci* 2019; **20** [PMID: 31052166 DOI: 10.3390/ijms20092132]

403 **Serfaty L**. Follow-up of patients with chronic hepatitis C and a sustained viral response. *Liver Int* 2016; **36** Suppl 1: 67-71 [PMID: 26725900 DOI: 10.1111/liv.13016]

404 **Calvaruso V**, Craxì A. Why do I treat my patients with mild hepatitis C? *Liver Int* 2016; **36** Suppl 1: 7-12 [PMID: 26725891 DOI: 10.1111/liv.13011]

405 **Zakhari S**. Bermuda Triangle for the liver: alcohol, obesity, and viral hepatitis. *J Gastroenterol Hepatol* 2013; **28** Suppl 1: 18-25 [PMID: 23855291 DOI: 10.1111/jgh.12207]

406 **Huiban L**, Stanciu C, Sfarti C, Muzica C, Cuciureanu T, Zenovia S, Frunzuc G, Damian I, Trifan A. Micro-elimination of hepatitis C virus infection - the beginning of the end. *J Gastrointestin Liver Dis* 2020; **29**: 688 [PMID: 33331344 DOI: 10.15403/jgld-3028]

407 **Shiha G**, Metwally AM, Soliman R, Elbasiony M, Mikhail NNH, Easterbrook P. An educate, test, and treat programme towards elimination of hepatitis C infection in Egypt: a community-based demonstration project. *Lancet Gastroenterol Hepatol* 2018; **3**: 778-789 [PMID: 30030068 DOI: 10.1016/S2468-1253(18)30139-0]

408 **Shiha G**, Soliman R, Mikhail NNH, Easterbrook P. An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages. *J Hepatol* 2020; **72**: 658-669 [PMID: 31734097 DOI: 10.1016/j.jhep.2019.11.004]

409 **Shiha G**, Soliman R, Mikhail NNH, Easterbrook P. Reduced incidence of hepatitis C in 9 villages in rural Egypt: Progress towards national elimination goals. *J Hepatol* 2021; **74**: 303-311 [PMID: 32931878 DOI: 10.1016/j.jhep.2020.09.008]

410 **Tatar M**, Keeshin SW, Mailliard M, Wilson FA. Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States. *JAMA Netw Open* 2020; **3**: e2015756 [PMID: 32880650 DOI: 10.1001/jamanetworkopen.2020.15756]

411 **Hollande C**, Parlati L, Pol S. Micro-elimination of hepatitis C virus. *Liver Int* 2020; **40** Suppl 1: 67-71 [PMID: 32077601 DOI: 10.1111/liv.14363]

412 **Proeschold-Bell RJ**, Evon DM, Yao J, Niedzwiecki D, Makarushka C, Keefe KA, Patkar AA, Mannelli P, Garbutt JC, Wong JB, Wilder JM, Datta SK, Hodge T, Naggie S, Fried MW, Muir AJ. A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection. *Hepatology* 2020; **71**: 1894-1909 [PMID: 31803945 DOI: 10.1002/hep.31058]

413 **Fitzpatrick C**, Asiedu K, Solomon AW, Mitja O, Marks M, Van der Stuyft P, Meheus F. Prioritizing surveillance activities for certification of yaws eradication based on a review and model of historical case reporting. *PLoS Negl Trop Dis* 2018; **12**: e0006953 [PMID: 30513075 DOI: 10.1371/journal.pntd.0006953]

**Footnotes**

**Conflict-of-interest statement:** There is no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author’s Membership in Professional Societies:** European Association for the Study of the Liver (EASL), 648.

**Peer-review started:** February 8, 2021

**First decision:** March 29, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Greece

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Campani C, Cojocariu C, Volynets GV **S-Editor:** Liu M **L-Editor:** Filipodia **P-Editor:** Liu M

**Table 1 Reasons for failure of the World Health Organization 2030 hepatitis C virus elimination program**

|  |
| --- |
| Treatment failure and non-compliance |
| Resistance of old and new subtypes |
| Occult HCV |
| Reinfection  People who inject drugs  Males having sex with males |
| Cost of treatment |

HCV: Hepatitis C virus.

**Table 2 Group targets in a hepatitis C virus micro-elimination program**

|  |
| --- |
| Alcohol consumers |
| Metabolic syndrome  Obesity-steatosis  Cirrhosis-HCC  Diabetes mellitus and insulin resistance |
| HCV/HIV coinfection |
| People who inject drugs |
| Males having sex with males |
| Hemophiliacs, thalassemia patients |
| Immunocompromised patients |

HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma.